Frontline Supervisor Perspectives on Enabling High Reliability and Fostering a Just Culture at the VHA

Article Type
Changed
Display Headline

Frontline Supervisor Perspectives on Enabling High Reliability and Fostering a Just Culture at the VHA

The Veterans Health Administration (VHA) is now in the sixth year of its enterprise-wide transformation into a high reliability organization (HRO). This effort began with a 2016 pilot project and is now implemented in 170 VHA medical centers.1-4 This transformation reflects a commitment to implementing standardized and reliable health care practices.

The VHA HRO implementation strategy includes a multifaceted approach to engage leadership through education, training, leader coaching, and change management initiatives.2 Despite the diversity of facilities in terms of cultures, geographies, and complexities, US Department of Veterans Affairs (VA) medical centers (VAMCs) have increasingly embraced standardized HRO practices. These changes are evident in improvements in VHA All Employee Survey scores, which assess 4 key patient safety culture dimensions: risk identification and just culture, error transparency and mitigation, supervisor communication and trust, and team cohesion and engagement.5 Positive trends in these dimensions highlight a cultural shift toward greater reliability, even amid challenges introduced by the COVID-19 pandemic.

However, this progress has encountered some challenges. Leadership turnover, budgetary constraints, and extensive educational demands for implementing and sustaining HRO practices have created obstacles, particularly for frontline health care practitioners.6 Additionally, there are pockets of resistance similar to what the airline industry faced when implementing crew resource management (CRM). Specifically, senior pilots and legacy leaders were reluctant to abandon their high-status, autocratic management styles and embrace CRM, despite its proven benefits for enhancing commercial airline safety.7 Similarly, some VHA staff have expressed resistance to foundational HRO practices, which include safety huddles, safety forums, leader rounding, and visual management systems.6,8

The training requirements for HRO practices range from a 25-minute introductory course (HRO 101) to a 7.5-hour team training session facilitated by the VHA National Center for Patient Safety (NCPS).9 While some supervisors view these requirements as burdensome, others have demonstrated strong enthusiasm for the process.6 Understanding the perspectives of unit and departmental managers regarding factors that enhance or hinder the adoption of HRO practices is critical for continuous improvement.10-12 Research has suggested that fostering psychological safety can create an environment where new ideas are shared openly, helping organizations navigate resistance to change.13-16

A 2024 quality improvement study, drawing on the perceptions of HRO leads, identified key facilitators, including training, coaching, leader approachability, and psychological safety, as well as barriers such as inadequate training and lack of accountability among managers.17 Building on this work, the current study focused on frontline supervisors, who are directly involved in integrating HRO practices into patient care activities. By addressing both barriers and facilitators, this expanded approach aims to provide a more comprehensive understanding of the challenges influencing HRO implementation in day-to-day operations.

Methods

This quality improvement initiative examined facilitators and barriers to establishing just culture and implementing high reliability practices, focusing on frontline supervisors overseeing clinical care teams (eg, emergency department, critical care) or patient-support functions (eg, dietary services). A questionnaire was sent to a randomized sample of VHA facility supervisors.

A qualitative grounded theory approach was employed to provide a deeper understanding of nuanced phenomena that cannot be captured through numerical data alone. This method enables systematic analysis using open, axial, and thematic coding, ensuring that emerging themes achieve saturation.18,19 It is particularly suited for this study, given the limited prior data on frontline supervisors. Additionally, qualitative methods help mitigate biases common in Likert-style scales, where respondents may lean toward agreement, potentially skewing results.20

Inclusion Criteria

Participants were required to have served as a frontline supervisor for ≥ 6 months. Frontline supervisors are assigned responsibility for supporting staff who deliver services to VHA patients, including clinical care, dietary support, and other functions. These staff must complete baseline HRO cultural training as well as NCPS team training and are responsible for supporting quality, safety, and patient experience. Potential participants were identified from a list of frontline supervisors provided by VHA management. A subset was chosen through random sampling across geographically distributed VHA hospital facilities that vary in size and complexity. Invitations to participate in completing the questionnaire were sent via email, explaining the quality improvement initiative’s purpose, and encouraging voluntary participation. Of 2000 frontline supervisors invited to participate in the initiative, 97 completed the questionnaire. Participants represented a mix of VHA sites in terms of geography, size, and complexity.

Procedures

The authors used a qualitative approach and administered a confidential online survey. Demographic data were collected within the survey to understand characteristics of the participant population, including length of time as a frontline supervisor, facility complexity level, and professional background (clinical vs nonclinical). Survey questions were developed to elicit responses to specific areas of interest based on existing literature related to HRO and just culture.

Facilitators were defined as factors that increase the likelihood of establishing or sustaining high reliability practices and/or culture. Barriers were defined as factors that decrease or inhibit the likelihood of establishing or sustaining high reliability practices and/or culture. The questionnaire consisted of open-ended questions asking frontline supervisors to describe HRO practices and just culture at their individual facility and within their role. Participants also were asked to identify facilitators and barriers that helped or hindered their efforts to establish and maintain high reliability practices and just culture. The questionnaire solicited recommendations for additional support, training, resources, or leadership interventions to strengthen high reliability practices and just culture from each participant.

Analysis

Participant characteristics were analyzed using descriptive statistics. Responses to the 7 open-ended questions were coded and analyzed using ATLAS.ti v.24 qualitative data analysis software by an experienced researcher and coauthor. Grounded theory methodology allowed themes to emerge from the data and although the response rate was limited, the themes reached a saturation point.18,19

Ethical Considerations

Institutional review board (IRB) review and approval were not required for this quality improvement initiative. Formal IRB review and approval of a quality improvement initiative are not required by VHA. Participation was confidential and voluntary, and participants could withdraw at any time without consequences. Completion of the survey indicated consent, and facility names and participant identifiers were not used. Unique numbers were assigned to each participant and all responses were kept confidential and nonattributional. Frequency coding was used to identify the facilitators and barriers to high reliability practices implementation and just culture among frontline supervisors until thematic saturation was obtained.

Results

A total of 2000 frontline supervisors were invited to participate, of whom 97 completed the questionnaire (response rate, 4.9%). Participants were first asked to describe just culture and high reliability practices in their own words. The consensus was that a just culture emphasizes a nonpunitive environment where employees can report errors or incidents without fear of retaliation. It encourages accountability at the systems level, focusing on learning from mistakes to improve processes. In response to a question asking respondents to describe HRO practices and just culture in their own words, participants noted that organizations with a just culture promote open communication, allowing staff to discuss safety issues and concerns without fear of personal blame. Additionally, participants agreed that HRO practices were defined as a set of principles and practices aimed at minimizing errors and promoting safety, especially within complex and high-risk environments. Participants responded that key characteristics include a preoccupation with failure, sensitivity to operations, reluctance to simplify, and a commitment to resilience. HRO practices entail proactively identifying and mitigating risks through open communication and collaboration among team members, they added.

Overall, participants were aligned with their view of the role a frontline supervisor plays in supporting just culture and HRO principles at their facility by fostering open communication and psychological safety, encouraging continuous learning and improvement, and promoting team collaboration and shared accountability. Among frontline supervisors, 93 (96%) identified their role as being critical to creating a safe space and reinforcing just culture and HRO principles at their facility, while 4 (4%) failed to identify a single duty.

Identified Themes

Table 1 summarizes 6 key themes identified from participants’ responses, highlighting the most frequently cited facilitators and barriers to implementing and sustaining high reliability practices and a just culture. Table 2 shows the classification of several themes in relation to facility complexity, emphasizing leadership commitment and support as a pivotal facilitator, while listing resistance to change and entrenched attitudes as a prominent barrier.

eJustculture_T1eJustculture-T2
Role of Leadership

Facilitators. Leadership commitment and support were the most frequently identified facilitator, accounting for 44 mentions (45%). This aligns with participants’ descriptions of leadership involvement as crucial, particularly in setting standards and fostering accountability throughout the organization. For example, a frontline supervisor with < 5 years of experience from a nonclinical background at a 1B facility remarked, “Facility leadership are involved, which trickles down to lower-level leads and supervisors, which keeps everyone accountable and holds everyone to the same standards.” Participants frequently identified that leaders setting the standard and communicating expectations as paramount facilitators for strengthening high reliability practices and just culture at their facility.

Barriers. A lack of leadership commitment and support was a significant barrier, cited in 17 responses (18%). Participants described this barrier as a deficiency in follow-through, transparency, and presence, which undermines efforts to sustain just culture and high reliability principles. Notably, the lack of leadership commitment and support stood out as a distinct and recurring theme, underscoring its critical role as an independent challenge to achieving organizational goals. “Many leaders are not yet fully bought in,” a respondent explained. “They take the training and pass it off and go right back to their units and focus on blaming or chastis[ing] people for speaking up.” This theme frequently intersected with mentions of insufficient resources and entrenched attitudes, amplifying other challenges.

Open Communication and Transparency

Facilitators. Open communication and transparency were identified as facilitators in 12 responses (12%). Participants emphasized the importance of mechanisms such as HRO meetings and the sharing of “real” examples of positive outcomes from applying HRO principles. Transparent communication fosters psychological safety, allowing staff to report concerns without fear of reprisal. One participant with < 5 years of experience from a clinical background at a 1A facility encapsulated this theme by saying, “Quarterly ‘fireside chats’ are helpful, [this] creates open dialogue about where the next safety issue may occur, what staff need to do their job safely, while also imparting more of the philosophy of HRO that staff may not be aware of.”

Barriers. While communication serves as a facilitator, participants also highlighted barriers such as siloed communication and fear of reprisal. These reflect challenges in creating open and transparent feedback loops essential to high reliability. For example, a participant concluded, “Leadership does not communicate problem-solving efforts and resolution down the chain, they do not see the problems.” Another participant added, “[HRO principles] are not discussed that much.” While this theme presented as a barrier, it was noted less frequently.

Education and Training

Facilitators. Education and training were noted as facilitators in 10 responses (10%), underscoring their role in establishing high reliability practices. Participants suggested tailored training, simulation-based exercises, and mentorship to enhance practical application. However, they noted the importance of linking training to real change and ensuring leadership enforcement of learned behaviors. This theme is best represented by a participant who concluded, “Trainings have helped, but I think as a supervisor, being involved and interacting with your staff, observing, doing the work they do to help identify potential problems areas, especially when new systems are introduced are key. Being hands-on is the only way to successfully manage your team.”

Barriers. Insufficient resources, including time and staffing constraints, were identified as barriers to education and training, accounting for 24 responses (25%). Participants observed that mandatory training without mentorship or application diminishes its effectiveness.

Insufficient Resources and Funding

Barriers. Resource constraints, including low staffing levels and budget cuts, accounted for 24 responses (25%). Participants reported these limitations prevented staff from attending training and affected the overall implementation of just culture and HRO principles. “Low staffing in supporting services as well as in my own service line have created barriers,” a participant reported. Another participant responded that barriers to HRO were primarily “…financial, as the focus is how to curb costs and bring in more funding rather than taking the time to review and apply the concepts of high reliability.”

Resistance to Change and Entrenched Attitudes

Barriers. Resistance to change was the most frequently identified barrier, with 31 responses (32%). One participant described a persistent “gotcha” culture, where blame and punishment hinder progress toward just culture. This entrenched mindset creates significant obstacles to adopting HRO practices and requires active leadership and supervisor intervention to overcome. This theme is best captured by a respondent who noted that “culture change is difficult, especially among staff with such long tenure. It’s a long game.”

Synthesis and Integration of Findings

The data in Table 1 and Table 2 reinforce the themes identified in the qualitative analysis. Leadership commitment and support are pivotal, both as a facilitator and barrier. Open communication and education and training, while recognized as facilitators, were less frequently mentioned, but still critical. Resistance to change and insufficient resources were the most prominent barriers, indicating where organizational efforts should focus to further foster a culture of high reliability.

By addressing these barriers, particularly resistance to change and resource constraints, and leveraging facilitators like leadership engagement and transparent communication, organizations can enhance their implementation of just culture and high reliability practices. These efforts require deliberate strategies, including effective training, mentorship, and the active presence of leadership.

Discussion

This quality improvement initiative builds on prior research by examining the implementation of HRO practices from the perspective of frontline supervisors. Unlike earlier research focused on HRO leads, this study explores the critical role of supervisors who integrate HRO principles into clinical and administrative operations.17 By analyzing their experiences, this study offers practical insights into facilitating HRO implementation across organizational levels.

The findings highlight broad agreement on the value of just culture and HRO principles in fostering safe, accountable health care environments. Participants described just culture as promoting system—level accountability rather than individual blame, encouraging error reporting and learning for continuous improvement. Similarly, HRO practices—emphasizing a preoccupation with failure, operational sensitivity, and resilience— were seen as vital for patient safety in complex settings.

Frontline supervisors play a pivotal role, with 96% of respondents identifying their influence on fostering open communication, psychological safety, and shared accountability. Key facilitators included leadership commitment, open communication, and mentorship. Active leadership involvement was particularly valued, as it trickles down to reinforce standards across all organizational levels. HRO meetings using real-world examples were seen as instrumental in demonstrating the tangible benefits of these principles, helping embed them into daily practices.

Despite these facilitators, several barriers to implementation were noted. Resistance to change and entrenched attitudes, and a persistent gotcha culture undermined efforts to establish just culture. Resource constraints, including staffing shortages and budget limitations, further hindered the adoption of HRO practices. The lack of consistent leadership engagement, marked by limited visibility, follow-through, and transparency, exacerbated these challenges.

HRO leads are important for promoting education and embedding HRO principles into daily operations. These individuals provide vital support to frontline supervisors, translating HRO concepts into actionable practices. However, organizational challenges such as staff turnover and redirected funding have weakened the infrastructure supporting HRO initiatives. The elimination of HRO lead roles due to budgetary pressures at several facilities reflects a short-term focus on operational demands at the expense of long-term cultural transformation.

Additional barriers included siloed communication, fear of reprisal, bureaucratic obstacles, and outdated technology. These challenges limit progress toward high reliability and diminish the effectiveness of HRO principles.

Participants proposed strategies focused on education, training, and leadership engagement. Simulation-based training tailored to specific roles was identified as an effective tool for preparing staff to apply HRO principles in real-world scenarios. Enhanced communication, such as regular leadership rounding and transparent updates on safety concerns, was also emphasized. Participants stressed the importance of showing staff how their feedback influences organizational decisions to build trust and accountability. Finally, standardizing procedures and protocols across facilities was seen as critical for aligning practices and reducing variability in safety processes.

This study underscores the need for sustained leadership commitment and infrastructure to ensure the long-term success of HRO implementation. Addressing the identified barriers and leveraging the proposed mitigation strategies can foster a culture of safety and reliability across the organization.

Limitations

This quality improvement initiative used qualitative grounded theory methods and sampled a relatively small group of experienced leaders specifically involved in implementing HRO within the VHA. In addition, while saturation of themes was reached, the number of responses represents a small sample of VHA frontline supervisors. As such, the findings may not be fully representative of the perspectives of all unit and departmental leaders across the VHA or other health care systems. A previous qualitative quality improvement initiative focused on the perceptions of HRO leads regarding facilitators and barriers to just culture.17 This quality improvement initiative broadened that focus by examining the perspectives of frontline supervisors in the operational environment, who may not be HRO experts but work to implement HRO principles with the guidance of HRO leads (HRO subject matter experts).

There remains an opportunity to address a critical gap by assessing facilitators and barriers beyond the facility level, incorporating both the Veterans Integrated Service Networks (VISN) and VHA Central Office (VHACO). While qualitative methods, such as those used in this study, provide deep insights and detailed understanding, they are limited in their ability to identify system-wide trends and variations at a more strategic VISN and VHACO level. Addressing this could enhance the broader applicability of HRO principles across the VHA.

Conclusions

Successful implementation of the recommendations reported in this study will require sustained focus and continued commitment from all stakeholders across the VHA. As the VHA enters its seventh year on the HRO journey, the risk of organizational drift remains an ongoing concern. Progress has been made, as evidenced by incremental improvements in All Employee Survey scores and increased reporting of adverse events and near misses, but the challenge will be to maintain focus and continue to build upon progress amid the current climate of budgetary constraints.

This study builds on previous quality improvement efforts and provides valuable insights into the barriers and facilitators that can either hinder or support the VHA’s ongoing pursuit of high reliability. The findings offer a model for understanding the complexities of this journey—one that requires continuous effort and adaptation, as there is no definitive endpoint in the quest for high reliability.

Since completion of this study in 2024, the VHA has entered a period of organizational transition and restructuring. Such transitions are often accompanied by increased operational demands and organizational strain. These include realignments, personnel changes, staffing adjustments, workforce reductions, and continued implementation of a new electronic health record system. In this context, maintaining attention to culture, communication, frontline engagement, and mechanisms that provide visibility into organizational climate is essential to sustain momentum in high-reliability efforts.

References
  1. Cox GR, Starr LM. VHA’s movement for change: implementing high-reliability principles and practices. J Healthc Manag. 2023;68:151-157. doi:10.1097/jhm-D-23-00056
  2. Sculli GL, Pendley-Louis R, Neily J, et al. A high-reliability organization framework for health care: A multiyear implementation strategy and associated outcomes. J Patient Saf. 2022;18:64-70. doi:10.1097/pts.0000000000000788
  3. Murray JS, Clifford J, Larson S, Lee JK, Sculli GL. Implementing just culture to improve patient safety. Mil Med. 2023;188:usac115. doi:10.1093/milmed/usac115
  4. Merchant NB, O’Neal J, Montoya A, Cox GR, Murray JS. Creating a process for the implementation of tiered huddles in a Veterans Affairs Medical Center. Mil Med. 2023;188:901-906. doi:10.1093/milmed/usac073
  5. Mohr DC, Chen C, Sullivan J, et al. Development and validation of the Veterans Health Administration Patient Safety Culture Survey. J Patient Saf. 2022;18:539-545. doi:10.1097/PTS.0000000000001027
  6. Leonard C, Gilmartin H, Starr L, Anderson T. Leadership and the high reliability transformation: a qualitative study at Truman VA medical center. J Healthc Risk Manag. 2024;44:17-23. doi:10.1002/jhrm.21580
  7. Sculli G, Essen K. Soaring to Success: The Path to Developing High-Reliability Teams. HCPro; 2021.
  8. Gupta JI, Sivils S, Reppert J, Paulot W, Houchens N, Hummel S. Visual management board implementation to enhance high reliability at a large VA health care system. Fed Pract. 2024;41:242-246. doi:10.12788/fp.0507
  9. Veterans Health Administration. High Reliability Organization Learning Catalog. US Dept of Veterans Affairs; 2024. Internal document.
  10. Jahn JLS, Black AE. A model of communicative and hierarchical foundations of high reliability organizing in wildland firefighting teams. Manag Commun Q. 2017;31:356-379. doi:10.1177/0893318917691358
  11. Myers CG, Sutcliffe KM. High reliability organising in healthcare: still a long way left to go. BMJ Qual Saf. 2022;31:845-848. doi:10.1136/bmjqs-2021-014141
  12. Abrams J. Model the way to navigate difficult topics. The Learning Professional. 2022;43:14-18.
  13. McCausland T. Creating psychological safety in the workplace. Research-Technology Management. 2023;66:56-58. doi:10.1080/08956308.2023.2164439
  14. Murray JS, Kelly S, Hanover C. Promoting psychological safety in healthcare organizations. Mil Med. 2022;187:808- 810. doi:10.1093/milmed/usac041
  15. Sutton RI, Rao H. The friction project: how smart leaders make the right things easier and the wrong things harder. St. Martin’s Press; 2024.
  16. Clark TR. The 4 stages of psychological safety: defining the path to inclusion and innovation. Berrett-Koehler Publishers, Inc.; 2020.
  17. Essen K, Villalobos C, Sculli G, Steinbach L. Establishing a just culture: implications for the Veterans Health Administration journey to high reliability. Fed Pract. 2024;41:290- 297. doi:10.12788/fp.0512
  18. Creswell JW. Research design: qualitative, quantitative, and mixed methods approaches. 4th ed. SAGE Publications; 2014.
  19. Patton MQ. Qualitative research & evaluation methods: integrating theory and practice. 4th ed. SAGE Publications, Inc.; 2015.
  20. Krumpal I. Determinants of social desirability bias in sensitive surveys: a literature review. Qual Quant. 2013;47:2025- 2047. doi:10.1007/s11135-011-9640-9
Article PDF
Author and Disclosure Information

Keith Essen, RN, PhD, MSSa; Christy Villalobos, MPPb; Ahnnya Slaughter, DNP, RN-C, CNS-BCc; Charles D. Leiner, MDd,e; Scott Mayof

Author affiliations
aVeterans Affairs National Center for Patient Safety, Ann Arbor, Michigan
bAccenture Federal Services, Arlington, Virginia
cVeterans Affairs Long Beach Healthcare System, California
dCentral Virginia Veterans Health Care System, Richmond
eVirginia Commonwealth University Health System School of Medicine, Richmond
fVeterans Health Administration, Office of Sterile Processing, Washington, DC

Author disclosures The authors report no actual or potential conflicts of interest regarding this article.

Disclaimer The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies.

Ethics and consent Based on review with government leaders overseeing this initiative and past precedents, the authors did not pursue and were not required to obtain formal institutional review board approval. The study was determined to be a quality improvement initiative, which is exempt from review in the Veterans Health Administration. All authors adhered to ethical standards of research, including asking participants for verbal consent and preserving participants’ confidentiality.

Artificial intelligence The transcribed data were organized, coded, and analyzed using Atlas.ti (version 24) qualitative data software to identify key themes and patterns for this publication.

Funding Contractor support for completion of this study was funded by the US Department of Veterans Affairs under contract number 36C10X24F0031.

Correspondence: Keith Essen (keith.essen@va.gov)

Fed Pract. 2026;43(5):e0693. Published online May 28. doi:10.12788/fp.0693

Issue
Federal Practitioner - 43(5)
Publications
Topics
Page Number
1-7
Sections
Author and Disclosure Information

Keith Essen, RN, PhD, MSSa; Christy Villalobos, MPPb; Ahnnya Slaughter, DNP, RN-C, CNS-BCc; Charles D. Leiner, MDd,e; Scott Mayof

Author affiliations
aVeterans Affairs National Center for Patient Safety, Ann Arbor, Michigan
bAccenture Federal Services, Arlington, Virginia
cVeterans Affairs Long Beach Healthcare System, California
dCentral Virginia Veterans Health Care System, Richmond
eVirginia Commonwealth University Health System School of Medicine, Richmond
fVeterans Health Administration, Office of Sterile Processing, Washington, DC

Author disclosures The authors report no actual or potential conflicts of interest regarding this article.

Disclaimer The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies.

Ethics and consent Based on review with government leaders overseeing this initiative and past precedents, the authors did not pursue and were not required to obtain formal institutional review board approval. The study was determined to be a quality improvement initiative, which is exempt from review in the Veterans Health Administration. All authors adhered to ethical standards of research, including asking participants for verbal consent and preserving participants’ confidentiality.

Artificial intelligence The transcribed data were organized, coded, and analyzed using Atlas.ti (version 24) qualitative data software to identify key themes and patterns for this publication.

Funding Contractor support for completion of this study was funded by the US Department of Veterans Affairs under contract number 36C10X24F0031.

Correspondence: Keith Essen (keith.essen@va.gov)

Fed Pract. 2026;43(5):e0693. Published online May 28. doi:10.12788/fp.0693

Author and Disclosure Information

Keith Essen, RN, PhD, MSSa; Christy Villalobos, MPPb; Ahnnya Slaughter, DNP, RN-C, CNS-BCc; Charles D. Leiner, MDd,e; Scott Mayof

Author affiliations
aVeterans Affairs National Center for Patient Safety, Ann Arbor, Michigan
bAccenture Federal Services, Arlington, Virginia
cVeterans Affairs Long Beach Healthcare System, California
dCentral Virginia Veterans Health Care System, Richmond
eVirginia Commonwealth University Health System School of Medicine, Richmond
fVeterans Health Administration, Office of Sterile Processing, Washington, DC

Author disclosures The authors report no actual or potential conflicts of interest regarding this article.

Disclaimer The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies.

Ethics and consent Based on review with government leaders overseeing this initiative and past precedents, the authors did not pursue and were not required to obtain formal institutional review board approval. The study was determined to be a quality improvement initiative, which is exempt from review in the Veterans Health Administration. All authors adhered to ethical standards of research, including asking participants for verbal consent and preserving participants’ confidentiality.

Artificial intelligence The transcribed data were organized, coded, and analyzed using Atlas.ti (version 24) qualitative data software to identify key themes and patterns for this publication.

Funding Contractor support for completion of this study was funded by the US Department of Veterans Affairs under contract number 36C10X24F0031.

Correspondence: Keith Essen (keith.essen@va.gov)

Fed Pract. 2026;43(5):e0693. Published online May 28. doi:10.12788/fp.0693

Article PDF
Article PDF

The Veterans Health Administration (VHA) is now in the sixth year of its enterprise-wide transformation into a high reliability organization (HRO). This effort began with a 2016 pilot project and is now implemented in 170 VHA medical centers.1-4 This transformation reflects a commitment to implementing standardized and reliable health care practices.

The VHA HRO implementation strategy includes a multifaceted approach to engage leadership through education, training, leader coaching, and change management initiatives.2 Despite the diversity of facilities in terms of cultures, geographies, and complexities, US Department of Veterans Affairs (VA) medical centers (VAMCs) have increasingly embraced standardized HRO practices. These changes are evident in improvements in VHA All Employee Survey scores, which assess 4 key patient safety culture dimensions: risk identification and just culture, error transparency and mitigation, supervisor communication and trust, and team cohesion and engagement.5 Positive trends in these dimensions highlight a cultural shift toward greater reliability, even amid challenges introduced by the COVID-19 pandemic.

However, this progress has encountered some challenges. Leadership turnover, budgetary constraints, and extensive educational demands for implementing and sustaining HRO practices have created obstacles, particularly for frontline health care practitioners.6 Additionally, there are pockets of resistance similar to what the airline industry faced when implementing crew resource management (CRM). Specifically, senior pilots and legacy leaders were reluctant to abandon their high-status, autocratic management styles and embrace CRM, despite its proven benefits for enhancing commercial airline safety.7 Similarly, some VHA staff have expressed resistance to foundational HRO practices, which include safety huddles, safety forums, leader rounding, and visual management systems.6,8

The training requirements for HRO practices range from a 25-minute introductory course (HRO 101) to a 7.5-hour team training session facilitated by the VHA National Center for Patient Safety (NCPS).9 While some supervisors view these requirements as burdensome, others have demonstrated strong enthusiasm for the process.6 Understanding the perspectives of unit and departmental managers regarding factors that enhance or hinder the adoption of HRO practices is critical for continuous improvement.10-12 Research has suggested that fostering psychological safety can create an environment where new ideas are shared openly, helping organizations navigate resistance to change.13-16

A 2024 quality improvement study, drawing on the perceptions of HRO leads, identified key facilitators, including training, coaching, leader approachability, and psychological safety, as well as barriers such as inadequate training and lack of accountability among managers.17 Building on this work, the current study focused on frontline supervisors, who are directly involved in integrating HRO practices into patient care activities. By addressing both barriers and facilitators, this expanded approach aims to provide a more comprehensive understanding of the challenges influencing HRO implementation in day-to-day operations.

Methods

This quality improvement initiative examined facilitators and barriers to establishing just culture and implementing high reliability practices, focusing on frontline supervisors overseeing clinical care teams (eg, emergency department, critical care) or patient-support functions (eg, dietary services). A questionnaire was sent to a randomized sample of VHA facility supervisors.

A qualitative grounded theory approach was employed to provide a deeper understanding of nuanced phenomena that cannot be captured through numerical data alone. This method enables systematic analysis using open, axial, and thematic coding, ensuring that emerging themes achieve saturation.18,19 It is particularly suited for this study, given the limited prior data on frontline supervisors. Additionally, qualitative methods help mitigate biases common in Likert-style scales, where respondents may lean toward agreement, potentially skewing results.20

Inclusion Criteria

Participants were required to have served as a frontline supervisor for ≥ 6 months. Frontline supervisors are assigned responsibility for supporting staff who deliver services to VHA patients, including clinical care, dietary support, and other functions. These staff must complete baseline HRO cultural training as well as NCPS team training and are responsible for supporting quality, safety, and patient experience. Potential participants were identified from a list of frontline supervisors provided by VHA management. A subset was chosen through random sampling across geographically distributed VHA hospital facilities that vary in size and complexity. Invitations to participate in completing the questionnaire were sent via email, explaining the quality improvement initiative’s purpose, and encouraging voluntary participation. Of 2000 frontline supervisors invited to participate in the initiative, 97 completed the questionnaire. Participants represented a mix of VHA sites in terms of geography, size, and complexity.

Procedures

The authors used a qualitative approach and administered a confidential online survey. Demographic data were collected within the survey to understand characteristics of the participant population, including length of time as a frontline supervisor, facility complexity level, and professional background (clinical vs nonclinical). Survey questions were developed to elicit responses to specific areas of interest based on existing literature related to HRO and just culture.

Facilitators were defined as factors that increase the likelihood of establishing or sustaining high reliability practices and/or culture. Barriers were defined as factors that decrease or inhibit the likelihood of establishing or sustaining high reliability practices and/or culture. The questionnaire consisted of open-ended questions asking frontline supervisors to describe HRO practices and just culture at their individual facility and within their role. Participants also were asked to identify facilitators and barriers that helped or hindered their efforts to establish and maintain high reliability practices and just culture. The questionnaire solicited recommendations for additional support, training, resources, or leadership interventions to strengthen high reliability practices and just culture from each participant.

Analysis

Participant characteristics were analyzed using descriptive statistics. Responses to the 7 open-ended questions were coded and analyzed using ATLAS.ti v.24 qualitative data analysis software by an experienced researcher and coauthor. Grounded theory methodology allowed themes to emerge from the data and although the response rate was limited, the themes reached a saturation point.18,19

Ethical Considerations

Institutional review board (IRB) review and approval were not required for this quality improvement initiative. Formal IRB review and approval of a quality improvement initiative are not required by VHA. Participation was confidential and voluntary, and participants could withdraw at any time without consequences. Completion of the survey indicated consent, and facility names and participant identifiers were not used. Unique numbers were assigned to each participant and all responses were kept confidential and nonattributional. Frequency coding was used to identify the facilitators and barriers to high reliability practices implementation and just culture among frontline supervisors until thematic saturation was obtained.

Results

A total of 2000 frontline supervisors were invited to participate, of whom 97 completed the questionnaire (response rate, 4.9%). Participants were first asked to describe just culture and high reliability practices in their own words. The consensus was that a just culture emphasizes a nonpunitive environment where employees can report errors or incidents without fear of retaliation. It encourages accountability at the systems level, focusing on learning from mistakes to improve processes. In response to a question asking respondents to describe HRO practices and just culture in their own words, participants noted that organizations with a just culture promote open communication, allowing staff to discuss safety issues and concerns without fear of personal blame. Additionally, participants agreed that HRO practices were defined as a set of principles and practices aimed at minimizing errors and promoting safety, especially within complex and high-risk environments. Participants responded that key characteristics include a preoccupation with failure, sensitivity to operations, reluctance to simplify, and a commitment to resilience. HRO practices entail proactively identifying and mitigating risks through open communication and collaboration among team members, they added.

Overall, participants were aligned with their view of the role a frontline supervisor plays in supporting just culture and HRO principles at their facility by fostering open communication and psychological safety, encouraging continuous learning and improvement, and promoting team collaboration and shared accountability. Among frontline supervisors, 93 (96%) identified their role as being critical to creating a safe space and reinforcing just culture and HRO principles at their facility, while 4 (4%) failed to identify a single duty.

Identified Themes

Table 1 summarizes 6 key themes identified from participants’ responses, highlighting the most frequently cited facilitators and barriers to implementing and sustaining high reliability practices and a just culture. Table 2 shows the classification of several themes in relation to facility complexity, emphasizing leadership commitment and support as a pivotal facilitator, while listing resistance to change and entrenched attitudes as a prominent barrier.

eJustculture_T1eJustculture-T2
Role of Leadership

Facilitators. Leadership commitment and support were the most frequently identified facilitator, accounting for 44 mentions (45%). This aligns with participants’ descriptions of leadership involvement as crucial, particularly in setting standards and fostering accountability throughout the organization. For example, a frontline supervisor with < 5 years of experience from a nonclinical background at a 1B facility remarked, “Facility leadership are involved, which trickles down to lower-level leads and supervisors, which keeps everyone accountable and holds everyone to the same standards.” Participants frequently identified that leaders setting the standard and communicating expectations as paramount facilitators for strengthening high reliability practices and just culture at their facility.

Barriers. A lack of leadership commitment and support was a significant barrier, cited in 17 responses (18%). Participants described this barrier as a deficiency in follow-through, transparency, and presence, which undermines efforts to sustain just culture and high reliability principles. Notably, the lack of leadership commitment and support stood out as a distinct and recurring theme, underscoring its critical role as an independent challenge to achieving organizational goals. “Many leaders are not yet fully bought in,” a respondent explained. “They take the training and pass it off and go right back to their units and focus on blaming or chastis[ing] people for speaking up.” This theme frequently intersected with mentions of insufficient resources and entrenched attitudes, amplifying other challenges.

Open Communication and Transparency

Facilitators. Open communication and transparency were identified as facilitators in 12 responses (12%). Participants emphasized the importance of mechanisms such as HRO meetings and the sharing of “real” examples of positive outcomes from applying HRO principles. Transparent communication fosters psychological safety, allowing staff to report concerns without fear of reprisal. One participant with < 5 years of experience from a clinical background at a 1A facility encapsulated this theme by saying, “Quarterly ‘fireside chats’ are helpful, [this] creates open dialogue about where the next safety issue may occur, what staff need to do their job safely, while also imparting more of the philosophy of HRO that staff may not be aware of.”

Barriers. While communication serves as a facilitator, participants also highlighted barriers such as siloed communication and fear of reprisal. These reflect challenges in creating open and transparent feedback loops essential to high reliability. For example, a participant concluded, “Leadership does not communicate problem-solving efforts and resolution down the chain, they do not see the problems.” Another participant added, “[HRO principles] are not discussed that much.” While this theme presented as a barrier, it was noted less frequently.

Education and Training

Facilitators. Education and training were noted as facilitators in 10 responses (10%), underscoring their role in establishing high reliability practices. Participants suggested tailored training, simulation-based exercises, and mentorship to enhance practical application. However, they noted the importance of linking training to real change and ensuring leadership enforcement of learned behaviors. This theme is best represented by a participant who concluded, “Trainings have helped, but I think as a supervisor, being involved and interacting with your staff, observing, doing the work they do to help identify potential problems areas, especially when new systems are introduced are key. Being hands-on is the only way to successfully manage your team.”

Barriers. Insufficient resources, including time and staffing constraints, were identified as barriers to education and training, accounting for 24 responses (25%). Participants observed that mandatory training without mentorship or application diminishes its effectiveness.

Insufficient Resources and Funding

Barriers. Resource constraints, including low staffing levels and budget cuts, accounted for 24 responses (25%). Participants reported these limitations prevented staff from attending training and affected the overall implementation of just culture and HRO principles. “Low staffing in supporting services as well as in my own service line have created barriers,” a participant reported. Another participant responded that barriers to HRO were primarily “…financial, as the focus is how to curb costs and bring in more funding rather than taking the time to review and apply the concepts of high reliability.”

Resistance to Change and Entrenched Attitudes

Barriers. Resistance to change was the most frequently identified barrier, with 31 responses (32%). One participant described a persistent “gotcha” culture, where blame and punishment hinder progress toward just culture. This entrenched mindset creates significant obstacles to adopting HRO practices and requires active leadership and supervisor intervention to overcome. This theme is best captured by a respondent who noted that “culture change is difficult, especially among staff with such long tenure. It’s a long game.”

Synthesis and Integration of Findings

The data in Table 1 and Table 2 reinforce the themes identified in the qualitative analysis. Leadership commitment and support are pivotal, both as a facilitator and barrier. Open communication and education and training, while recognized as facilitators, were less frequently mentioned, but still critical. Resistance to change and insufficient resources were the most prominent barriers, indicating where organizational efforts should focus to further foster a culture of high reliability.

By addressing these barriers, particularly resistance to change and resource constraints, and leveraging facilitators like leadership engagement and transparent communication, organizations can enhance their implementation of just culture and high reliability practices. These efforts require deliberate strategies, including effective training, mentorship, and the active presence of leadership.

Discussion

This quality improvement initiative builds on prior research by examining the implementation of HRO practices from the perspective of frontline supervisors. Unlike earlier research focused on HRO leads, this study explores the critical role of supervisors who integrate HRO principles into clinical and administrative operations.17 By analyzing their experiences, this study offers practical insights into facilitating HRO implementation across organizational levels.

The findings highlight broad agreement on the value of just culture and HRO principles in fostering safe, accountable health care environments. Participants described just culture as promoting system—level accountability rather than individual blame, encouraging error reporting and learning for continuous improvement. Similarly, HRO practices—emphasizing a preoccupation with failure, operational sensitivity, and resilience— were seen as vital for patient safety in complex settings.

Frontline supervisors play a pivotal role, with 96% of respondents identifying their influence on fostering open communication, psychological safety, and shared accountability. Key facilitators included leadership commitment, open communication, and mentorship. Active leadership involvement was particularly valued, as it trickles down to reinforce standards across all organizational levels. HRO meetings using real-world examples were seen as instrumental in demonstrating the tangible benefits of these principles, helping embed them into daily practices.

Despite these facilitators, several barriers to implementation were noted. Resistance to change and entrenched attitudes, and a persistent gotcha culture undermined efforts to establish just culture. Resource constraints, including staffing shortages and budget limitations, further hindered the adoption of HRO practices. The lack of consistent leadership engagement, marked by limited visibility, follow-through, and transparency, exacerbated these challenges.

HRO leads are important for promoting education and embedding HRO principles into daily operations. These individuals provide vital support to frontline supervisors, translating HRO concepts into actionable practices. However, organizational challenges such as staff turnover and redirected funding have weakened the infrastructure supporting HRO initiatives. The elimination of HRO lead roles due to budgetary pressures at several facilities reflects a short-term focus on operational demands at the expense of long-term cultural transformation.

Additional barriers included siloed communication, fear of reprisal, bureaucratic obstacles, and outdated technology. These challenges limit progress toward high reliability and diminish the effectiveness of HRO principles.

Participants proposed strategies focused on education, training, and leadership engagement. Simulation-based training tailored to specific roles was identified as an effective tool for preparing staff to apply HRO principles in real-world scenarios. Enhanced communication, such as regular leadership rounding and transparent updates on safety concerns, was also emphasized. Participants stressed the importance of showing staff how their feedback influences organizational decisions to build trust and accountability. Finally, standardizing procedures and protocols across facilities was seen as critical for aligning practices and reducing variability in safety processes.

This study underscores the need for sustained leadership commitment and infrastructure to ensure the long-term success of HRO implementation. Addressing the identified barriers and leveraging the proposed mitigation strategies can foster a culture of safety and reliability across the organization.

Limitations

This quality improvement initiative used qualitative grounded theory methods and sampled a relatively small group of experienced leaders specifically involved in implementing HRO within the VHA. In addition, while saturation of themes was reached, the number of responses represents a small sample of VHA frontline supervisors. As such, the findings may not be fully representative of the perspectives of all unit and departmental leaders across the VHA or other health care systems. A previous qualitative quality improvement initiative focused on the perceptions of HRO leads regarding facilitators and barriers to just culture.17 This quality improvement initiative broadened that focus by examining the perspectives of frontline supervisors in the operational environment, who may not be HRO experts but work to implement HRO principles with the guidance of HRO leads (HRO subject matter experts).

There remains an opportunity to address a critical gap by assessing facilitators and barriers beyond the facility level, incorporating both the Veterans Integrated Service Networks (VISN) and VHA Central Office (VHACO). While qualitative methods, such as those used in this study, provide deep insights and detailed understanding, they are limited in their ability to identify system-wide trends and variations at a more strategic VISN and VHACO level. Addressing this could enhance the broader applicability of HRO principles across the VHA.

Conclusions

Successful implementation of the recommendations reported in this study will require sustained focus and continued commitment from all stakeholders across the VHA. As the VHA enters its seventh year on the HRO journey, the risk of organizational drift remains an ongoing concern. Progress has been made, as evidenced by incremental improvements in All Employee Survey scores and increased reporting of adverse events and near misses, but the challenge will be to maintain focus and continue to build upon progress amid the current climate of budgetary constraints.

This study builds on previous quality improvement efforts and provides valuable insights into the barriers and facilitators that can either hinder or support the VHA’s ongoing pursuit of high reliability. The findings offer a model for understanding the complexities of this journey—one that requires continuous effort and adaptation, as there is no definitive endpoint in the quest for high reliability.

Since completion of this study in 2024, the VHA has entered a period of organizational transition and restructuring. Such transitions are often accompanied by increased operational demands and organizational strain. These include realignments, personnel changes, staffing adjustments, workforce reductions, and continued implementation of a new electronic health record system. In this context, maintaining attention to culture, communication, frontline engagement, and mechanisms that provide visibility into organizational climate is essential to sustain momentum in high-reliability efforts.

The Veterans Health Administration (VHA) is now in the sixth year of its enterprise-wide transformation into a high reliability organization (HRO). This effort began with a 2016 pilot project and is now implemented in 170 VHA medical centers.1-4 This transformation reflects a commitment to implementing standardized and reliable health care practices.

The VHA HRO implementation strategy includes a multifaceted approach to engage leadership through education, training, leader coaching, and change management initiatives.2 Despite the diversity of facilities in terms of cultures, geographies, and complexities, US Department of Veterans Affairs (VA) medical centers (VAMCs) have increasingly embraced standardized HRO practices. These changes are evident in improvements in VHA All Employee Survey scores, which assess 4 key patient safety culture dimensions: risk identification and just culture, error transparency and mitigation, supervisor communication and trust, and team cohesion and engagement.5 Positive trends in these dimensions highlight a cultural shift toward greater reliability, even amid challenges introduced by the COVID-19 pandemic.

However, this progress has encountered some challenges. Leadership turnover, budgetary constraints, and extensive educational demands for implementing and sustaining HRO practices have created obstacles, particularly for frontline health care practitioners.6 Additionally, there are pockets of resistance similar to what the airline industry faced when implementing crew resource management (CRM). Specifically, senior pilots and legacy leaders were reluctant to abandon their high-status, autocratic management styles and embrace CRM, despite its proven benefits for enhancing commercial airline safety.7 Similarly, some VHA staff have expressed resistance to foundational HRO practices, which include safety huddles, safety forums, leader rounding, and visual management systems.6,8

The training requirements for HRO practices range from a 25-minute introductory course (HRO 101) to a 7.5-hour team training session facilitated by the VHA National Center for Patient Safety (NCPS).9 While some supervisors view these requirements as burdensome, others have demonstrated strong enthusiasm for the process.6 Understanding the perspectives of unit and departmental managers regarding factors that enhance or hinder the adoption of HRO practices is critical for continuous improvement.10-12 Research has suggested that fostering psychological safety can create an environment where new ideas are shared openly, helping organizations navigate resistance to change.13-16

A 2024 quality improvement study, drawing on the perceptions of HRO leads, identified key facilitators, including training, coaching, leader approachability, and psychological safety, as well as barriers such as inadequate training and lack of accountability among managers.17 Building on this work, the current study focused on frontline supervisors, who are directly involved in integrating HRO practices into patient care activities. By addressing both barriers and facilitators, this expanded approach aims to provide a more comprehensive understanding of the challenges influencing HRO implementation in day-to-day operations.

Methods

This quality improvement initiative examined facilitators and barriers to establishing just culture and implementing high reliability practices, focusing on frontline supervisors overseeing clinical care teams (eg, emergency department, critical care) or patient-support functions (eg, dietary services). A questionnaire was sent to a randomized sample of VHA facility supervisors.

A qualitative grounded theory approach was employed to provide a deeper understanding of nuanced phenomena that cannot be captured through numerical data alone. This method enables systematic analysis using open, axial, and thematic coding, ensuring that emerging themes achieve saturation.18,19 It is particularly suited for this study, given the limited prior data on frontline supervisors. Additionally, qualitative methods help mitigate biases common in Likert-style scales, where respondents may lean toward agreement, potentially skewing results.20

Inclusion Criteria

Participants were required to have served as a frontline supervisor for ≥ 6 months. Frontline supervisors are assigned responsibility for supporting staff who deliver services to VHA patients, including clinical care, dietary support, and other functions. These staff must complete baseline HRO cultural training as well as NCPS team training and are responsible for supporting quality, safety, and patient experience. Potential participants were identified from a list of frontline supervisors provided by VHA management. A subset was chosen through random sampling across geographically distributed VHA hospital facilities that vary in size and complexity. Invitations to participate in completing the questionnaire were sent via email, explaining the quality improvement initiative’s purpose, and encouraging voluntary participation. Of 2000 frontline supervisors invited to participate in the initiative, 97 completed the questionnaire. Participants represented a mix of VHA sites in terms of geography, size, and complexity.

Procedures

The authors used a qualitative approach and administered a confidential online survey. Demographic data were collected within the survey to understand characteristics of the participant population, including length of time as a frontline supervisor, facility complexity level, and professional background (clinical vs nonclinical). Survey questions were developed to elicit responses to specific areas of interest based on existing literature related to HRO and just culture.

Facilitators were defined as factors that increase the likelihood of establishing or sustaining high reliability practices and/or culture. Barriers were defined as factors that decrease or inhibit the likelihood of establishing or sustaining high reliability practices and/or culture. The questionnaire consisted of open-ended questions asking frontline supervisors to describe HRO practices and just culture at their individual facility and within their role. Participants also were asked to identify facilitators and barriers that helped or hindered their efforts to establish and maintain high reliability practices and just culture. The questionnaire solicited recommendations for additional support, training, resources, or leadership interventions to strengthen high reliability practices and just culture from each participant.

Analysis

Participant characteristics were analyzed using descriptive statistics. Responses to the 7 open-ended questions were coded and analyzed using ATLAS.ti v.24 qualitative data analysis software by an experienced researcher and coauthor. Grounded theory methodology allowed themes to emerge from the data and although the response rate was limited, the themes reached a saturation point.18,19

Ethical Considerations

Institutional review board (IRB) review and approval were not required for this quality improvement initiative. Formal IRB review and approval of a quality improvement initiative are not required by VHA. Participation was confidential and voluntary, and participants could withdraw at any time without consequences. Completion of the survey indicated consent, and facility names and participant identifiers were not used. Unique numbers were assigned to each participant and all responses were kept confidential and nonattributional. Frequency coding was used to identify the facilitators and barriers to high reliability practices implementation and just culture among frontline supervisors until thematic saturation was obtained.

Results

A total of 2000 frontline supervisors were invited to participate, of whom 97 completed the questionnaire (response rate, 4.9%). Participants were first asked to describe just culture and high reliability practices in their own words. The consensus was that a just culture emphasizes a nonpunitive environment where employees can report errors or incidents without fear of retaliation. It encourages accountability at the systems level, focusing on learning from mistakes to improve processes. In response to a question asking respondents to describe HRO practices and just culture in their own words, participants noted that organizations with a just culture promote open communication, allowing staff to discuss safety issues and concerns without fear of personal blame. Additionally, participants agreed that HRO practices were defined as a set of principles and practices aimed at minimizing errors and promoting safety, especially within complex and high-risk environments. Participants responded that key characteristics include a preoccupation with failure, sensitivity to operations, reluctance to simplify, and a commitment to resilience. HRO practices entail proactively identifying and mitigating risks through open communication and collaboration among team members, they added.

Overall, participants were aligned with their view of the role a frontline supervisor plays in supporting just culture and HRO principles at their facility by fostering open communication and psychological safety, encouraging continuous learning and improvement, and promoting team collaboration and shared accountability. Among frontline supervisors, 93 (96%) identified their role as being critical to creating a safe space and reinforcing just culture and HRO principles at their facility, while 4 (4%) failed to identify a single duty.

Identified Themes

Table 1 summarizes 6 key themes identified from participants’ responses, highlighting the most frequently cited facilitators and barriers to implementing and sustaining high reliability practices and a just culture. Table 2 shows the classification of several themes in relation to facility complexity, emphasizing leadership commitment and support as a pivotal facilitator, while listing resistance to change and entrenched attitudes as a prominent barrier.

eJustculture_T1eJustculture-T2
Role of Leadership

Facilitators. Leadership commitment and support were the most frequently identified facilitator, accounting for 44 mentions (45%). This aligns with participants’ descriptions of leadership involvement as crucial, particularly in setting standards and fostering accountability throughout the organization. For example, a frontline supervisor with < 5 years of experience from a nonclinical background at a 1B facility remarked, “Facility leadership are involved, which trickles down to lower-level leads and supervisors, which keeps everyone accountable and holds everyone to the same standards.” Participants frequently identified that leaders setting the standard and communicating expectations as paramount facilitators for strengthening high reliability practices and just culture at their facility.

Barriers. A lack of leadership commitment and support was a significant barrier, cited in 17 responses (18%). Participants described this barrier as a deficiency in follow-through, transparency, and presence, which undermines efforts to sustain just culture and high reliability principles. Notably, the lack of leadership commitment and support stood out as a distinct and recurring theme, underscoring its critical role as an independent challenge to achieving organizational goals. “Many leaders are not yet fully bought in,” a respondent explained. “They take the training and pass it off and go right back to their units and focus on blaming or chastis[ing] people for speaking up.” This theme frequently intersected with mentions of insufficient resources and entrenched attitudes, amplifying other challenges.

Open Communication and Transparency

Facilitators. Open communication and transparency were identified as facilitators in 12 responses (12%). Participants emphasized the importance of mechanisms such as HRO meetings and the sharing of “real” examples of positive outcomes from applying HRO principles. Transparent communication fosters psychological safety, allowing staff to report concerns without fear of reprisal. One participant with < 5 years of experience from a clinical background at a 1A facility encapsulated this theme by saying, “Quarterly ‘fireside chats’ are helpful, [this] creates open dialogue about where the next safety issue may occur, what staff need to do their job safely, while also imparting more of the philosophy of HRO that staff may not be aware of.”

Barriers. While communication serves as a facilitator, participants also highlighted barriers such as siloed communication and fear of reprisal. These reflect challenges in creating open and transparent feedback loops essential to high reliability. For example, a participant concluded, “Leadership does not communicate problem-solving efforts and resolution down the chain, they do not see the problems.” Another participant added, “[HRO principles] are not discussed that much.” While this theme presented as a barrier, it was noted less frequently.

Education and Training

Facilitators. Education and training were noted as facilitators in 10 responses (10%), underscoring their role in establishing high reliability practices. Participants suggested tailored training, simulation-based exercises, and mentorship to enhance practical application. However, they noted the importance of linking training to real change and ensuring leadership enforcement of learned behaviors. This theme is best represented by a participant who concluded, “Trainings have helped, but I think as a supervisor, being involved and interacting with your staff, observing, doing the work they do to help identify potential problems areas, especially when new systems are introduced are key. Being hands-on is the only way to successfully manage your team.”

Barriers. Insufficient resources, including time and staffing constraints, were identified as barriers to education and training, accounting for 24 responses (25%). Participants observed that mandatory training without mentorship or application diminishes its effectiveness.

Insufficient Resources and Funding

Barriers. Resource constraints, including low staffing levels and budget cuts, accounted for 24 responses (25%). Participants reported these limitations prevented staff from attending training and affected the overall implementation of just culture and HRO principles. “Low staffing in supporting services as well as in my own service line have created barriers,” a participant reported. Another participant responded that barriers to HRO were primarily “…financial, as the focus is how to curb costs and bring in more funding rather than taking the time to review and apply the concepts of high reliability.”

Resistance to Change and Entrenched Attitudes

Barriers. Resistance to change was the most frequently identified barrier, with 31 responses (32%). One participant described a persistent “gotcha” culture, where blame and punishment hinder progress toward just culture. This entrenched mindset creates significant obstacles to adopting HRO practices and requires active leadership and supervisor intervention to overcome. This theme is best captured by a respondent who noted that “culture change is difficult, especially among staff with such long tenure. It’s a long game.”

Synthesis and Integration of Findings

The data in Table 1 and Table 2 reinforce the themes identified in the qualitative analysis. Leadership commitment and support are pivotal, both as a facilitator and barrier. Open communication and education and training, while recognized as facilitators, were less frequently mentioned, but still critical. Resistance to change and insufficient resources were the most prominent barriers, indicating where organizational efforts should focus to further foster a culture of high reliability.

By addressing these barriers, particularly resistance to change and resource constraints, and leveraging facilitators like leadership engagement and transparent communication, organizations can enhance their implementation of just culture and high reliability practices. These efforts require deliberate strategies, including effective training, mentorship, and the active presence of leadership.

Discussion

This quality improvement initiative builds on prior research by examining the implementation of HRO practices from the perspective of frontline supervisors. Unlike earlier research focused on HRO leads, this study explores the critical role of supervisors who integrate HRO principles into clinical and administrative operations.17 By analyzing their experiences, this study offers practical insights into facilitating HRO implementation across organizational levels.

The findings highlight broad agreement on the value of just culture and HRO principles in fostering safe, accountable health care environments. Participants described just culture as promoting system—level accountability rather than individual blame, encouraging error reporting and learning for continuous improvement. Similarly, HRO practices—emphasizing a preoccupation with failure, operational sensitivity, and resilience— were seen as vital for patient safety in complex settings.

Frontline supervisors play a pivotal role, with 96% of respondents identifying their influence on fostering open communication, psychological safety, and shared accountability. Key facilitators included leadership commitment, open communication, and mentorship. Active leadership involvement was particularly valued, as it trickles down to reinforce standards across all organizational levels. HRO meetings using real-world examples were seen as instrumental in demonstrating the tangible benefits of these principles, helping embed them into daily practices.

Despite these facilitators, several barriers to implementation were noted. Resistance to change and entrenched attitudes, and a persistent gotcha culture undermined efforts to establish just culture. Resource constraints, including staffing shortages and budget limitations, further hindered the adoption of HRO practices. The lack of consistent leadership engagement, marked by limited visibility, follow-through, and transparency, exacerbated these challenges.

HRO leads are important for promoting education and embedding HRO principles into daily operations. These individuals provide vital support to frontline supervisors, translating HRO concepts into actionable practices. However, organizational challenges such as staff turnover and redirected funding have weakened the infrastructure supporting HRO initiatives. The elimination of HRO lead roles due to budgetary pressures at several facilities reflects a short-term focus on operational demands at the expense of long-term cultural transformation.

Additional barriers included siloed communication, fear of reprisal, bureaucratic obstacles, and outdated technology. These challenges limit progress toward high reliability and diminish the effectiveness of HRO principles.

Participants proposed strategies focused on education, training, and leadership engagement. Simulation-based training tailored to specific roles was identified as an effective tool for preparing staff to apply HRO principles in real-world scenarios. Enhanced communication, such as regular leadership rounding and transparent updates on safety concerns, was also emphasized. Participants stressed the importance of showing staff how their feedback influences organizational decisions to build trust and accountability. Finally, standardizing procedures and protocols across facilities was seen as critical for aligning practices and reducing variability in safety processes.

This study underscores the need for sustained leadership commitment and infrastructure to ensure the long-term success of HRO implementation. Addressing the identified barriers and leveraging the proposed mitigation strategies can foster a culture of safety and reliability across the organization.

Limitations

This quality improvement initiative used qualitative grounded theory methods and sampled a relatively small group of experienced leaders specifically involved in implementing HRO within the VHA. In addition, while saturation of themes was reached, the number of responses represents a small sample of VHA frontline supervisors. As such, the findings may not be fully representative of the perspectives of all unit and departmental leaders across the VHA or other health care systems. A previous qualitative quality improvement initiative focused on the perceptions of HRO leads regarding facilitators and barriers to just culture.17 This quality improvement initiative broadened that focus by examining the perspectives of frontline supervisors in the operational environment, who may not be HRO experts but work to implement HRO principles with the guidance of HRO leads (HRO subject matter experts).

There remains an opportunity to address a critical gap by assessing facilitators and barriers beyond the facility level, incorporating both the Veterans Integrated Service Networks (VISN) and VHA Central Office (VHACO). While qualitative methods, such as those used in this study, provide deep insights and detailed understanding, they are limited in their ability to identify system-wide trends and variations at a more strategic VISN and VHACO level. Addressing this could enhance the broader applicability of HRO principles across the VHA.

Conclusions

Successful implementation of the recommendations reported in this study will require sustained focus and continued commitment from all stakeholders across the VHA. As the VHA enters its seventh year on the HRO journey, the risk of organizational drift remains an ongoing concern. Progress has been made, as evidenced by incremental improvements in All Employee Survey scores and increased reporting of adverse events and near misses, but the challenge will be to maintain focus and continue to build upon progress amid the current climate of budgetary constraints.

This study builds on previous quality improvement efforts and provides valuable insights into the barriers and facilitators that can either hinder or support the VHA’s ongoing pursuit of high reliability. The findings offer a model for understanding the complexities of this journey—one that requires continuous effort and adaptation, as there is no definitive endpoint in the quest for high reliability.

Since completion of this study in 2024, the VHA has entered a period of organizational transition and restructuring. Such transitions are often accompanied by increased operational demands and organizational strain. These include realignments, personnel changes, staffing adjustments, workforce reductions, and continued implementation of a new electronic health record system. In this context, maintaining attention to culture, communication, frontline engagement, and mechanisms that provide visibility into organizational climate is essential to sustain momentum in high-reliability efforts.

References
  1. Cox GR, Starr LM. VHA’s movement for change: implementing high-reliability principles and practices. J Healthc Manag. 2023;68:151-157. doi:10.1097/jhm-D-23-00056
  2. Sculli GL, Pendley-Louis R, Neily J, et al. A high-reliability organization framework for health care: A multiyear implementation strategy and associated outcomes. J Patient Saf. 2022;18:64-70. doi:10.1097/pts.0000000000000788
  3. Murray JS, Clifford J, Larson S, Lee JK, Sculli GL. Implementing just culture to improve patient safety. Mil Med. 2023;188:usac115. doi:10.1093/milmed/usac115
  4. Merchant NB, O’Neal J, Montoya A, Cox GR, Murray JS. Creating a process for the implementation of tiered huddles in a Veterans Affairs Medical Center. Mil Med. 2023;188:901-906. doi:10.1093/milmed/usac073
  5. Mohr DC, Chen C, Sullivan J, et al. Development and validation of the Veterans Health Administration Patient Safety Culture Survey. J Patient Saf. 2022;18:539-545. doi:10.1097/PTS.0000000000001027
  6. Leonard C, Gilmartin H, Starr L, Anderson T. Leadership and the high reliability transformation: a qualitative study at Truman VA medical center. J Healthc Risk Manag. 2024;44:17-23. doi:10.1002/jhrm.21580
  7. Sculli G, Essen K. Soaring to Success: The Path to Developing High-Reliability Teams. HCPro; 2021.
  8. Gupta JI, Sivils S, Reppert J, Paulot W, Houchens N, Hummel S. Visual management board implementation to enhance high reliability at a large VA health care system. Fed Pract. 2024;41:242-246. doi:10.12788/fp.0507
  9. Veterans Health Administration. High Reliability Organization Learning Catalog. US Dept of Veterans Affairs; 2024. Internal document.
  10. Jahn JLS, Black AE. A model of communicative and hierarchical foundations of high reliability organizing in wildland firefighting teams. Manag Commun Q. 2017;31:356-379. doi:10.1177/0893318917691358
  11. Myers CG, Sutcliffe KM. High reliability organising in healthcare: still a long way left to go. BMJ Qual Saf. 2022;31:845-848. doi:10.1136/bmjqs-2021-014141
  12. Abrams J. Model the way to navigate difficult topics. The Learning Professional. 2022;43:14-18.
  13. McCausland T. Creating psychological safety in the workplace. Research-Technology Management. 2023;66:56-58. doi:10.1080/08956308.2023.2164439
  14. Murray JS, Kelly S, Hanover C. Promoting psychological safety in healthcare organizations. Mil Med. 2022;187:808- 810. doi:10.1093/milmed/usac041
  15. Sutton RI, Rao H. The friction project: how smart leaders make the right things easier and the wrong things harder. St. Martin’s Press; 2024.
  16. Clark TR. The 4 stages of psychological safety: defining the path to inclusion and innovation. Berrett-Koehler Publishers, Inc.; 2020.
  17. Essen K, Villalobos C, Sculli G, Steinbach L. Establishing a just culture: implications for the Veterans Health Administration journey to high reliability. Fed Pract. 2024;41:290- 297. doi:10.12788/fp.0512
  18. Creswell JW. Research design: qualitative, quantitative, and mixed methods approaches. 4th ed. SAGE Publications; 2014.
  19. Patton MQ. Qualitative research & evaluation methods: integrating theory and practice. 4th ed. SAGE Publications, Inc.; 2015.
  20. Krumpal I. Determinants of social desirability bias in sensitive surveys: a literature review. Qual Quant. 2013;47:2025- 2047. doi:10.1007/s11135-011-9640-9
References
  1. Cox GR, Starr LM. VHA’s movement for change: implementing high-reliability principles and practices. J Healthc Manag. 2023;68:151-157. doi:10.1097/jhm-D-23-00056
  2. Sculli GL, Pendley-Louis R, Neily J, et al. A high-reliability organization framework for health care: A multiyear implementation strategy and associated outcomes. J Patient Saf. 2022;18:64-70. doi:10.1097/pts.0000000000000788
  3. Murray JS, Clifford J, Larson S, Lee JK, Sculli GL. Implementing just culture to improve patient safety. Mil Med. 2023;188:usac115. doi:10.1093/milmed/usac115
  4. Merchant NB, O’Neal J, Montoya A, Cox GR, Murray JS. Creating a process for the implementation of tiered huddles in a Veterans Affairs Medical Center. Mil Med. 2023;188:901-906. doi:10.1093/milmed/usac073
  5. Mohr DC, Chen C, Sullivan J, et al. Development and validation of the Veterans Health Administration Patient Safety Culture Survey. J Patient Saf. 2022;18:539-545. doi:10.1097/PTS.0000000000001027
  6. Leonard C, Gilmartin H, Starr L, Anderson T. Leadership and the high reliability transformation: a qualitative study at Truman VA medical center. J Healthc Risk Manag. 2024;44:17-23. doi:10.1002/jhrm.21580
  7. Sculli G, Essen K. Soaring to Success: The Path to Developing High-Reliability Teams. HCPro; 2021.
  8. Gupta JI, Sivils S, Reppert J, Paulot W, Houchens N, Hummel S. Visual management board implementation to enhance high reliability at a large VA health care system. Fed Pract. 2024;41:242-246. doi:10.12788/fp.0507
  9. Veterans Health Administration. High Reliability Organization Learning Catalog. US Dept of Veterans Affairs; 2024. Internal document.
  10. Jahn JLS, Black AE. A model of communicative and hierarchical foundations of high reliability organizing in wildland firefighting teams. Manag Commun Q. 2017;31:356-379. doi:10.1177/0893318917691358
  11. Myers CG, Sutcliffe KM. High reliability organising in healthcare: still a long way left to go. BMJ Qual Saf. 2022;31:845-848. doi:10.1136/bmjqs-2021-014141
  12. Abrams J. Model the way to navigate difficult topics. The Learning Professional. 2022;43:14-18.
  13. McCausland T. Creating psychological safety in the workplace. Research-Technology Management. 2023;66:56-58. doi:10.1080/08956308.2023.2164439
  14. Murray JS, Kelly S, Hanover C. Promoting psychological safety in healthcare organizations. Mil Med. 2022;187:808- 810. doi:10.1093/milmed/usac041
  15. Sutton RI, Rao H. The friction project: how smart leaders make the right things easier and the wrong things harder. St. Martin’s Press; 2024.
  16. Clark TR. The 4 stages of psychological safety: defining the path to inclusion and innovation. Berrett-Koehler Publishers, Inc.; 2020.
  17. Essen K, Villalobos C, Sculli G, Steinbach L. Establishing a just culture: implications for the Veterans Health Administration journey to high reliability. Fed Pract. 2024;41:290- 297. doi:10.12788/fp.0512
  18. Creswell JW. Research design: qualitative, quantitative, and mixed methods approaches. 4th ed. SAGE Publications; 2014.
  19. Patton MQ. Qualitative research & evaluation methods: integrating theory and practice. 4th ed. SAGE Publications, Inc.; 2015.
  20. Krumpal I. Determinants of social desirability bias in sensitive surveys: a literature review. Qual Quant. 2013;47:2025- 2047. doi:10.1007/s11135-011-9640-9
Issue
Federal Practitioner - 43(5)
Issue
Federal Practitioner - 43(5)
Page Number
1-7
Page Number
1-7
Publications
Publications
Topics
Article Type
Display Headline

Frontline Supervisor Perspectives on Enabling High Reliability and Fostering a Just Culture at the VHA

Display Headline

Frontline Supervisor Perspectives on Enabling High Reliability and Fostering a Just Culture at the VHA

Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

Evaluation of Health Professions Trainee Experiences Transitioning to New VHA Electronic Health Record

Article Type
Changed
Display Headline

Evaluation of Health Professions Trainee Experiences Transitioning to New VHA Electronic Health Record

The Veterans Health Administration (VHA) is transitioning from its native electronic health record (EHR) Vista/Computerized Patient Record System to the commercial Cerner/Oracle Health EHR. Though this process was temporarily discontinued in April 2023 due to patient safety, usability, and reliability concerns, it resumed in April 2026. It was originally projected to cost $50 billion to implement. 1-3 As of March 9, 2024, 6 sites had transitioned to the new EHR.2 The transition is the largest of its kind in the US, offering an unparalleled opportunity to examine the effects of EHR transitions on an often overlooked part of the workforce: health professions trainees (HPTs).

HPTs serve a central role in VHA. About one-third of patients receive care directly from HPTs who make up about one-third of the VHA workforce. VHA trains > 60 clinical disciplines, comprising > 122,000 trainees annually.4,5 A paucity of literature exists exploring the experiences of HPTs during EHR transitions, and many studies are often limited to single-site or small populations. HPTs face distinct challenges and needs during EHR transitions and are particularly vulnerable to their negative impacts on retention, clinical training, and efficiency and confidence in EHR use.6-10 HPTs at VHA sites that have already transitioned to the Cerner/Oracle Health EHR identified many challenges, including significant delays in gaining EHR access, pervasive perceptions of poor training, concerns that EHR functionality issues limited patient care, and decreased ability to track clinical skill acquisition.6 These challenges may impact some HPTs more than others (eg, students on short rotations are affected more acutely by delayed EHR access and usage).

This quality improvement project evaluated HPT EHR transition experiences at the Captain James A. Lovell Federal Health Care Center (FHCC). This article contributes to the limited literature on HPT transition experiences, identifies opportunities to support HPTs, and informs broader efforts in teaching HPTs new technologies.

Methods

FHCC is jointly operated by the US Department of Defense and US Department of Veterans Affairs (VA). It treats 80,000 inpatient and outpatients annually. FHCC was the sixth VA facility to transition to the new EHR, which went live on March 9, 2024.2,11 About 700 HPTs rotate through FHCC annually. HPTs were eligible for inclusion if they were present during the March 9 transition according to a VA Office of Academic Affiliations database. A total of 216 HPTs were identified for inclusion.

Preparations for the transition included scaling down operations (ie, blocking clinician schedules, not scheduling future appointments that may conflict with the transition, making decisions on new facility- and service-line workflows, required EHR training, and speaking with support staff, including VHA National EHR Modernization Supplemental Staffing Unit [NESSU]). This evaluation was designated nonresearch/quality improvement by the VA Bedford Healthcare System Institutional Review Board.

Surveys

Forty-seven interviews were conducted with HPTs, site leaders, and supervisors from January 2024 to June 2024 (Table 1). Participants were identified by service leads and recruited via email; snowball sampling identified additional participants.

FDP04305186_T1

The evaluation team developed semistructured interview guides using grounded probes based on a pilot evaluation and existing research on EHR transitions.12 Questions focused on participant experiences preparing for the EHR transition, learning and using the site’s EHR, and the impact the transition had on clinical training experiences. Interviews were conducted at different times to capture the range of user experiences: 1 month prelaunch, 2 to 6 weeks postlaunch, and 2 months postlaunch. Interviewees were informed of participant rights and provided verbal consent.

HPTs present at FHCC at each survey’s release were emailed invitations and 2 reminders. The anonymous surveys took about 10 minutes to complete. Survey items queried HPTs about their experiences preparing to use the new EHR, perceptions of the current EHR (adapted from the System Usability Scale), satisfaction with VHA training, impact on clinical training, ability to work with preceptors and patients, and experiences with the VHA clinical learning environment (adapted from the VHA Learners Preceptor Survey).13-15 Survey questions used a 5-point Likert response scale.

Analysis

Interviewers completed postinterview summaries for team debriefing and consensus building. Interviews were coded using a priori (from piloting evaluations and relevant literature) and emergent (refined and developed from data) codes. Deductive and inductive content analyses were conducted. 16 Deductive analysis used a priori categories (eg, care coordination, EHR training). Inductive content analysis consisted of open and unstructured coding, capturing data outside a priori categories. Emergent codes captured unidentified categories. Qualitative researchers met weekly to discuss data and reach consensus on interpretation.

Descriptive analysis was conducted using top-2 box scoring (proportion responding within the 2 most favorable responses [agree/ strongly agree]). Survey data were analyzed in SAS.17 The analysis used a merging approach on simultaneously collected qualitative and quantitative data to reach findings consensus.18

Researcher and research team decisions may shape the data collected due to prior assumptions and experience.19 This analysis attempted to integrate reflexivity practices to enhance awareness of the researchers’ assumptions and positionality, including by integrating intent collaborative conversing and memorandum writing into the processes.20,21

Results

This analysis created a survey and fielded responses from HPTs present at FHCC across 3 time points (6 months prelaunch, 1 month prelaunch, and 2 months postlaunch), resulting in a total of 103 responses and an average response rate of 19.0% (Table 2). Six key findings were identified in analysis of responses: (1) critiques of transition management; (2) concerns with training; (3) hope about the EHR; (4) at-the-elbow support was essential; (5) HPTs adjusted to, and later preferred, the new EHR; and (6) transition impacted clinical training, but not overall career plans for HPTs. Findings are presented in this section, with illustrative quantitative data and qualitative data quotes available in the eAppendix.

FDP04305186_T2
Critiques of the Transition’s Management

While participants were aware of the transition to the new EHR, most felt they did not have enough information or time to prepare for it, indicating it was “too little, too late.” HPTs felt necessary workflow processes for Cerner/Oracle Health were not determined with enough time to learn them prior to transition. Supervisors shared that important workflow and onboarding decisions remained undecided mere weeks before the transition. Some service lines did not decrease patient loads until right before the transition, making it difficult to manage their schedules and resulting in insufficient time to learn the new EHR.

EHR Training Concerns

Overall, HPTs expressed low satisfaction with computer-based Training Management System (TMS) EHR training, believing it did not prepare them for the new EHR. The percentage of HPTs satisfied or very satisfied with the quality of TMS training was lower than that of instructor-based training pre- and posttransition, with 50% of 36 prelaunch respondents, and 43% of 29 postlaunch respondents expressing satisfaction with computer-based trainings (Figure 1). HPTs were dissatisfied with the training content. They felt it was too general and failed to teach basic tasks in the workflow for their service areas and roles, such as writing a note or order. Furthermore, poor content was exacerbated by poor and unengaging instruction, and HPTs were dissatisfied with the practice EHR used in training, which glitched frequently.

FDP04305186_F1
FIGURE 1. Health professions trainees satisfied/very satisfied with
quality of electronic health record training.
EHR Transition Optimism

Even though the transition was stressful, most HPTs hoped it would be a temporary disruption and that they would quickly adjust to the new EHR. Many participants expected that once they switched to the new EHR, they would pick it up quickly. In addition, many anticipated Cerner/Oracle Health would be better and easier to use in the long run.

At-The-Elbow Support Essential

VHA peer support with NESSU was highly valued among HPTs. NESSU staff were highly knowledgeable and could provide both broad and service-line-specific support. NESSU provided prompt answers to EHR questions. This was particularly critical as other forms of in-person support were often inaccessible or absent during the transition.

HPTs found facility support helpful: 85% of 36 respondents reported being satisfied/ very satisfied with support from supervisors and preceptors, and 84% of 36 respondents were satisfied/very satisfied with technical support from facility informatics staff pretransition (n = 36) (Figure 2). NESSU and supervisor support with daily workflows were particularly helpful, as pretransition training only provided a general introduction to the EHR.

FDP04305186_F2
FIGURE 2. Health professions trainees satisfaction with electronic
health record training.
 
 
HPTs Adjusted to and Later Preferred the New EHR

The EHR learning experience was intense but short, with many HPTs feeling able to use it only 2 to 4 weeks posttransition. Confidence grew as HPTs came to view Cerner/Oracle Health as a more integrated and intuitive system than the previous EHR. Most participants preferred the new EHR, even if they criticized some features (eg, no group documentation capabilities). Survey participants frequently rated Cerner/Oracle Health usability higher than the original. A total of 32% of 29 posttransition respondents agreed or strongly agreed that Cerner/Oracle Health helps prevent situations that can lead to patient safety risks—higher than pretransition rates. Additionally, fewer respondents found the new EHR unnecessarily complex or thought it contained too many alerts and flags compared to the original EHR (Figure 3).

FDP04305186_F3
FIGURE 3. Health professions trainees perceptions of new electronic
health record usability.
 
 
Impact on Clinical Training, Not Career Plans

The extensive time and energy the transition demanded of HPTs caused stress and affected their clinical training. Many believed they would have learned more if their training had happened outside the transition.

Concerns that the transition affected learning were most acutely felt pretransition. HPTs reporting that EHR implementation positively affected their clinical education fell from 38% of 36 respondents 6 months pretransition to 19% of 29 respondents 1 month pretransition, but returned to 37% posttransition (Figure 4). However, some HPTs believed there was a silver lining: it provided a learning experience they otherwise would not have had.

FDP04305186_F4
FIGURE 4. Health professions trainees perceptions of training for
new Veterans Health Administration (VHA) electronic health record.

 

 

HPTs who believed the transition positively impacted their likelihood of pursuing future career opportunities within the VHA rose to 33% of 29 respondents posttransition. Overall, Cerner/Oracle Health was characterized as a tool: something used in training, but not something that precluded wanting VHA careers or having meaningful experiences, such as caring for patients.

Discussion

This evaluation addressed an underexplored aspect of EHR transitions: their impact on HPTs. It identified HPT challenges, including dissatisfaction with poor transition preparation and EHR training experiences. Promising findings include positive experiences with transition support, EHR uptake, and overall positive educational experiences despite the transition’s disruption.

When EHR users, including HPTs, are dissatisfied with transition preparations, consequent stress can lead to undesired effects, including increased burnout, inappropriate EHR use, and low work satisfaction.22-24 Negative EHR transition experiences shape HPTs’ subsequent EHR adoption, user satisfaction, as well as confidence and career intent.3,25,26 Health systems have strong incentives to implement effective transition change management.

HPTs at previous VHA EHR transition sites reported significantly more disruption to their clinical training compared with HPTs at FHCC. Academic programs were shut down at the first transition site, and HPTs expressed decreased interest in VHA careers at another, even a year posttransition.6,27 These findings are consistent with the limited literature on the adverse impacts that EHR transitions have on HPTs.7,28

HPT retention is critical. VA is mandated to prepare the next generation of HPTs for its needs, and those of the nation. The VA relies heavily on HPT retention to recruit clinicians: > 65% of VHA physicians nationwide participated in VHA training programs prior to recruitment into staff positions.5,29

VHA should invest in transition change management with demonstrated, positive impacts on HPTs, such as in-house support from clinicians. Previous research found that lack of support was a major source of stress and negative outcomes.6,27 Consequently, supporting HPTs through EHR transitions directly contributes to the VHA’s ability to attract high-quality staff from its HPTs. The challenges and promising practices described in this analysis underscore the necessity of understanding how all EHR users are affected by transitions. What happens to them has direct implications for the VA mission to provide safe, efficient care, and its mandate to provide quality clinical training to HPTs.

These findings hold hopeful implications for supporting HPT EHR use, both during and outside EHR transitions. HPTs expressing that an EHR is only 1 part of their clinical training experience suggests that change management can improve EHR transitions. HPT learning can enhance known factors that are important for HPTs in clinical training, including the health care organization’s mission, caring for patients, and personal development.

Further investigations may engage HPTs at future VHA sites making the transition to the new EHR. One focus would involve applying a learning health systems framework to examine the nature of change management efforts—and their effects on HPT transition experiences—iteratively across transition sites to evaluate the effect of the efforts. Another focus may be longitudinal engagement with HPTs at health care systems and sites transitioning to new EHRs. Research has found that disruptions to EHR usability, satisfaction, and care provision can persist for 2 years and beyond following an EHR transition.30 Evaluating the long-term effects of transitions on HPTs is of interest, given their distinct characteristics and differences from employees.

Limitations

Study data came from voluntary participants at 1 highly engaged site, raising the possibility of self-selection bias. HPT experiences at other VA and non-VA sites may differ. Employees and HPTs were engaged during a high-stress event; snowballing recruitment reach was limited by high workloads and limited time for engagement. Statistical data were descriptive and should not be interpreted as causal. Results may reflect, in part, temporal effects, and respondents include HPTs at different stages of training and with different levels of VA experience. Survey sample sizes may limit generalizability; however, merging data streams strengthened the reliability of findings.

Conclusions

The results of this analysis of FHCC HPTs were notably more positive than those of HPTs at previous VHA EHR transition sites. VHA is one of many health care systems that provide clinical training for HPTs and relies on this population to provide patient care. By highlighting challenges and positive experiences of HPTs during an EHR transition, this evaluation produces actionable insights that can inform the actions of health care systems seeking to support HPTs during disruptive EHR transitions.

References
  1. US Department of Veterans Affairs Office of the Inspector General. VA needs to strengthen controls to address electronic health record system major performance incidents. September 23, 2024. Accessed February 3, 2026. https://www.vaoig.gov/sites/default/files /reports/2024-09/vaoig-22-03591-231.pdf
  2. EHR deployment schedule. VA EHR Modernization. Updated February 2, 2026. Accessed February 3, 2026. https://digital.va.gov/ehr-modernization/ehr-deployment -schedule/
  3. Heckman J. VA in 2026 looks to get EHR rollout back on track, embark on health care reorganization. Federal News Network. December 24, 2025. Accessed February 3, 2026. https://federalnewsnetwork.com/veterans-affairs/2025/12 /va-in-2026-looks-to-get-ehr-rollout-back-on-track -embark-on-health-care-reorganization/
  4. US Department of Veterans Affairs Office of Academic Affiliations. Medical and dental education. Updated September 12, 2025. Accessed February 3, 2026. https://department.va.gov/academic-affiliations /medical-and-dental/
  5. Functions of Veterans Health Administration: health-care personnel education and training programs. 38 U.S.C. § 7302 (2026). Accessed February 3, 2026. https://uscode.house.gov/view.xhtml ?req=(title:38%20section:7302%20edition:prelim)
  6. Ahlness EA, Molloy-Paolillo BK, Brunner J, et al. Impacts of an electronic health record transition on Veterans Health Administration health professions trainee experience. J Gen Intern Med. 2023;38:1031-1039. doi:10.1007/s11606-023-08283-4
  7. Roberts DL, Mishark KJ, Alessandro STD, et al. Impact of electronic medical record transitions on the educational experiences of medical students. J Health Care Finance. 2014;41:1-5.
  8. Varpio L, Day K, Elliot‐Miller P, et al. The impact of adopting EHRs: how losing connectivity affects clinical reasoning. Med Educ. 2015;49:476-486. doi:10.1111/medu.12665
  9. Gali HE, Baxter SL, Lander L, et al. Impact of electronic health record implementation on ophthalmology trainee time expenditures. J Acad Ophthalmol (2017). 2019;11:e65-e72. doi:10.1055/s-0039-3401986
  10. Humphrey‐Murto S, Makus D, Moore S, et al. Training physicians and residents for the use of electronic health records— a comparative case study between two hospitals. Med Educ. 2023;57:337-348. doi:10.1111/medu.14944
  11. US Department of Defense. Captain James A. Lovell Federal Health Care Center: readying warriors & caring for heroes. Presentation August 10, 2022.
  12. Sayre G, Young J. Beyond openended questions: purposeful interview guide development to elicit rich, trustworthy data. Patient Aligned Care Teams (PACT) Demonstration Labs cyber seminar. March 21, 2018. Accessed February 3, 2026. https://www.hsrd.research.va.gov/for _researchers/cyber_seminars/catalog/transcripts/2439.doc
  13. Jordan PW, Thomas B, McClelland IL, Weerdmeester B, eds. Usability Evaluation In Industry. CRC Press; 1996.
  14. Keitz SA, Holland GJ, Melander EH, et al. The Veterans Affairs Learners’ Perceptions Survey: the foundation for educational quality improvement. Acad Med. 2003;78:910- 917. doi:10.1097/00001888-200309000-00016
  15. Byrne JM, Chang BK, Gilman SC, et al. The learners’ perceptions survey—primary care: assessing resident perceptions of internal medicine continuity clinics and patient- centered care. J Grad Med Educ. 2013;5:587-593. doi:10.4300/JGME-D-12-00233.1
  16. Elo S, Kyngäs H. The qualitative content analysis process. J Adv Nurs. 2008;62:107-115. doi:10.1111/j.1365-2648.2007.04569.x
  17. Siller AB, Tompkins L. The big four: analyzing complex sample survey data using SAS, SPSS, STATA, and SUDAAN. Poster presented at: 31st Annual SAS Users Group International Conference; March 27, 2006; San Francisco, CA. Accessed February 3, 2026. https://support.sas.com /resources/papers/proceedings/proceedings/sugi31/172 -31.pdf
  18. Tashakkori A, Johnson RB, Teddlie C. Foundations of Mixed Methods Research: Integrating Quantitative and Qualitative Approaches in the Social and Behavioral Sciences. 2nd ed. SAGE Publications, Inc.; 2020.
  19. Olmos-Vega FM, Stalmeijer RE, Varpio L, et al. A practical guide to reflexivity in qualitative research: AMEE Guide No. 149. Med Teach. 2023;45:241-251. doi:10.1080/0142159X.2022.2057287
  20. Mezirow J. Fostering Critical Reflection in Adulthood: A Guide to Transformative and Emancipatory Learning. JosseyBass; 1991.
  21. Probst B, Berenson L. The double arrow: how qualitative social work researchers use reflexivity. Qual Soc Work. 2014;13:813-827. doi:10.1177/1473325013506248
  22. Huang C, Koppel R, McGreevey JD 3rd, et al. Transitions from one electronic health record to another: challenges, pitfalls, and recommendations. Appl Clin Infor. 2020;11:742-754. doi:10.1055/s-0040-1718535
  23. Zheng K, Abraham J, Novak LL, et al. A survey of the literature on unintended consequences associated with health information technology: 2014–2015. Yearb Med Inform. 2016;25:13-29. doi:10.15265/IY-2016-036
  24. Campbell EM, Sittig DF, Ash JS, et al. Types of unintended consequences related to computerized provider order entry. J Am Med Inform Assoc. 2006;13:547-556. doi:10.1197/jamia.M2042
  25. Sittig DF, Lakhani P, Singh H. Applying requisite imagination to safeguard electronic health record transitions. JAMA. 2022;29:1014-1018. doi:10.1093/jamia/ocab291
  26. Ko HH, Lee TK, Leung Y, et al. Factors influencing career choices made by medical students, residents, and practising physicians. B C Med J. 2007;49:482-489.
  27. Brunner J, Ahlness EA, Anderson E, et al. VA’s EHR transition and health professions trainee programs: findings and impacts of a multistakeholder learning community. Learn Health Sys. 2024;9:e10460. doi:10.1002/lrh2.10460
  28. Rosdahl JA, Rudd M, Benjamin R, et al. Effect of the adoption of a comprehensive electronic health record on graduate medical education: perceptions of faculty and trainees. South Med J. 2018;111:476-483. doi:10.14423/SMJ.0000000000000847
  29. Hill C. U.S. Medical education at VA: it’s all about the veterans. VA News. August 18, 2021. Accessed February 3, 2026. https://news.va.gov/93370/medical-education-at-va -its-all-about-the-veterans
  30. Hanauer DA, Branford GL, Greenberg G, et al. Twoyear longitudinal assessment of physicians’ perceptions after replacement of a longstanding homegrown electronic health record: does a J-curve of satisfaction really exist? J Am Med Inform Assoc. 2017;24:e157-e165. doi:10.1093/jamia/ocw077
Article PDF
Author and Disclosure Information

Ellen A. Ahlness, PhDa,b; George Sayre, PsyDa,b; Erin Matteau, DPT, CHESc; Edward Walton, MD, MHPEc; Seppo Rinne, MD, PhDd,e

Author affiliations
aSeattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care, Washington
bUniversity of Washington School of Public Health, Seattle
cVeterans Affairs Office of Academic Affiliations, Washington, DC
dVeterans Affairs Bedford Healthcare System, Massachusetts
eGeisel School of Medicine at Dartmouth, Hanover, New Hampshire

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Disclaimer The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies.

Ethics and consent This evaluation was designated as nonresearch/quality improvement by the Veterans Affairs Bedford Healthcare System Institutional Review Board.

Funding This work was supported by funding from the US Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development Quality Enhancement Research Initiative (QUERI) (PEC 21-280) and the Office of Academic Affiliations.

Correspondence: Ellen Ahlness (ellen.a.ahlnessabdul muminov@va.gov)

Fed Pract. 2026;43(5). Published online May 15. doi:10.12788/fp.0682

Issue
Federal Practitioner - 43(5)
Publications
Topics
Page Number
186-192
Sections
Author and Disclosure Information

Ellen A. Ahlness, PhDa,b; George Sayre, PsyDa,b; Erin Matteau, DPT, CHESc; Edward Walton, MD, MHPEc; Seppo Rinne, MD, PhDd,e

Author affiliations
aSeattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care, Washington
bUniversity of Washington School of Public Health, Seattle
cVeterans Affairs Office of Academic Affiliations, Washington, DC
dVeterans Affairs Bedford Healthcare System, Massachusetts
eGeisel School of Medicine at Dartmouth, Hanover, New Hampshire

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Disclaimer The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies.

Ethics and consent This evaluation was designated as nonresearch/quality improvement by the Veterans Affairs Bedford Healthcare System Institutional Review Board.

Funding This work was supported by funding from the US Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development Quality Enhancement Research Initiative (QUERI) (PEC 21-280) and the Office of Academic Affiliations.

Correspondence: Ellen Ahlness (ellen.a.ahlnessabdul muminov@va.gov)

Fed Pract. 2026;43(5). Published online May 15. doi:10.12788/fp.0682

Author and Disclosure Information

Ellen A. Ahlness, PhDa,b; George Sayre, PsyDa,b; Erin Matteau, DPT, CHESc; Edward Walton, MD, MHPEc; Seppo Rinne, MD, PhDd,e

Author affiliations
aSeattle-Denver Center of Innovation for Veteran-Centered and Value-Driven Care, Washington
bUniversity of Washington School of Public Health, Seattle
cVeterans Affairs Office of Academic Affiliations, Washington, DC
dVeterans Affairs Bedford Healthcare System, Massachusetts
eGeisel School of Medicine at Dartmouth, Hanover, New Hampshire

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Disclaimer The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies.

Ethics and consent This evaluation was designated as nonresearch/quality improvement by the Veterans Affairs Bedford Healthcare System Institutional Review Board.

Funding This work was supported by funding from the US Department of Veterans Affairs, Veterans Health Administration, Health Services Research & Development Quality Enhancement Research Initiative (QUERI) (PEC 21-280) and the Office of Academic Affiliations.

Correspondence: Ellen Ahlness (ellen.a.ahlnessabdul muminov@va.gov)

Fed Pract. 2026;43(5). Published online May 15. doi:10.12788/fp.0682

Article PDF
Article PDF

The Veterans Health Administration (VHA) is transitioning from its native electronic health record (EHR) Vista/Computerized Patient Record System to the commercial Cerner/Oracle Health EHR. Though this process was temporarily discontinued in April 2023 due to patient safety, usability, and reliability concerns, it resumed in April 2026. It was originally projected to cost $50 billion to implement. 1-3 As of March 9, 2024, 6 sites had transitioned to the new EHR.2 The transition is the largest of its kind in the US, offering an unparalleled opportunity to examine the effects of EHR transitions on an often overlooked part of the workforce: health professions trainees (HPTs).

HPTs serve a central role in VHA. About one-third of patients receive care directly from HPTs who make up about one-third of the VHA workforce. VHA trains > 60 clinical disciplines, comprising > 122,000 trainees annually.4,5 A paucity of literature exists exploring the experiences of HPTs during EHR transitions, and many studies are often limited to single-site or small populations. HPTs face distinct challenges and needs during EHR transitions and are particularly vulnerable to their negative impacts on retention, clinical training, and efficiency and confidence in EHR use.6-10 HPTs at VHA sites that have already transitioned to the Cerner/Oracle Health EHR identified many challenges, including significant delays in gaining EHR access, pervasive perceptions of poor training, concerns that EHR functionality issues limited patient care, and decreased ability to track clinical skill acquisition.6 These challenges may impact some HPTs more than others (eg, students on short rotations are affected more acutely by delayed EHR access and usage).

This quality improvement project evaluated HPT EHR transition experiences at the Captain James A. Lovell Federal Health Care Center (FHCC). This article contributes to the limited literature on HPT transition experiences, identifies opportunities to support HPTs, and informs broader efforts in teaching HPTs new technologies.

Methods

FHCC is jointly operated by the US Department of Defense and US Department of Veterans Affairs (VA). It treats 80,000 inpatient and outpatients annually. FHCC was the sixth VA facility to transition to the new EHR, which went live on March 9, 2024.2,11 About 700 HPTs rotate through FHCC annually. HPTs were eligible for inclusion if they were present during the March 9 transition according to a VA Office of Academic Affiliations database. A total of 216 HPTs were identified for inclusion.

Preparations for the transition included scaling down operations (ie, blocking clinician schedules, not scheduling future appointments that may conflict with the transition, making decisions on new facility- and service-line workflows, required EHR training, and speaking with support staff, including VHA National EHR Modernization Supplemental Staffing Unit [NESSU]). This evaluation was designated nonresearch/quality improvement by the VA Bedford Healthcare System Institutional Review Board.

Surveys

Forty-seven interviews were conducted with HPTs, site leaders, and supervisors from January 2024 to June 2024 (Table 1). Participants were identified by service leads and recruited via email; snowball sampling identified additional participants.

FDP04305186_T1

The evaluation team developed semistructured interview guides using grounded probes based on a pilot evaluation and existing research on EHR transitions.12 Questions focused on participant experiences preparing for the EHR transition, learning and using the site’s EHR, and the impact the transition had on clinical training experiences. Interviews were conducted at different times to capture the range of user experiences: 1 month prelaunch, 2 to 6 weeks postlaunch, and 2 months postlaunch. Interviewees were informed of participant rights and provided verbal consent.

HPTs present at FHCC at each survey’s release were emailed invitations and 2 reminders. The anonymous surveys took about 10 minutes to complete. Survey items queried HPTs about their experiences preparing to use the new EHR, perceptions of the current EHR (adapted from the System Usability Scale), satisfaction with VHA training, impact on clinical training, ability to work with preceptors and patients, and experiences with the VHA clinical learning environment (adapted from the VHA Learners Preceptor Survey).13-15 Survey questions used a 5-point Likert response scale.

Analysis

Interviewers completed postinterview summaries for team debriefing and consensus building. Interviews were coded using a priori (from piloting evaluations and relevant literature) and emergent (refined and developed from data) codes. Deductive and inductive content analyses were conducted. 16 Deductive analysis used a priori categories (eg, care coordination, EHR training). Inductive content analysis consisted of open and unstructured coding, capturing data outside a priori categories. Emergent codes captured unidentified categories. Qualitative researchers met weekly to discuss data and reach consensus on interpretation.

Descriptive analysis was conducted using top-2 box scoring (proportion responding within the 2 most favorable responses [agree/ strongly agree]). Survey data were analyzed in SAS.17 The analysis used a merging approach on simultaneously collected qualitative and quantitative data to reach findings consensus.18

Researcher and research team decisions may shape the data collected due to prior assumptions and experience.19 This analysis attempted to integrate reflexivity practices to enhance awareness of the researchers’ assumptions and positionality, including by integrating intent collaborative conversing and memorandum writing into the processes.20,21

Results

This analysis created a survey and fielded responses from HPTs present at FHCC across 3 time points (6 months prelaunch, 1 month prelaunch, and 2 months postlaunch), resulting in a total of 103 responses and an average response rate of 19.0% (Table 2). Six key findings were identified in analysis of responses: (1) critiques of transition management; (2) concerns with training; (3) hope about the EHR; (4) at-the-elbow support was essential; (5) HPTs adjusted to, and later preferred, the new EHR; and (6) transition impacted clinical training, but not overall career plans for HPTs. Findings are presented in this section, with illustrative quantitative data and qualitative data quotes available in the eAppendix.

FDP04305186_T2
Critiques of the Transition’s Management

While participants were aware of the transition to the new EHR, most felt they did not have enough information or time to prepare for it, indicating it was “too little, too late.” HPTs felt necessary workflow processes for Cerner/Oracle Health were not determined with enough time to learn them prior to transition. Supervisors shared that important workflow and onboarding decisions remained undecided mere weeks before the transition. Some service lines did not decrease patient loads until right before the transition, making it difficult to manage their schedules and resulting in insufficient time to learn the new EHR.

EHR Training Concerns

Overall, HPTs expressed low satisfaction with computer-based Training Management System (TMS) EHR training, believing it did not prepare them for the new EHR. The percentage of HPTs satisfied or very satisfied with the quality of TMS training was lower than that of instructor-based training pre- and posttransition, with 50% of 36 prelaunch respondents, and 43% of 29 postlaunch respondents expressing satisfaction with computer-based trainings (Figure 1). HPTs were dissatisfied with the training content. They felt it was too general and failed to teach basic tasks in the workflow for their service areas and roles, such as writing a note or order. Furthermore, poor content was exacerbated by poor and unengaging instruction, and HPTs were dissatisfied with the practice EHR used in training, which glitched frequently.

FDP04305186_F1
FIGURE 1. Health professions trainees satisfied/very satisfied with
quality of electronic health record training.
EHR Transition Optimism

Even though the transition was stressful, most HPTs hoped it would be a temporary disruption and that they would quickly adjust to the new EHR. Many participants expected that once they switched to the new EHR, they would pick it up quickly. In addition, many anticipated Cerner/Oracle Health would be better and easier to use in the long run.

At-The-Elbow Support Essential

VHA peer support with NESSU was highly valued among HPTs. NESSU staff were highly knowledgeable and could provide both broad and service-line-specific support. NESSU provided prompt answers to EHR questions. This was particularly critical as other forms of in-person support were often inaccessible or absent during the transition.

HPTs found facility support helpful: 85% of 36 respondents reported being satisfied/ very satisfied with support from supervisors and preceptors, and 84% of 36 respondents were satisfied/very satisfied with technical support from facility informatics staff pretransition (n = 36) (Figure 2). NESSU and supervisor support with daily workflows were particularly helpful, as pretransition training only provided a general introduction to the EHR.

FDP04305186_F2
FIGURE 2. Health professions trainees satisfaction with electronic
health record training.
 
 
HPTs Adjusted to and Later Preferred the New EHR

The EHR learning experience was intense but short, with many HPTs feeling able to use it only 2 to 4 weeks posttransition. Confidence grew as HPTs came to view Cerner/Oracle Health as a more integrated and intuitive system than the previous EHR. Most participants preferred the new EHR, even if they criticized some features (eg, no group documentation capabilities). Survey participants frequently rated Cerner/Oracle Health usability higher than the original. A total of 32% of 29 posttransition respondents agreed or strongly agreed that Cerner/Oracle Health helps prevent situations that can lead to patient safety risks—higher than pretransition rates. Additionally, fewer respondents found the new EHR unnecessarily complex or thought it contained too many alerts and flags compared to the original EHR (Figure 3).

FDP04305186_F3
FIGURE 3. Health professions trainees perceptions of new electronic
health record usability.
 
 
Impact on Clinical Training, Not Career Plans

The extensive time and energy the transition demanded of HPTs caused stress and affected their clinical training. Many believed they would have learned more if their training had happened outside the transition.

Concerns that the transition affected learning were most acutely felt pretransition. HPTs reporting that EHR implementation positively affected their clinical education fell from 38% of 36 respondents 6 months pretransition to 19% of 29 respondents 1 month pretransition, but returned to 37% posttransition (Figure 4). However, some HPTs believed there was a silver lining: it provided a learning experience they otherwise would not have had.

FDP04305186_F4
FIGURE 4. Health professions trainees perceptions of training for
new Veterans Health Administration (VHA) electronic health record.

 

 

HPTs who believed the transition positively impacted their likelihood of pursuing future career opportunities within the VHA rose to 33% of 29 respondents posttransition. Overall, Cerner/Oracle Health was characterized as a tool: something used in training, but not something that precluded wanting VHA careers or having meaningful experiences, such as caring for patients.

Discussion

This evaluation addressed an underexplored aspect of EHR transitions: their impact on HPTs. It identified HPT challenges, including dissatisfaction with poor transition preparation and EHR training experiences. Promising findings include positive experiences with transition support, EHR uptake, and overall positive educational experiences despite the transition’s disruption.

When EHR users, including HPTs, are dissatisfied with transition preparations, consequent stress can lead to undesired effects, including increased burnout, inappropriate EHR use, and low work satisfaction.22-24 Negative EHR transition experiences shape HPTs’ subsequent EHR adoption, user satisfaction, as well as confidence and career intent.3,25,26 Health systems have strong incentives to implement effective transition change management.

HPTs at previous VHA EHR transition sites reported significantly more disruption to their clinical training compared with HPTs at FHCC. Academic programs were shut down at the first transition site, and HPTs expressed decreased interest in VHA careers at another, even a year posttransition.6,27 These findings are consistent with the limited literature on the adverse impacts that EHR transitions have on HPTs.7,28

HPT retention is critical. VA is mandated to prepare the next generation of HPTs for its needs, and those of the nation. The VA relies heavily on HPT retention to recruit clinicians: > 65% of VHA physicians nationwide participated in VHA training programs prior to recruitment into staff positions.5,29

VHA should invest in transition change management with demonstrated, positive impacts on HPTs, such as in-house support from clinicians. Previous research found that lack of support was a major source of stress and negative outcomes.6,27 Consequently, supporting HPTs through EHR transitions directly contributes to the VHA’s ability to attract high-quality staff from its HPTs. The challenges and promising practices described in this analysis underscore the necessity of understanding how all EHR users are affected by transitions. What happens to them has direct implications for the VA mission to provide safe, efficient care, and its mandate to provide quality clinical training to HPTs.

These findings hold hopeful implications for supporting HPT EHR use, both during and outside EHR transitions. HPTs expressing that an EHR is only 1 part of their clinical training experience suggests that change management can improve EHR transitions. HPT learning can enhance known factors that are important for HPTs in clinical training, including the health care organization’s mission, caring for patients, and personal development.

Further investigations may engage HPTs at future VHA sites making the transition to the new EHR. One focus would involve applying a learning health systems framework to examine the nature of change management efforts—and their effects on HPT transition experiences—iteratively across transition sites to evaluate the effect of the efforts. Another focus may be longitudinal engagement with HPTs at health care systems and sites transitioning to new EHRs. Research has found that disruptions to EHR usability, satisfaction, and care provision can persist for 2 years and beyond following an EHR transition.30 Evaluating the long-term effects of transitions on HPTs is of interest, given their distinct characteristics and differences from employees.

Limitations

Study data came from voluntary participants at 1 highly engaged site, raising the possibility of self-selection bias. HPT experiences at other VA and non-VA sites may differ. Employees and HPTs were engaged during a high-stress event; snowballing recruitment reach was limited by high workloads and limited time for engagement. Statistical data were descriptive and should not be interpreted as causal. Results may reflect, in part, temporal effects, and respondents include HPTs at different stages of training and with different levels of VA experience. Survey sample sizes may limit generalizability; however, merging data streams strengthened the reliability of findings.

Conclusions

The results of this analysis of FHCC HPTs were notably more positive than those of HPTs at previous VHA EHR transition sites. VHA is one of many health care systems that provide clinical training for HPTs and relies on this population to provide patient care. By highlighting challenges and positive experiences of HPTs during an EHR transition, this evaluation produces actionable insights that can inform the actions of health care systems seeking to support HPTs during disruptive EHR transitions.

The Veterans Health Administration (VHA) is transitioning from its native electronic health record (EHR) Vista/Computerized Patient Record System to the commercial Cerner/Oracle Health EHR. Though this process was temporarily discontinued in April 2023 due to patient safety, usability, and reliability concerns, it resumed in April 2026. It was originally projected to cost $50 billion to implement. 1-3 As of March 9, 2024, 6 sites had transitioned to the new EHR.2 The transition is the largest of its kind in the US, offering an unparalleled opportunity to examine the effects of EHR transitions on an often overlooked part of the workforce: health professions trainees (HPTs).

HPTs serve a central role in VHA. About one-third of patients receive care directly from HPTs who make up about one-third of the VHA workforce. VHA trains > 60 clinical disciplines, comprising > 122,000 trainees annually.4,5 A paucity of literature exists exploring the experiences of HPTs during EHR transitions, and many studies are often limited to single-site or small populations. HPTs face distinct challenges and needs during EHR transitions and are particularly vulnerable to their negative impacts on retention, clinical training, and efficiency and confidence in EHR use.6-10 HPTs at VHA sites that have already transitioned to the Cerner/Oracle Health EHR identified many challenges, including significant delays in gaining EHR access, pervasive perceptions of poor training, concerns that EHR functionality issues limited patient care, and decreased ability to track clinical skill acquisition.6 These challenges may impact some HPTs more than others (eg, students on short rotations are affected more acutely by delayed EHR access and usage).

This quality improvement project evaluated HPT EHR transition experiences at the Captain James A. Lovell Federal Health Care Center (FHCC). This article contributes to the limited literature on HPT transition experiences, identifies opportunities to support HPTs, and informs broader efforts in teaching HPTs new technologies.

Methods

FHCC is jointly operated by the US Department of Defense and US Department of Veterans Affairs (VA). It treats 80,000 inpatient and outpatients annually. FHCC was the sixth VA facility to transition to the new EHR, which went live on March 9, 2024.2,11 About 700 HPTs rotate through FHCC annually. HPTs were eligible for inclusion if they were present during the March 9 transition according to a VA Office of Academic Affiliations database. A total of 216 HPTs were identified for inclusion.

Preparations for the transition included scaling down operations (ie, blocking clinician schedules, not scheduling future appointments that may conflict with the transition, making decisions on new facility- and service-line workflows, required EHR training, and speaking with support staff, including VHA National EHR Modernization Supplemental Staffing Unit [NESSU]). This evaluation was designated nonresearch/quality improvement by the VA Bedford Healthcare System Institutional Review Board.

Surveys

Forty-seven interviews were conducted with HPTs, site leaders, and supervisors from January 2024 to June 2024 (Table 1). Participants were identified by service leads and recruited via email; snowball sampling identified additional participants.

FDP04305186_T1

The evaluation team developed semistructured interview guides using grounded probes based on a pilot evaluation and existing research on EHR transitions.12 Questions focused on participant experiences preparing for the EHR transition, learning and using the site’s EHR, and the impact the transition had on clinical training experiences. Interviews were conducted at different times to capture the range of user experiences: 1 month prelaunch, 2 to 6 weeks postlaunch, and 2 months postlaunch. Interviewees were informed of participant rights and provided verbal consent.

HPTs present at FHCC at each survey’s release were emailed invitations and 2 reminders. The anonymous surveys took about 10 minutes to complete. Survey items queried HPTs about their experiences preparing to use the new EHR, perceptions of the current EHR (adapted from the System Usability Scale), satisfaction with VHA training, impact on clinical training, ability to work with preceptors and patients, and experiences with the VHA clinical learning environment (adapted from the VHA Learners Preceptor Survey).13-15 Survey questions used a 5-point Likert response scale.

Analysis

Interviewers completed postinterview summaries for team debriefing and consensus building. Interviews were coded using a priori (from piloting evaluations and relevant literature) and emergent (refined and developed from data) codes. Deductive and inductive content analyses were conducted. 16 Deductive analysis used a priori categories (eg, care coordination, EHR training). Inductive content analysis consisted of open and unstructured coding, capturing data outside a priori categories. Emergent codes captured unidentified categories. Qualitative researchers met weekly to discuss data and reach consensus on interpretation.

Descriptive analysis was conducted using top-2 box scoring (proportion responding within the 2 most favorable responses [agree/ strongly agree]). Survey data were analyzed in SAS.17 The analysis used a merging approach on simultaneously collected qualitative and quantitative data to reach findings consensus.18

Researcher and research team decisions may shape the data collected due to prior assumptions and experience.19 This analysis attempted to integrate reflexivity practices to enhance awareness of the researchers’ assumptions and positionality, including by integrating intent collaborative conversing and memorandum writing into the processes.20,21

Results

This analysis created a survey and fielded responses from HPTs present at FHCC across 3 time points (6 months prelaunch, 1 month prelaunch, and 2 months postlaunch), resulting in a total of 103 responses and an average response rate of 19.0% (Table 2). Six key findings were identified in analysis of responses: (1) critiques of transition management; (2) concerns with training; (3) hope about the EHR; (4) at-the-elbow support was essential; (5) HPTs adjusted to, and later preferred, the new EHR; and (6) transition impacted clinical training, but not overall career plans for HPTs. Findings are presented in this section, with illustrative quantitative data and qualitative data quotes available in the eAppendix.

FDP04305186_T2
Critiques of the Transition’s Management

While participants were aware of the transition to the new EHR, most felt they did not have enough information or time to prepare for it, indicating it was “too little, too late.” HPTs felt necessary workflow processes for Cerner/Oracle Health were not determined with enough time to learn them prior to transition. Supervisors shared that important workflow and onboarding decisions remained undecided mere weeks before the transition. Some service lines did not decrease patient loads until right before the transition, making it difficult to manage their schedules and resulting in insufficient time to learn the new EHR.

EHR Training Concerns

Overall, HPTs expressed low satisfaction with computer-based Training Management System (TMS) EHR training, believing it did not prepare them for the new EHR. The percentage of HPTs satisfied or very satisfied with the quality of TMS training was lower than that of instructor-based training pre- and posttransition, with 50% of 36 prelaunch respondents, and 43% of 29 postlaunch respondents expressing satisfaction with computer-based trainings (Figure 1). HPTs were dissatisfied with the training content. They felt it was too general and failed to teach basic tasks in the workflow for their service areas and roles, such as writing a note or order. Furthermore, poor content was exacerbated by poor and unengaging instruction, and HPTs were dissatisfied with the practice EHR used in training, which glitched frequently.

FDP04305186_F1
FIGURE 1. Health professions trainees satisfied/very satisfied with
quality of electronic health record training.
EHR Transition Optimism

Even though the transition was stressful, most HPTs hoped it would be a temporary disruption and that they would quickly adjust to the new EHR. Many participants expected that once they switched to the new EHR, they would pick it up quickly. In addition, many anticipated Cerner/Oracle Health would be better and easier to use in the long run.

At-The-Elbow Support Essential

VHA peer support with NESSU was highly valued among HPTs. NESSU staff were highly knowledgeable and could provide both broad and service-line-specific support. NESSU provided prompt answers to EHR questions. This was particularly critical as other forms of in-person support were often inaccessible or absent during the transition.

HPTs found facility support helpful: 85% of 36 respondents reported being satisfied/ very satisfied with support from supervisors and preceptors, and 84% of 36 respondents were satisfied/very satisfied with technical support from facility informatics staff pretransition (n = 36) (Figure 2). NESSU and supervisor support with daily workflows were particularly helpful, as pretransition training only provided a general introduction to the EHR.

FDP04305186_F2
FIGURE 2. Health professions trainees satisfaction with electronic
health record training.
 
 
HPTs Adjusted to and Later Preferred the New EHR

The EHR learning experience was intense but short, with many HPTs feeling able to use it only 2 to 4 weeks posttransition. Confidence grew as HPTs came to view Cerner/Oracle Health as a more integrated and intuitive system than the previous EHR. Most participants preferred the new EHR, even if they criticized some features (eg, no group documentation capabilities). Survey participants frequently rated Cerner/Oracle Health usability higher than the original. A total of 32% of 29 posttransition respondents agreed or strongly agreed that Cerner/Oracle Health helps prevent situations that can lead to patient safety risks—higher than pretransition rates. Additionally, fewer respondents found the new EHR unnecessarily complex or thought it contained too many alerts and flags compared to the original EHR (Figure 3).

FDP04305186_F3
FIGURE 3. Health professions trainees perceptions of new electronic
health record usability.
 
 
Impact on Clinical Training, Not Career Plans

The extensive time and energy the transition demanded of HPTs caused stress and affected their clinical training. Many believed they would have learned more if their training had happened outside the transition.

Concerns that the transition affected learning were most acutely felt pretransition. HPTs reporting that EHR implementation positively affected their clinical education fell from 38% of 36 respondents 6 months pretransition to 19% of 29 respondents 1 month pretransition, but returned to 37% posttransition (Figure 4). However, some HPTs believed there was a silver lining: it provided a learning experience they otherwise would not have had.

FDP04305186_F4
FIGURE 4. Health professions trainees perceptions of training for
new Veterans Health Administration (VHA) electronic health record.

 

 

HPTs who believed the transition positively impacted their likelihood of pursuing future career opportunities within the VHA rose to 33% of 29 respondents posttransition. Overall, Cerner/Oracle Health was characterized as a tool: something used in training, but not something that precluded wanting VHA careers or having meaningful experiences, such as caring for patients.

Discussion

This evaluation addressed an underexplored aspect of EHR transitions: their impact on HPTs. It identified HPT challenges, including dissatisfaction with poor transition preparation and EHR training experiences. Promising findings include positive experiences with transition support, EHR uptake, and overall positive educational experiences despite the transition’s disruption.

When EHR users, including HPTs, are dissatisfied with transition preparations, consequent stress can lead to undesired effects, including increased burnout, inappropriate EHR use, and low work satisfaction.22-24 Negative EHR transition experiences shape HPTs’ subsequent EHR adoption, user satisfaction, as well as confidence and career intent.3,25,26 Health systems have strong incentives to implement effective transition change management.

HPTs at previous VHA EHR transition sites reported significantly more disruption to their clinical training compared with HPTs at FHCC. Academic programs were shut down at the first transition site, and HPTs expressed decreased interest in VHA careers at another, even a year posttransition.6,27 These findings are consistent with the limited literature on the adverse impacts that EHR transitions have on HPTs.7,28

HPT retention is critical. VA is mandated to prepare the next generation of HPTs for its needs, and those of the nation. The VA relies heavily on HPT retention to recruit clinicians: > 65% of VHA physicians nationwide participated in VHA training programs prior to recruitment into staff positions.5,29

VHA should invest in transition change management with demonstrated, positive impacts on HPTs, such as in-house support from clinicians. Previous research found that lack of support was a major source of stress and negative outcomes.6,27 Consequently, supporting HPTs through EHR transitions directly contributes to the VHA’s ability to attract high-quality staff from its HPTs. The challenges and promising practices described in this analysis underscore the necessity of understanding how all EHR users are affected by transitions. What happens to them has direct implications for the VA mission to provide safe, efficient care, and its mandate to provide quality clinical training to HPTs.

These findings hold hopeful implications for supporting HPT EHR use, both during and outside EHR transitions. HPTs expressing that an EHR is only 1 part of their clinical training experience suggests that change management can improve EHR transitions. HPT learning can enhance known factors that are important for HPTs in clinical training, including the health care organization’s mission, caring for patients, and personal development.

Further investigations may engage HPTs at future VHA sites making the transition to the new EHR. One focus would involve applying a learning health systems framework to examine the nature of change management efforts—and their effects on HPT transition experiences—iteratively across transition sites to evaluate the effect of the efforts. Another focus may be longitudinal engagement with HPTs at health care systems and sites transitioning to new EHRs. Research has found that disruptions to EHR usability, satisfaction, and care provision can persist for 2 years and beyond following an EHR transition.30 Evaluating the long-term effects of transitions on HPTs is of interest, given their distinct characteristics and differences from employees.

Limitations

Study data came from voluntary participants at 1 highly engaged site, raising the possibility of self-selection bias. HPT experiences at other VA and non-VA sites may differ. Employees and HPTs were engaged during a high-stress event; snowballing recruitment reach was limited by high workloads and limited time for engagement. Statistical data were descriptive and should not be interpreted as causal. Results may reflect, in part, temporal effects, and respondents include HPTs at different stages of training and with different levels of VA experience. Survey sample sizes may limit generalizability; however, merging data streams strengthened the reliability of findings.

Conclusions

The results of this analysis of FHCC HPTs were notably more positive than those of HPTs at previous VHA EHR transition sites. VHA is one of many health care systems that provide clinical training for HPTs and relies on this population to provide patient care. By highlighting challenges and positive experiences of HPTs during an EHR transition, this evaluation produces actionable insights that can inform the actions of health care systems seeking to support HPTs during disruptive EHR transitions.

References
  1. US Department of Veterans Affairs Office of the Inspector General. VA needs to strengthen controls to address electronic health record system major performance incidents. September 23, 2024. Accessed February 3, 2026. https://www.vaoig.gov/sites/default/files /reports/2024-09/vaoig-22-03591-231.pdf
  2. EHR deployment schedule. VA EHR Modernization. Updated February 2, 2026. Accessed February 3, 2026. https://digital.va.gov/ehr-modernization/ehr-deployment -schedule/
  3. Heckman J. VA in 2026 looks to get EHR rollout back on track, embark on health care reorganization. Federal News Network. December 24, 2025. Accessed February 3, 2026. https://federalnewsnetwork.com/veterans-affairs/2025/12 /va-in-2026-looks-to-get-ehr-rollout-back-on-track -embark-on-health-care-reorganization/
  4. US Department of Veterans Affairs Office of Academic Affiliations. Medical and dental education. Updated September 12, 2025. Accessed February 3, 2026. https://department.va.gov/academic-affiliations /medical-and-dental/
  5. Functions of Veterans Health Administration: health-care personnel education and training programs. 38 U.S.C. § 7302 (2026). Accessed February 3, 2026. https://uscode.house.gov/view.xhtml ?req=(title:38%20section:7302%20edition:prelim)
  6. Ahlness EA, Molloy-Paolillo BK, Brunner J, et al. Impacts of an electronic health record transition on Veterans Health Administration health professions trainee experience. J Gen Intern Med. 2023;38:1031-1039. doi:10.1007/s11606-023-08283-4
  7. Roberts DL, Mishark KJ, Alessandro STD, et al. Impact of electronic medical record transitions on the educational experiences of medical students. J Health Care Finance. 2014;41:1-5.
  8. Varpio L, Day K, Elliot‐Miller P, et al. The impact of adopting EHRs: how losing connectivity affects clinical reasoning. Med Educ. 2015;49:476-486. doi:10.1111/medu.12665
  9. Gali HE, Baxter SL, Lander L, et al. Impact of electronic health record implementation on ophthalmology trainee time expenditures. J Acad Ophthalmol (2017). 2019;11:e65-e72. doi:10.1055/s-0039-3401986
  10. Humphrey‐Murto S, Makus D, Moore S, et al. Training physicians and residents for the use of electronic health records— a comparative case study between two hospitals. Med Educ. 2023;57:337-348. doi:10.1111/medu.14944
  11. US Department of Defense. Captain James A. Lovell Federal Health Care Center: readying warriors & caring for heroes. Presentation August 10, 2022.
  12. Sayre G, Young J. Beyond openended questions: purposeful interview guide development to elicit rich, trustworthy data. Patient Aligned Care Teams (PACT) Demonstration Labs cyber seminar. March 21, 2018. Accessed February 3, 2026. https://www.hsrd.research.va.gov/for _researchers/cyber_seminars/catalog/transcripts/2439.doc
  13. Jordan PW, Thomas B, McClelland IL, Weerdmeester B, eds. Usability Evaluation In Industry. CRC Press; 1996.
  14. Keitz SA, Holland GJ, Melander EH, et al. The Veterans Affairs Learners’ Perceptions Survey: the foundation for educational quality improvement. Acad Med. 2003;78:910- 917. doi:10.1097/00001888-200309000-00016
  15. Byrne JM, Chang BK, Gilman SC, et al. The learners’ perceptions survey—primary care: assessing resident perceptions of internal medicine continuity clinics and patient- centered care. J Grad Med Educ. 2013;5:587-593. doi:10.4300/JGME-D-12-00233.1
  16. Elo S, Kyngäs H. The qualitative content analysis process. J Adv Nurs. 2008;62:107-115. doi:10.1111/j.1365-2648.2007.04569.x
  17. Siller AB, Tompkins L. The big four: analyzing complex sample survey data using SAS, SPSS, STATA, and SUDAAN. Poster presented at: 31st Annual SAS Users Group International Conference; March 27, 2006; San Francisco, CA. Accessed February 3, 2026. https://support.sas.com /resources/papers/proceedings/proceedings/sugi31/172 -31.pdf
  18. Tashakkori A, Johnson RB, Teddlie C. Foundations of Mixed Methods Research: Integrating Quantitative and Qualitative Approaches in the Social and Behavioral Sciences. 2nd ed. SAGE Publications, Inc.; 2020.
  19. Olmos-Vega FM, Stalmeijer RE, Varpio L, et al. A practical guide to reflexivity in qualitative research: AMEE Guide No. 149. Med Teach. 2023;45:241-251. doi:10.1080/0142159X.2022.2057287
  20. Mezirow J. Fostering Critical Reflection in Adulthood: A Guide to Transformative and Emancipatory Learning. JosseyBass; 1991.
  21. Probst B, Berenson L. The double arrow: how qualitative social work researchers use reflexivity. Qual Soc Work. 2014;13:813-827. doi:10.1177/1473325013506248
  22. Huang C, Koppel R, McGreevey JD 3rd, et al. Transitions from one electronic health record to another: challenges, pitfalls, and recommendations. Appl Clin Infor. 2020;11:742-754. doi:10.1055/s-0040-1718535
  23. Zheng K, Abraham J, Novak LL, et al. A survey of the literature on unintended consequences associated with health information technology: 2014–2015. Yearb Med Inform. 2016;25:13-29. doi:10.15265/IY-2016-036
  24. Campbell EM, Sittig DF, Ash JS, et al. Types of unintended consequences related to computerized provider order entry. J Am Med Inform Assoc. 2006;13:547-556. doi:10.1197/jamia.M2042
  25. Sittig DF, Lakhani P, Singh H. Applying requisite imagination to safeguard electronic health record transitions. JAMA. 2022;29:1014-1018. doi:10.1093/jamia/ocab291
  26. Ko HH, Lee TK, Leung Y, et al. Factors influencing career choices made by medical students, residents, and practising physicians. B C Med J. 2007;49:482-489.
  27. Brunner J, Ahlness EA, Anderson E, et al. VA’s EHR transition and health professions trainee programs: findings and impacts of a multistakeholder learning community. Learn Health Sys. 2024;9:e10460. doi:10.1002/lrh2.10460
  28. Rosdahl JA, Rudd M, Benjamin R, et al. Effect of the adoption of a comprehensive electronic health record on graduate medical education: perceptions of faculty and trainees. South Med J. 2018;111:476-483. doi:10.14423/SMJ.0000000000000847
  29. Hill C. U.S. Medical education at VA: it’s all about the veterans. VA News. August 18, 2021. Accessed February 3, 2026. https://news.va.gov/93370/medical-education-at-va -its-all-about-the-veterans
  30. Hanauer DA, Branford GL, Greenberg G, et al. Twoyear longitudinal assessment of physicians’ perceptions after replacement of a longstanding homegrown electronic health record: does a J-curve of satisfaction really exist? J Am Med Inform Assoc. 2017;24:e157-e165. doi:10.1093/jamia/ocw077
References
  1. US Department of Veterans Affairs Office of the Inspector General. VA needs to strengthen controls to address electronic health record system major performance incidents. September 23, 2024. Accessed February 3, 2026. https://www.vaoig.gov/sites/default/files /reports/2024-09/vaoig-22-03591-231.pdf
  2. EHR deployment schedule. VA EHR Modernization. Updated February 2, 2026. Accessed February 3, 2026. https://digital.va.gov/ehr-modernization/ehr-deployment -schedule/
  3. Heckman J. VA in 2026 looks to get EHR rollout back on track, embark on health care reorganization. Federal News Network. December 24, 2025. Accessed February 3, 2026. https://federalnewsnetwork.com/veterans-affairs/2025/12 /va-in-2026-looks-to-get-ehr-rollout-back-on-track -embark-on-health-care-reorganization/
  4. US Department of Veterans Affairs Office of Academic Affiliations. Medical and dental education. Updated September 12, 2025. Accessed February 3, 2026. https://department.va.gov/academic-affiliations /medical-and-dental/
  5. Functions of Veterans Health Administration: health-care personnel education and training programs. 38 U.S.C. § 7302 (2026). Accessed February 3, 2026. https://uscode.house.gov/view.xhtml ?req=(title:38%20section:7302%20edition:prelim)
  6. Ahlness EA, Molloy-Paolillo BK, Brunner J, et al. Impacts of an electronic health record transition on Veterans Health Administration health professions trainee experience. J Gen Intern Med. 2023;38:1031-1039. doi:10.1007/s11606-023-08283-4
  7. Roberts DL, Mishark KJ, Alessandro STD, et al. Impact of electronic medical record transitions on the educational experiences of medical students. J Health Care Finance. 2014;41:1-5.
  8. Varpio L, Day K, Elliot‐Miller P, et al. The impact of adopting EHRs: how losing connectivity affects clinical reasoning. Med Educ. 2015;49:476-486. doi:10.1111/medu.12665
  9. Gali HE, Baxter SL, Lander L, et al. Impact of electronic health record implementation on ophthalmology trainee time expenditures. J Acad Ophthalmol (2017). 2019;11:e65-e72. doi:10.1055/s-0039-3401986
  10. Humphrey‐Murto S, Makus D, Moore S, et al. Training physicians and residents for the use of electronic health records— a comparative case study between two hospitals. Med Educ. 2023;57:337-348. doi:10.1111/medu.14944
  11. US Department of Defense. Captain James A. Lovell Federal Health Care Center: readying warriors & caring for heroes. Presentation August 10, 2022.
  12. Sayre G, Young J. Beyond openended questions: purposeful interview guide development to elicit rich, trustworthy data. Patient Aligned Care Teams (PACT) Demonstration Labs cyber seminar. March 21, 2018. Accessed February 3, 2026. https://www.hsrd.research.va.gov/for _researchers/cyber_seminars/catalog/transcripts/2439.doc
  13. Jordan PW, Thomas B, McClelland IL, Weerdmeester B, eds. Usability Evaluation In Industry. CRC Press; 1996.
  14. Keitz SA, Holland GJ, Melander EH, et al. The Veterans Affairs Learners’ Perceptions Survey: the foundation for educational quality improvement. Acad Med. 2003;78:910- 917. doi:10.1097/00001888-200309000-00016
  15. Byrne JM, Chang BK, Gilman SC, et al. The learners’ perceptions survey—primary care: assessing resident perceptions of internal medicine continuity clinics and patient- centered care. J Grad Med Educ. 2013;5:587-593. doi:10.4300/JGME-D-12-00233.1
  16. Elo S, Kyngäs H. The qualitative content analysis process. J Adv Nurs. 2008;62:107-115. doi:10.1111/j.1365-2648.2007.04569.x
  17. Siller AB, Tompkins L. The big four: analyzing complex sample survey data using SAS, SPSS, STATA, and SUDAAN. Poster presented at: 31st Annual SAS Users Group International Conference; March 27, 2006; San Francisco, CA. Accessed February 3, 2026. https://support.sas.com /resources/papers/proceedings/proceedings/sugi31/172 -31.pdf
  18. Tashakkori A, Johnson RB, Teddlie C. Foundations of Mixed Methods Research: Integrating Quantitative and Qualitative Approaches in the Social and Behavioral Sciences. 2nd ed. SAGE Publications, Inc.; 2020.
  19. Olmos-Vega FM, Stalmeijer RE, Varpio L, et al. A practical guide to reflexivity in qualitative research: AMEE Guide No. 149. Med Teach. 2023;45:241-251. doi:10.1080/0142159X.2022.2057287
  20. Mezirow J. Fostering Critical Reflection in Adulthood: A Guide to Transformative and Emancipatory Learning. JosseyBass; 1991.
  21. Probst B, Berenson L. The double arrow: how qualitative social work researchers use reflexivity. Qual Soc Work. 2014;13:813-827. doi:10.1177/1473325013506248
  22. Huang C, Koppel R, McGreevey JD 3rd, et al. Transitions from one electronic health record to another: challenges, pitfalls, and recommendations. Appl Clin Infor. 2020;11:742-754. doi:10.1055/s-0040-1718535
  23. Zheng K, Abraham J, Novak LL, et al. A survey of the literature on unintended consequences associated with health information technology: 2014–2015. Yearb Med Inform. 2016;25:13-29. doi:10.15265/IY-2016-036
  24. Campbell EM, Sittig DF, Ash JS, et al. Types of unintended consequences related to computerized provider order entry. J Am Med Inform Assoc. 2006;13:547-556. doi:10.1197/jamia.M2042
  25. Sittig DF, Lakhani P, Singh H. Applying requisite imagination to safeguard electronic health record transitions. JAMA. 2022;29:1014-1018. doi:10.1093/jamia/ocab291
  26. Ko HH, Lee TK, Leung Y, et al. Factors influencing career choices made by medical students, residents, and practising physicians. B C Med J. 2007;49:482-489.
  27. Brunner J, Ahlness EA, Anderson E, et al. VA’s EHR transition and health professions trainee programs: findings and impacts of a multistakeholder learning community. Learn Health Sys. 2024;9:e10460. doi:10.1002/lrh2.10460
  28. Rosdahl JA, Rudd M, Benjamin R, et al. Effect of the adoption of a comprehensive electronic health record on graduate medical education: perceptions of faculty and trainees. South Med J. 2018;111:476-483. doi:10.14423/SMJ.0000000000000847
  29. Hill C. U.S. Medical education at VA: it’s all about the veterans. VA News. August 18, 2021. Accessed February 3, 2026. https://news.va.gov/93370/medical-education-at-va -its-all-about-the-veterans
  30. Hanauer DA, Branford GL, Greenberg G, et al. Twoyear longitudinal assessment of physicians’ perceptions after replacement of a longstanding homegrown electronic health record: does a J-curve of satisfaction really exist? J Am Med Inform Assoc. 2017;24:e157-e165. doi:10.1093/jamia/ocw077
Issue
Federal Practitioner - 43(5)
Issue
Federal Practitioner - 43(5)
Page Number
186-192
Page Number
186-192
Publications
Publications
Topics
Article Type
Display Headline

Evaluation of Health Professions Trainee Experiences Transitioning to New VHA Electronic Health Record

Display Headline

Evaluation of Health Professions Trainee Experiences Transitioning to New VHA Electronic Health Record

Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date
Media Files

Effectiveness and Safety of Droperidol Use in the VA Greater Los Angeles Healthcare System Emergency Department

Article Type
Changed
Display Headline

Effectiveness and Safety of Droperidol Use in the VA Greater Los Angeles Healthcare System Emergency Department

Droperidol is a butyrophenone antipsychotic approved by the US Food and Drug Administration (FDA) for use in postoperative nausea and vomiting (PONV). Off-label, it has also been utilized for its sedative, anxiolytic, and analgesic properties.1 While its exact mechanism of action remains elusive, it is believed that binding to postsynaptic γ-aminobutyric acid receptors induces anxiolysis and sedation, while dopaminergic activity in the chemoreceptor trigger zone contributes to its antiemetic effects.2 Since the introduction of droperidol in 1967, it has been widely used by emergency physicians, psychiatrists, and anesthesiologists globally.1

Despite its therapeutic efficacy, use of droperidol has been tempered by concerns regarding its cardiovascular safety profile, specifically its potential to prolong the QT interval and precipitate cardiac arrhythmias. In 2001, the FDA placed a boxed warning on droperidol that mandated electrocardiogram (EKG) monitoring before and after treatment. This requirement has led to a widespread decrease in use, and the FDA decision sparked significant controversy among clinicians, with many organizations arguing that the evidence did not support this mandate.1

Further review of the cases cited by the FDA revealed that there were 277 reported cases of droperidol-related adverse events (AEs), but many of these cases were duplicates and occurred outside the US.3 Additionally, the doses of droperidol used in these cases were significantly higher than the typical doses used in the emergency department (ED), ranging from 25 to 250 mg.4 Typical doses for PONV range from 0.625 to 2.5 mg intravenous (IV) or intramuscular (IM). Recommended doses for agitation typically range from 2.5 to 10 mg IV and 5 to 10 mg IM.5

There has been growing interest in reevaluating the risk-benefit profile of droperidol in the ED. Since the original decision by the FDA, multiple publications have challenged the idea that droperidol has significantly higher risks associated with its use. The 2014 review by the Clinical Guidelines Committee of the American Academy of Emergency Medicine did not find evidence that low-dose droperidol (< 2.5 is unsafe for use in the ED.6 A retrospective cohort study from 2020 found no fatalities in 5784 patients. Furthermore, a prospective observational study of 1009 patients at 6 EDs who received high-dose droperidol (≤ 20.0 mg) found no evidence of increased risk for QT prolongation.7 The evidence supports the safety of droperidol for use in prehospital and hospital settings as well as in pediatric, adult, and geriatric populations.8-14 Droperidol was eventually reintroduced in 2019, which led to increased use.

The US Department of Veterans Affairs (VA) formulary has limited options (eg, haloperidol and olanzapine) that have robust evidence supporting their use to treat aggression or psychosis-related agitation. Ziprasidone injections are not on the formulary and require authorization for use, which may delay patient care and pose a safety risk. In 2021, VA Greater Los Angeles Healthcare System (VAGLAHS) received Pharmacy and Therapeutics Committee approval to use droperidol in the ED for agitation or nausea and vomiting. The purpose of this study was to evaluate safety outcomes for patients prescribed droperidol and the need for rescue medications (ie, effectiveness) in the VAGLAHS ED.

Methods

This retrospective chart review analyzed patients administered droperidol in the VAGLAHS ED from February 1, 2021, through April 30, 2023. A list of patients who had droperidol ordered in the VAGLAHS ED was obtained from the Veterans Health Information Systems and Technology Architecture. Charts were reviewed using the Computerized Patient Record System to confirm droperidol administration. Nurse documentation was reviewed to confirm the time, dose, and route of administration. In addition, droperidol dosages were categorized as < 5 mg, 5 to 10 mg, and > 10 mg to review outcomes based on the total amount administered to each patient.

Patients included in the study received droperidol in the ED within the study period, were aged ≥ 18 years, and received droperidol for acute agitation or antiemesis. Patients were excluded if they received droperidol for an indication other than agitation or antiemesis.

The study team reviewed the list of patients and audited the collected data. Reviewers were trained on the study protocols and variables identified. The following data were collected: patient demographics (age, sex, race, height, weight, allergies), Charlson Comorbidity Index (CCI) conditions, cardiac comorbidities, laboratory values at admission, basic metabolic panels, liver function tests, droperidol use (doses, indications, and documentation of safety), concomitant medications ordered with the initial droperidol order, AEs (arrhythmias, extrapyramidal symptoms [EPS], respiratory depression, mortality), medications used within 60 minutes of droperidol administration (rescue medications), other medications used within 24 hours after droperidol administration, and EKG/QTc (corrected QT interval) intervals. The data reviewed and recorded were from the date of the initial patient ED visit.

Outcomes

The primary outcome was all-cause mortality within 24 hours after droperidol administration. This outcome was measured in all patients included in this study. Secondary outcomes included rescue medications needed after droperidol administration, incidence of QT prolongation, incidence of EPS (defined as akathisia, dystonia, parkinsonism, or tardive dyskinesia), and incidence of respiratory depression. Clinically significant QTc was defined as an interval of ≥ 500 ms with incidence of arrhythmias, code blues, or intubations. Baseline risk factors for QTc prolongation were taken into consideration including electrolyte abnormalities, concomitant QT-prolonging medications, CCI score, and cardiac comorbidities. Incidence of EPS was counted if patients received medications such as diphenhydramine or benztropine after droperidol administration in addition to documentation of EPS signs and symptoms. Incidences of EPS findings were reviewed by emergency department physicians to confirm the diagnosis.

Safety was assessed by quantifying mortality rates 24 hours after droperidol administration along with incidence of AEs associated with droperidol use including QT prolongation, EPS, and respiratory depression.

The necessity of rescue medication use was assessed by nursing documentation, additional medications ordered, and/or no additional medications required for agitation within 60 minutes of droperidol administration. Sixty minutes was the chosen timeframe given that the onset of droperidol action is between 3 and 10 minutes and peaks in about 30 minutes. Medications that were considered rescue medications included diphenhydramine < 25 mg, diphenhydramine 25 to 50 mg, lorazepam < 1 mg, lorazepam 1 to 2 mg, diphenhydramine < 25 mg and lorazepam < 1 mg, diphenhydramine < 25 mg and lorazepam 1 to 2 mg, diphenhydramine 25 to 50 mg and lorazepam 1 to 2 mg, and other medications, the names and doses of which were manually documented by investigators.

Statistical Analysis

For all variables in the study, descriptive analysis was used to categorize findings. Microsoft Excel was used to calculate means, frequency counts, percentages, and categorize data.

Results

Between February 1, 2021, and April 16, 2023, 214 patients received droperidol in the VAGLAHS ED, and 207 patients were included in the study. Seven patients did not receive droperidol for the indications included (acute agitation or antiemesis). Most of the study population (89.4%) was male, and the mean age was 51.0 years. The mean CCI was 1.6. In the study, 183 (88.4%) patients received droperidol for agitation and 24 (11.6%) for nausea and vomiting (Table 1).

FDP04305180_T1
Primary Outcome

No deaths were observed in a 24-hour period after droperidol administration among the 207 patients included in the study. There were also no arrhythmias, code blues, or intubations observed with the administration of droperidol (Table 2).

FDP04305180_T2
Secondary Outcomes

A total of 144 patients (69.6%) received droperidol alone to resolve agitation or nausea and vomiting. In the remaining population, 63 (30.4%) patients were given medications concomitantly with droperidol.

Fifteen patients (7.2%) required rescue medications that were administered within 60 minutes of droperidol administration. Rescue medications were required for 7 patients (4.9%) who initially received droperidol alone compared with 8 patients (12.7%) who were administered concomitant medications with droperidol (Figure).

FDP04305180_F1
FIGURE. Rescue Medication Distribution
Extrapyramidal Symptoms

EPS occurred in 2 patients (1.0%). There was 1 incidence of tardive dyskinesia (TD) in which the patient received droperidol 2.5 mg IM for emesis. TD was resolved with diphenhydramine 50 mg. A second patient who experienced dystonia received droperidol 10 mg IM for agitation. Dystonia was resolved with benztropine 2 mg. Both patients had a CCI of 0, no cardiac comorbidities, and laboratory test results were within reference ranges. The second patient received olanzapine within 24 hours of droperidol administration; however, it was after the EPS event.

QTc Prolongation

Baseline EKGs (within 6 months prior to ED visit) were available for 102 patients (49.3%). Nine patients (8.8%) had a reported baseline QTc of ≥ 500 ms (Table 3). Of these patients, 6 had a repeat EKG and 5 had a repeat QTc < 500 ms. One patient had a baseline and repeated QTc of 512 ms with essentially no change after droperidol administration. Only 1 patient was on a potentially QTc-prolonging medication at home. None of the patients with baseline QTc > 500 ms experienced arrhythmias after droperidol administration.

FDP04305180_T3

We found that 59 patients (28.5%) had EKGs performed within 24 hours after droperidol administration. Five patients had documented QTc ≥ 500 ms, but no arrhythmias were observed in a 24-hour period. Table 4 describes the additional medications administered after the 60-minute window but within 24 hours after droperidol administration. Quetiapine 300 mg and metoclopramide 5 mg were the only medications documented that can potentially increase QTc. Patient adherence to home medications and the timing of the last dose prior to ED visit were unknown. However, no arrhythmias were noted in these patients with QTc changes. No patients experienced respiratory depression within 24 hours of droperidol administration.

FDP04305180_T4
Older Adult Patients

Thirty-eight patients were aged ≥ 65 years with a mean age of 74.2 years. Thirty-four patients (89.5%) received droperidol for agitation and 4 (10.6%) for nausea and vomiting. Only 21 patients had a baseline EKG, and 4 had QTc ≤ 500 ms. At 24 hours, EKGs were performed for 18 patients and 3 had a QTc ≤ 500 ms. No mortality or arrhythmias were reported and there were no incidences of rescue medications, EPS, or respiratory depression.

Discussion

The study included 207 patients who received droperidol for either agitation or nausea/vomiting in the VAGLAHS ED. No mortality occurred within 24 hours of droperidol administration, which is consistent with recent studies.8-14

Furthermore, 59 patients (28.5%) had an EKG performed within 24 hours of droperidol administration; 5 patients had documented QTc ≥ 500 ms. Only 3 of the patients with prolonged QTc had baseline readings for comparison. Only 2 patients had an increase in QTc interval. No arrhythmias were observed; however, the effects of observing QTc prolongation were limited due to the lack of post-EKG readings following droperidol administration. Because of the retrospective nature of the study, neither standardization of EKG at baseline nor 24-hour postadministration were possible. The study found that droperidol was effective with only 15 patients (7.3%) requiring rescue medications. In the patients who were given medications concomitantly with droperidol, it was not possible to conclude whether the patients would have required rescue medications to resolve their agitation or nausea/vomiting. Administration of concomitant medications with droperidol may be attributed to practice patterns associated with haloperidol use, which is frequently administered with concomitant medications such as diphenhydramine and/or a benzodiazepine.

AEs were rare with no documentation of respiratory depression and 2 cases (1.0%) of EPS. Both incidences of EPS resolved with diphenhydramine or benztropine. However, given the reliance on nursing documentation to capture AEs, the number of events may have been underreported.

Limitations

Standardization of dosing was a limiting factor that could affect the need for rescue medications. Another limitation was reliance on nursing reports of resolution of symptoms and comfort with agitated patients. Given the retrospective design and small sample size, this study may not have captured all potential AEs. However, the doses administered within this study population were consistent with what was expected based on other studies.8-14

Conclusions

Droperidol, an antipsychotic, is currently approved for PONV, but is also used off-label for agitation. This study found no fatalities among patients who received droperidol in the ED. The findings suggest that droperidol used for agitation and as an antiemetic, despite its FDA boxed warning, appears to be safe and showed no evidence of mortality, arrhythmias, code blues, or intubations despite the lack of postdose EKG monitoring. Among the 38 patients aged ≥ 65 years, the use of droperidol revealed no increased risks. It should be noted that droperidol appeared safe and few patients required rescue medications within this study population.

References
  1. Perkins J, Ho JD, Vilke GM, DeMers G. American Academy of Emergency Medicine Position Statement: Safety of droperidol use in the emergency department. J Emerg Med. 2015;49:91-97. doi:10.1016/j.jemermed.2014.12.024
  2. Siegel RB, Motov SM, Marcolini EG. Droperidol use in the emergency department: a clinical review. J Emerg Med. 2023;64:289-294. doi:10.1016/j.jemermed.2022.12.012
  3. Jackson CW, Sheehan AH, Reddan JG. Evidencebased review of the black-box warning for droperidol. Am J Health Syst Pharm. 2007;64:1174-1186. doi:10.2146/ajhp060505
  4. Habib AS, Gan TJ. Food and Drug Administration black box warning on the perioperative use of droperidol: a review of the cases. Anesth Analg. 2003;96(5):1377-1379. doi:10.1213/01.ane.0000063923.87560.37
  5. Droperidol. In: Micromedex (electronic version). IBM Watson Health; 2019. Accessed March 2, 2026. https://www .micromedexsolutions.com
  6. Gaw CM, Cabrera D, Bellolio F, Mattson AE, Lohse CM, Jeffery MM. Effectiveness and safety of droperidol in a United States emergency department. Am J Emerg Med. 2020;38:1310-1314. doi:10.1016/j.ajem.2019.09.007
  7. Calver L, Page CB, Downes MA, et al. The safety and effectiveness of droperidol for sedation of acute behavioral disturbance in the emergency department. Ann Emerg Med. 2015;66(3):230-238.e1. doi:10.1016/j.annemergmed.2015.03.016
  8. Ernst R, Wagstaff H, Smith M, et al. Droperidol administration among emergency department patients with abdominal pain, nausea, and vomiting. Am J Emerg Med. 2024;85:44-47. doi:10.1016/j.ajem.2024.07.060
  9. Szwak K, Sacchetti A. Droperidol use in pediatric emergency department patients. Pediatr Emerg Care. 2010;26:248-250. doi:10.1097/pec.0b013e3181d6d9f2
  10. Chase PB, Biros MH. A retrospective review of the use and safety of droperidol in a large, high-risk, inner-city emergency department patient population. Acad Emerg Med. 2002;9:1402-1410. doi:10.1111/j.1553-2712.2002.tb01609.x
  11. Mattson A, Friend K, Brown CS, Cabrera D. Reintegrating droperidol into emergency medicine practice. Am J Health Syst Pharm. 2020;77(22):1838-1845. doi:10.1093/ajhp/zxaa271
  12. Cole JB, Stang JL, DeVries PA, Martel ML, Miner JR, Driver BE. A prospective study of intramuscular droperidol or olanzapine for acute agitation in the emergency department: a natural experiment owing to drug shortages. Ann Emerg Med. 2021;78(2):274-286. doi:10.1016/j.annemergmed.2021.01.005
  13. Page CB, Parker LE, Rashford SJ, et al. Prospective study of the safety and effectiveness of droperidol in elderly patients for pre-hospital acute behavioural disturbance. Emerg Med Australas. 2020;32(5):731-736. doi:10.1111/1742-6723.13496
  14. Page CB, Parker LE, Rashford SJ, et al. A prospective study of the safety and effectiveness of droperidol inchildren for prehospital acute behavioral disturbance. Prehosp Emerg Care. 2018;23:519-526. doi:10.1080/10903127.2018.1542473
Article PDF
Author and Disclosure Information

Emily Minoda, PharmDa; Shogo Kono, PharmDa; My-Phuong Pham, PharmDa; Hemang Acharya, MDa,b; Jonathan Balakumar, MDa,b

Author affiliations
aVeterans Affairs Greater Los Angeles Healthcare System, California
bDavid Geffen School of Medicine, University of California, Los Angeles

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Correspondence: Jonathan Balakumar (jonathan.balakumar@va.gov)

Disclaimer The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.

Ethics and consent This project was reviewed and approved by the Veterans Affairs Greater Los Angeles Institutional Review Board.

Fed Pract. 2026;43(5). Published online May 20. doi:10.12788/fp.0699

Issue
Federal Practitioner - 43(5)
Publications
Topics
Page Number
180-185
Sections
Author and Disclosure Information

Emily Minoda, PharmDa; Shogo Kono, PharmDa; My-Phuong Pham, PharmDa; Hemang Acharya, MDa,b; Jonathan Balakumar, MDa,b

Author affiliations
aVeterans Affairs Greater Los Angeles Healthcare System, California
bDavid Geffen School of Medicine, University of California, Los Angeles

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Correspondence: Jonathan Balakumar (jonathan.balakumar@va.gov)

Disclaimer The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.

Ethics and consent This project was reviewed and approved by the Veterans Affairs Greater Los Angeles Institutional Review Board.

Fed Pract. 2026;43(5). Published online May 20. doi:10.12788/fp.0699

Author and Disclosure Information

Emily Minoda, PharmDa; Shogo Kono, PharmDa; My-Phuong Pham, PharmDa; Hemang Acharya, MDa,b; Jonathan Balakumar, MDa,b

Author affiliations
aVeterans Affairs Greater Los Angeles Healthcare System, California
bDavid Geffen School of Medicine, University of California, Los Angeles

Author disclosures The authors report no actual or potential conflicts of interest with regard to this article.

Correspondence: Jonathan Balakumar (jonathan.balakumar@va.gov)

Disclaimer The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations—including indications, contraindications, warnings, and adverse effects—before administering pharmacologic therapy to patients.

Ethics and consent This project was reviewed and approved by the Veterans Affairs Greater Los Angeles Institutional Review Board.

Fed Pract. 2026;43(5). Published online May 20. doi:10.12788/fp.0699

Article PDF
Article PDF

Droperidol is a butyrophenone antipsychotic approved by the US Food and Drug Administration (FDA) for use in postoperative nausea and vomiting (PONV). Off-label, it has also been utilized for its sedative, anxiolytic, and analgesic properties.1 While its exact mechanism of action remains elusive, it is believed that binding to postsynaptic γ-aminobutyric acid receptors induces anxiolysis and sedation, while dopaminergic activity in the chemoreceptor trigger zone contributes to its antiemetic effects.2 Since the introduction of droperidol in 1967, it has been widely used by emergency physicians, psychiatrists, and anesthesiologists globally.1

Despite its therapeutic efficacy, use of droperidol has been tempered by concerns regarding its cardiovascular safety profile, specifically its potential to prolong the QT interval and precipitate cardiac arrhythmias. In 2001, the FDA placed a boxed warning on droperidol that mandated electrocardiogram (EKG) monitoring before and after treatment. This requirement has led to a widespread decrease in use, and the FDA decision sparked significant controversy among clinicians, with many organizations arguing that the evidence did not support this mandate.1

Further review of the cases cited by the FDA revealed that there were 277 reported cases of droperidol-related adverse events (AEs), but many of these cases were duplicates and occurred outside the US.3 Additionally, the doses of droperidol used in these cases were significantly higher than the typical doses used in the emergency department (ED), ranging from 25 to 250 mg.4 Typical doses for PONV range from 0.625 to 2.5 mg intravenous (IV) or intramuscular (IM). Recommended doses for agitation typically range from 2.5 to 10 mg IV and 5 to 10 mg IM.5

There has been growing interest in reevaluating the risk-benefit profile of droperidol in the ED. Since the original decision by the FDA, multiple publications have challenged the idea that droperidol has significantly higher risks associated with its use. The 2014 review by the Clinical Guidelines Committee of the American Academy of Emergency Medicine did not find evidence that low-dose droperidol (< 2.5 is unsafe for use in the ED.6 A retrospective cohort study from 2020 found no fatalities in 5784 patients. Furthermore, a prospective observational study of 1009 patients at 6 EDs who received high-dose droperidol (≤ 20.0 mg) found no evidence of increased risk for QT prolongation.7 The evidence supports the safety of droperidol for use in prehospital and hospital settings as well as in pediatric, adult, and geriatric populations.8-14 Droperidol was eventually reintroduced in 2019, which led to increased use.

The US Department of Veterans Affairs (VA) formulary has limited options (eg, haloperidol and olanzapine) that have robust evidence supporting their use to treat aggression or psychosis-related agitation. Ziprasidone injections are not on the formulary and require authorization for use, which may delay patient care and pose a safety risk. In 2021, VA Greater Los Angeles Healthcare System (VAGLAHS) received Pharmacy and Therapeutics Committee approval to use droperidol in the ED for agitation or nausea and vomiting. The purpose of this study was to evaluate safety outcomes for patients prescribed droperidol and the need for rescue medications (ie, effectiveness) in the VAGLAHS ED.

Methods

This retrospective chart review analyzed patients administered droperidol in the VAGLAHS ED from February 1, 2021, through April 30, 2023. A list of patients who had droperidol ordered in the VAGLAHS ED was obtained from the Veterans Health Information Systems and Technology Architecture. Charts were reviewed using the Computerized Patient Record System to confirm droperidol administration. Nurse documentation was reviewed to confirm the time, dose, and route of administration. In addition, droperidol dosages were categorized as < 5 mg, 5 to 10 mg, and > 10 mg to review outcomes based on the total amount administered to each patient.

Patients included in the study received droperidol in the ED within the study period, were aged ≥ 18 years, and received droperidol for acute agitation or antiemesis. Patients were excluded if they received droperidol for an indication other than agitation or antiemesis.

The study team reviewed the list of patients and audited the collected data. Reviewers were trained on the study protocols and variables identified. The following data were collected: patient demographics (age, sex, race, height, weight, allergies), Charlson Comorbidity Index (CCI) conditions, cardiac comorbidities, laboratory values at admission, basic metabolic panels, liver function tests, droperidol use (doses, indications, and documentation of safety), concomitant medications ordered with the initial droperidol order, AEs (arrhythmias, extrapyramidal symptoms [EPS], respiratory depression, mortality), medications used within 60 minutes of droperidol administration (rescue medications), other medications used within 24 hours after droperidol administration, and EKG/QTc (corrected QT interval) intervals. The data reviewed and recorded were from the date of the initial patient ED visit.

Outcomes

The primary outcome was all-cause mortality within 24 hours after droperidol administration. This outcome was measured in all patients included in this study. Secondary outcomes included rescue medications needed after droperidol administration, incidence of QT prolongation, incidence of EPS (defined as akathisia, dystonia, parkinsonism, or tardive dyskinesia), and incidence of respiratory depression. Clinically significant QTc was defined as an interval of ≥ 500 ms with incidence of arrhythmias, code blues, or intubations. Baseline risk factors for QTc prolongation were taken into consideration including electrolyte abnormalities, concomitant QT-prolonging medications, CCI score, and cardiac comorbidities. Incidence of EPS was counted if patients received medications such as diphenhydramine or benztropine after droperidol administration in addition to documentation of EPS signs and symptoms. Incidences of EPS findings were reviewed by emergency department physicians to confirm the diagnosis.

Safety was assessed by quantifying mortality rates 24 hours after droperidol administration along with incidence of AEs associated with droperidol use including QT prolongation, EPS, and respiratory depression.

The necessity of rescue medication use was assessed by nursing documentation, additional medications ordered, and/or no additional medications required for agitation within 60 minutes of droperidol administration. Sixty minutes was the chosen timeframe given that the onset of droperidol action is between 3 and 10 minutes and peaks in about 30 minutes. Medications that were considered rescue medications included diphenhydramine < 25 mg, diphenhydramine 25 to 50 mg, lorazepam < 1 mg, lorazepam 1 to 2 mg, diphenhydramine < 25 mg and lorazepam < 1 mg, diphenhydramine < 25 mg and lorazepam 1 to 2 mg, diphenhydramine 25 to 50 mg and lorazepam 1 to 2 mg, and other medications, the names and doses of which were manually documented by investigators.

Statistical Analysis

For all variables in the study, descriptive analysis was used to categorize findings. Microsoft Excel was used to calculate means, frequency counts, percentages, and categorize data.

Results

Between February 1, 2021, and April 16, 2023, 214 patients received droperidol in the VAGLAHS ED, and 207 patients were included in the study. Seven patients did not receive droperidol for the indications included (acute agitation or antiemesis). Most of the study population (89.4%) was male, and the mean age was 51.0 years. The mean CCI was 1.6. In the study, 183 (88.4%) patients received droperidol for agitation and 24 (11.6%) for nausea and vomiting (Table 1).

FDP04305180_T1
Primary Outcome

No deaths were observed in a 24-hour period after droperidol administration among the 207 patients included in the study. There were also no arrhythmias, code blues, or intubations observed with the administration of droperidol (Table 2).

FDP04305180_T2
Secondary Outcomes

A total of 144 patients (69.6%) received droperidol alone to resolve agitation or nausea and vomiting. In the remaining population, 63 (30.4%) patients were given medications concomitantly with droperidol.

Fifteen patients (7.2%) required rescue medications that were administered within 60 minutes of droperidol administration. Rescue medications were required for 7 patients (4.9%) who initially received droperidol alone compared with 8 patients (12.7%) who were administered concomitant medications with droperidol (Figure).

FDP04305180_F1
FIGURE. Rescue Medication Distribution
Extrapyramidal Symptoms

EPS occurred in 2 patients (1.0%). There was 1 incidence of tardive dyskinesia (TD) in which the patient received droperidol 2.5 mg IM for emesis. TD was resolved with diphenhydramine 50 mg. A second patient who experienced dystonia received droperidol 10 mg IM for agitation. Dystonia was resolved with benztropine 2 mg. Both patients had a CCI of 0, no cardiac comorbidities, and laboratory test results were within reference ranges. The second patient received olanzapine within 24 hours of droperidol administration; however, it was after the EPS event.

QTc Prolongation

Baseline EKGs (within 6 months prior to ED visit) were available for 102 patients (49.3%). Nine patients (8.8%) had a reported baseline QTc of ≥ 500 ms (Table 3). Of these patients, 6 had a repeat EKG and 5 had a repeat QTc < 500 ms. One patient had a baseline and repeated QTc of 512 ms with essentially no change after droperidol administration. Only 1 patient was on a potentially QTc-prolonging medication at home. None of the patients with baseline QTc > 500 ms experienced arrhythmias after droperidol administration.

FDP04305180_T3

We found that 59 patients (28.5%) had EKGs performed within 24 hours after droperidol administration. Five patients had documented QTc ≥ 500 ms, but no arrhythmias were observed in a 24-hour period. Table 4 describes the additional medications administered after the 60-minute window but within 24 hours after droperidol administration. Quetiapine 300 mg and metoclopramide 5 mg were the only medications documented that can potentially increase QTc. Patient adherence to home medications and the timing of the last dose prior to ED visit were unknown. However, no arrhythmias were noted in these patients with QTc changes. No patients experienced respiratory depression within 24 hours of droperidol administration.

FDP04305180_T4
Older Adult Patients

Thirty-eight patients were aged ≥ 65 years with a mean age of 74.2 years. Thirty-four patients (89.5%) received droperidol for agitation and 4 (10.6%) for nausea and vomiting. Only 21 patients had a baseline EKG, and 4 had QTc ≤ 500 ms. At 24 hours, EKGs were performed for 18 patients and 3 had a QTc ≤ 500 ms. No mortality or arrhythmias were reported and there were no incidences of rescue medications, EPS, or respiratory depression.

Discussion

The study included 207 patients who received droperidol for either agitation or nausea/vomiting in the VAGLAHS ED. No mortality occurred within 24 hours of droperidol administration, which is consistent with recent studies.8-14

Furthermore, 59 patients (28.5%) had an EKG performed within 24 hours of droperidol administration; 5 patients had documented QTc ≥ 500 ms. Only 3 of the patients with prolonged QTc had baseline readings for comparison. Only 2 patients had an increase in QTc interval. No arrhythmias were observed; however, the effects of observing QTc prolongation were limited due to the lack of post-EKG readings following droperidol administration. Because of the retrospective nature of the study, neither standardization of EKG at baseline nor 24-hour postadministration were possible. The study found that droperidol was effective with only 15 patients (7.3%) requiring rescue medications. In the patients who were given medications concomitantly with droperidol, it was not possible to conclude whether the patients would have required rescue medications to resolve their agitation or nausea/vomiting. Administration of concomitant medications with droperidol may be attributed to practice patterns associated with haloperidol use, which is frequently administered with concomitant medications such as diphenhydramine and/or a benzodiazepine.

AEs were rare with no documentation of respiratory depression and 2 cases (1.0%) of EPS. Both incidences of EPS resolved with diphenhydramine or benztropine. However, given the reliance on nursing documentation to capture AEs, the number of events may have been underreported.

Limitations

Standardization of dosing was a limiting factor that could affect the need for rescue medications. Another limitation was reliance on nursing reports of resolution of symptoms and comfort with agitated patients. Given the retrospective design and small sample size, this study may not have captured all potential AEs. However, the doses administered within this study population were consistent with what was expected based on other studies.8-14

Conclusions

Droperidol, an antipsychotic, is currently approved for PONV, but is also used off-label for agitation. This study found no fatalities among patients who received droperidol in the ED. The findings suggest that droperidol used for agitation and as an antiemetic, despite its FDA boxed warning, appears to be safe and showed no evidence of mortality, arrhythmias, code blues, or intubations despite the lack of postdose EKG monitoring. Among the 38 patients aged ≥ 65 years, the use of droperidol revealed no increased risks. It should be noted that droperidol appeared safe and few patients required rescue medications within this study population.

Droperidol is a butyrophenone antipsychotic approved by the US Food and Drug Administration (FDA) for use in postoperative nausea and vomiting (PONV). Off-label, it has also been utilized for its sedative, anxiolytic, and analgesic properties.1 While its exact mechanism of action remains elusive, it is believed that binding to postsynaptic γ-aminobutyric acid receptors induces anxiolysis and sedation, while dopaminergic activity in the chemoreceptor trigger zone contributes to its antiemetic effects.2 Since the introduction of droperidol in 1967, it has been widely used by emergency physicians, psychiatrists, and anesthesiologists globally.1

Despite its therapeutic efficacy, use of droperidol has been tempered by concerns regarding its cardiovascular safety profile, specifically its potential to prolong the QT interval and precipitate cardiac arrhythmias. In 2001, the FDA placed a boxed warning on droperidol that mandated electrocardiogram (EKG) monitoring before and after treatment. This requirement has led to a widespread decrease in use, and the FDA decision sparked significant controversy among clinicians, with many organizations arguing that the evidence did not support this mandate.1

Further review of the cases cited by the FDA revealed that there were 277 reported cases of droperidol-related adverse events (AEs), but many of these cases were duplicates and occurred outside the US.3 Additionally, the doses of droperidol used in these cases were significantly higher than the typical doses used in the emergency department (ED), ranging from 25 to 250 mg.4 Typical doses for PONV range from 0.625 to 2.5 mg intravenous (IV) or intramuscular (IM). Recommended doses for agitation typically range from 2.5 to 10 mg IV and 5 to 10 mg IM.5

There has been growing interest in reevaluating the risk-benefit profile of droperidol in the ED. Since the original decision by the FDA, multiple publications have challenged the idea that droperidol has significantly higher risks associated with its use. The 2014 review by the Clinical Guidelines Committee of the American Academy of Emergency Medicine did not find evidence that low-dose droperidol (< 2.5 is unsafe for use in the ED.6 A retrospective cohort study from 2020 found no fatalities in 5784 patients. Furthermore, a prospective observational study of 1009 patients at 6 EDs who received high-dose droperidol (≤ 20.0 mg) found no evidence of increased risk for QT prolongation.7 The evidence supports the safety of droperidol for use in prehospital and hospital settings as well as in pediatric, adult, and geriatric populations.8-14 Droperidol was eventually reintroduced in 2019, which led to increased use.

The US Department of Veterans Affairs (VA) formulary has limited options (eg, haloperidol and olanzapine) that have robust evidence supporting their use to treat aggression or psychosis-related agitation. Ziprasidone injections are not on the formulary and require authorization for use, which may delay patient care and pose a safety risk. In 2021, VA Greater Los Angeles Healthcare System (VAGLAHS) received Pharmacy and Therapeutics Committee approval to use droperidol in the ED for agitation or nausea and vomiting. The purpose of this study was to evaluate safety outcomes for patients prescribed droperidol and the need for rescue medications (ie, effectiveness) in the VAGLAHS ED.

Methods

This retrospective chart review analyzed patients administered droperidol in the VAGLAHS ED from February 1, 2021, through April 30, 2023. A list of patients who had droperidol ordered in the VAGLAHS ED was obtained from the Veterans Health Information Systems and Technology Architecture. Charts were reviewed using the Computerized Patient Record System to confirm droperidol administration. Nurse documentation was reviewed to confirm the time, dose, and route of administration. In addition, droperidol dosages were categorized as < 5 mg, 5 to 10 mg, and > 10 mg to review outcomes based on the total amount administered to each patient.

Patients included in the study received droperidol in the ED within the study period, were aged ≥ 18 years, and received droperidol for acute agitation or antiemesis. Patients were excluded if they received droperidol for an indication other than agitation or antiemesis.

The study team reviewed the list of patients and audited the collected data. Reviewers were trained on the study protocols and variables identified. The following data were collected: patient demographics (age, sex, race, height, weight, allergies), Charlson Comorbidity Index (CCI) conditions, cardiac comorbidities, laboratory values at admission, basic metabolic panels, liver function tests, droperidol use (doses, indications, and documentation of safety), concomitant medications ordered with the initial droperidol order, AEs (arrhythmias, extrapyramidal symptoms [EPS], respiratory depression, mortality), medications used within 60 minutes of droperidol administration (rescue medications), other medications used within 24 hours after droperidol administration, and EKG/QTc (corrected QT interval) intervals. The data reviewed and recorded were from the date of the initial patient ED visit.

Outcomes

The primary outcome was all-cause mortality within 24 hours after droperidol administration. This outcome was measured in all patients included in this study. Secondary outcomes included rescue medications needed after droperidol administration, incidence of QT prolongation, incidence of EPS (defined as akathisia, dystonia, parkinsonism, or tardive dyskinesia), and incidence of respiratory depression. Clinically significant QTc was defined as an interval of ≥ 500 ms with incidence of arrhythmias, code blues, or intubations. Baseline risk factors for QTc prolongation were taken into consideration including electrolyte abnormalities, concomitant QT-prolonging medications, CCI score, and cardiac comorbidities. Incidence of EPS was counted if patients received medications such as diphenhydramine or benztropine after droperidol administration in addition to documentation of EPS signs and symptoms. Incidences of EPS findings were reviewed by emergency department physicians to confirm the diagnosis.

Safety was assessed by quantifying mortality rates 24 hours after droperidol administration along with incidence of AEs associated with droperidol use including QT prolongation, EPS, and respiratory depression.

The necessity of rescue medication use was assessed by nursing documentation, additional medications ordered, and/or no additional medications required for agitation within 60 minutes of droperidol administration. Sixty minutes was the chosen timeframe given that the onset of droperidol action is between 3 and 10 minutes and peaks in about 30 minutes. Medications that were considered rescue medications included diphenhydramine < 25 mg, diphenhydramine 25 to 50 mg, lorazepam < 1 mg, lorazepam 1 to 2 mg, diphenhydramine < 25 mg and lorazepam < 1 mg, diphenhydramine < 25 mg and lorazepam 1 to 2 mg, diphenhydramine 25 to 50 mg and lorazepam 1 to 2 mg, and other medications, the names and doses of which were manually documented by investigators.

Statistical Analysis

For all variables in the study, descriptive analysis was used to categorize findings. Microsoft Excel was used to calculate means, frequency counts, percentages, and categorize data.

Results

Between February 1, 2021, and April 16, 2023, 214 patients received droperidol in the VAGLAHS ED, and 207 patients were included in the study. Seven patients did not receive droperidol for the indications included (acute agitation or antiemesis). Most of the study population (89.4%) was male, and the mean age was 51.0 years. The mean CCI was 1.6. In the study, 183 (88.4%) patients received droperidol for agitation and 24 (11.6%) for nausea and vomiting (Table 1).

FDP04305180_T1
Primary Outcome

No deaths were observed in a 24-hour period after droperidol administration among the 207 patients included in the study. There were also no arrhythmias, code blues, or intubations observed with the administration of droperidol (Table 2).

FDP04305180_T2
Secondary Outcomes

A total of 144 patients (69.6%) received droperidol alone to resolve agitation or nausea and vomiting. In the remaining population, 63 (30.4%) patients were given medications concomitantly with droperidol.

Fifteen patients (7.2%) required rescue medications that were administered within 60 minutes of droperidol administration. Rescue medications were required for 7 patients (4.9%) who initially received droperidol alone compared with 8 patients (12.7%) who were administered concomitant medications with droperidol (Figure).

FDP04305180_F1
FIGURE. Rescue Medication Distribution
Extrapyramidal Symptoms

EPS occurred in 2 patients (1.0%). There was 1 incidence of tardive dyskinesia (TD) in which the patient received droperidol 2.5 mg IM for emesis. TD was resolved with diphenhydramine 50 mg. A second patient who experienced dystonia received droperidol 10 mg IM for agitation. Dystonia was resolved with benztropine 2 mg. Both patients had a CCI of 0, no cardiac comorbidities, and laboratory test results were within reference ranges. The second patient received olanzapine within 24 hours of droperidol administration; however, it was after the EPS event.

QTc Prolongation

Baseline EKGs (within 6 months prior to ED visit) were available for 102 patients (49.3%). Nine patients (8.8%) had a reported baseline QTc of ≥ 500 ms (Table 3). Of these patients, 6 had a repeat EKG and 5 had a repeat QTc < 500 ms. One patient had a baseline and repeated QTc of 512 ms with essentially no change after droperidol administration. Only 1 patient was on a potentially QTc-prolonging medication at home. None of the patients with baseline QTc > 500 ms experienced arrhythmias after droperidol administration.

FDP04305180_T3

We found that 59 patients (28.5%) had EKGs performed within 24 hours after droperidol administration. Five patients had documented QTc ≥ 500 ms, but no arrhythmias were observed in a 24-hour period. Table 4 describes the additional medications administered after the 60-minute window but within 24 hours after droperidol administration. Quetiapine 300 mg and metoclopramide 5 mg were the only medications documented that can potentially increase QTc. Patient adherence to home medications and the timing of the last dose prior to ED visit were unknown. However, no arrhythmias were noted in these patients with QTc changes. No patients experienced respiratory depression within 24 hours of droperidol administration.

FDP04305180_T4
Older Adult Patients

Thirty-eight patients were aged ≥ 65 years with a mean age of 74.2 years. Thirty-four patients (89.5%) received droperidol for agitation and 4 (10.6%) for nausea and vomiting. Only 21 patients had a baseline EKG, and 4 had QTc ≤ 500 ms. At 24 hours, EKGs were performed for 18 patients and 3 had a QTc ≤ 500 ms. No mortality or arrhythmias were reported and there were no incidences of rescue medications, EPS, or respiratory depression.

Discussion

The study included 207 patients who received droperidol for either agitation or nausea/vomiting in the VAGLAHS ED. No mortality occurred within 24 hours of droperidol administration, which is consistent with recent studies.8-14

Furthermore, 59 patients (28.5%) had an EKG performed within 24 hours of droperidol administration; 5 patients had documented QTc ≥ 500 ms. Only 3 of the patients with prolonged QTc had baseline readings for comparison. Only 2 patients had an increase in QTc interval. No arrhythmias were observed; however, the effects of observing QTc prolongation were limited due to the lack of post-EKG readings following droperidol administration. Because of the retrospective nature of the study, neither standardization of EKG at baseline nor 24-hour postadministration were possible. The study found that droperidol was effective with only 15 patients (7.3%) requiring rescue medications. In the patients who were given medications concomitantly with droperidol, it was not possible to conclude whether the patients would have required rescue medications to resolve their agitation or nausea/vomiting. Administration of concomitant medications with droperidol may be attributed to practice patterns associated with haloperidol use, which is frequently administered with concomitant medications such as diphenhydramine and/or a benzodiazepine.

AEs were rare with no documentation of respiratory depression and 2 cases (1.0%) of EPS. Both incidences of EPS resolved with diphenhydramine or benztropine. However, given the reliance on nursing documentation to capture AEs, the number of events may have been underreported.

Limitations

Standardization of dosing was a limiting factor that could affect the need for rescue medications. Another limitation was reliance on nursing reports of resolution of symptoms and comfort with agitated patients. Given the retrospective design and small sample size, this study may not have captured all potential AEs. However, the doses administered within this study population were consistent with what was expected based on other studies.8-14

Conclusions

Droperidol, an antipsychotic, is currently approved for PONV, but is also used off-label for agitation. This study found no fatalities among patients who received droperidol in the ED. The findings suggest that droperidol used for agitation and as an antiemetic, despite its FDA boxed warning, appears to be safe and showed no evidence of mortality, arrhythmias, code blues, or intubations despite the lack of postdose EKG monitoring. Among the 38 patients aged ≥ 65 years, the use of droperidol revealed no increased risks. It should be noted that droperidol appeared safe and few patients required rescue medications within this study population.

References
  1. Perkins J, Ho JD, Vilke GM, DeMers G. American Academy of Emergency Medicine Position Statement: Safety of droperidol use in the emergency department. J Emerg Med. 2015;49:91-97. doi:10.1016/j.jemermed.2014.12.024
  2. Siegel RB, Motov SM, Marcolini EG. Droperidol use in the emergency department: a clinical review. J Emerg Med. 2023;64:289-294. doi:10.1016/j.jemermed.2022.12.012
  3. Jackson CW, Sheehan AH, Reddan JG. Evidencebased review of the black-box warning for droperidol. Am J Health Syst Pharm. 2007;64:1174-1186. doi:10.2146/ajhp060505
  4. Habib AS, Gan TJ. Food and Drug Administration black box warning on the perioperative use of droperidol: a review of the cases. Anesth Analg. 2003;96(5):1377-1379. doi:10.1213/01.ane.0000063923.87560.37
  5. Droperidol. In: Micromedex (electronic version). IBM Watson Health; 2019. Accessed March 2, 2026. https://www .micromedexsolutions.com
  6. Gaw CM, Cabrera D, Bellolio F, Mattson AE, Lohse CM, Jeffery MM. Effectiveness and safety of droperidol in a United States emergency department. Am J Emerg Med. 2020;38:1310-1314. doi:10.1016/j.ajem.2019.09.007
  7. Calver L, Page CB, Downes MA, et al. The safety and effectiveness of droperidol for sedation of acute behavioral disturbance in the emergency department. Ann Emerg Med. 2015;66(3):230-238.e1. doi:10.1016/j.annemergmed.2015.03.016
  8. Ernst R, Wagstaff H, Smith M, et al. Droperidol administration among emergency department patients with abdominal pain, nausea, and vomiting. Am J Emerg Med. 2024;85:44-47. doi:10.1016/j.ajem.2024.07.060
  9. Szwak K, Sacchetti A. Droperidol use in pediatric emergency department patients. Pediatr Emerg Care. 2010;26:248-250. doi:10.1097/pec.0b013e3181d6d9f2
  10. Chase PB, Biros MH. A retrospective review of the use and safety of droperidol in a large, high-risk, inner-city emergency department patient population. Acad Emerg Med. 2002;9:1402-1410. doi:10.1111/j.1553-2712.2002.tb01609.x
  11. Mattson A, Friend K, Brown CS, Cabrera D. Reintegrating droperidol into emergency medicine practice. Am J Health Syst Pharm. 2020;77(22):1838-1845. doi:10.1093/ajhp/zxaa271
  12. Cole JB, Stang JL, DeVries PA, Martel ML, Miner JR, Driver BE. A prospective study of intramuscular droperidol or olanzapine for acute agitation in the emergency department: a natural experiment owing to drug shortages. Ann Emerg Med. 2021;78(2):274-286. doi:10.1016/j.annemergmed.2021.01.005
  13. Page CB, Parker LE, Rashford SJ, et al. Prospective study of the safety and effectiveness of droperidol in elderly patients for pre-hospital acute behavioural disturbance. Emerg Med Australas. 2020;32(5):731-736. doi:10.1111/1742-6723.13496
  14. Page CB, Parker LE, Rashford SJ, et al. A prospective study of the safety and effectiveness of droperidol inchildren for prehospital acute behavioral disturbance. Prehosp Emerg Care. 2018;23:519-526. doi:10.1080/10903127.2018.1542473
References
  1. Perkins J, Ho JD, Vilke GM, DeMers G. American Academy of Emergency Medicine Position Statement: Safety of droperidol use in the emergency department. J Emerg Med. 2015;49:91-97. doi:10.1016/j.jemermed.2014.12.024
  2. Siegel RB, Motov SM, Marcolini EG. Droperidol use in the emergency department: a clinical review. J Emerg Med. 2023;64:289-294. doi:10.1016/j.jemermed.2022.12.012
  3. Jackson CW, Sheehan AH, Reddan JG. Evidencebased review of the black-box warning for droperidol. Am J Health Syst Pharm. 2007;64:1174-1186. doi:10.2146/ajhp060505
  4. Habib AS, Gan TJ. Food and Drug Administration black box warning on the perioperative use of droperidol: a review of the cases. Anesth Analg. 2003;96(5):1377-1379. doi:10.1213/01.ane.0000063923.87560.37
  5. Droperidol. In: Micromedex (electronic version). IBM Watson Health; 2019. Accessed March 2, 2026. https://www .micromedexsolutions.com
  6. Gaw CM, Cabrera D, Bellolio F, Mattson AE, Lohse CM, Jeffery MM. Effectiveness and safety of droperidol in a United States emergency department. Am J Emerg Med. 2020;38:1310-1314. doi:10.1016/j.ajem.2019.09.007
  7. Calver L, Page CB, Downes MA, et al. The safety and effectiveness of droperidol for sedation of acute behavioral disturbance in the emergency department. Ann Emerg Med. 2015;66(3):230-238.e1. doi:10.1016/j.annemergmed.2015.03.016
  8. Ernst R, Wagstaff H, Smith M, et al. Droperidol administration among emergency department patients with abdominal pain, nausea, and vomiting. Am J Emerg Med. 2024;85:44-47. doi:10.1016/j.ajem.2024.07.060
  9. Szwak K, Sacchetti A. Droperidol use in pediatric emergency department patients. Pediatr Emerg Care. 2010;26:248-250. doi:10.1097/pec.0b013e3181d6d9f2
  10. Chase PB, Biros MH. A retrospective review of the use and safety of droperidol in a large, high-risk, inner-city emergency department patient population. Acad Emerg Med. 2002;9:1402-1410. doi:10.1111/j.1553-2712.2002.tb01609.x
  11. Mattson A, Friend K, Brown CS, Cabrera D. Reintegrating droperidol into emergency medicine practice. Am J Health Syst Pharm. 2020;77(22):1838-1845. doi:10.1093/ajhp/zxaa271
  12. Cole JB, Stang JL, DeVries PA, Martel ML, Miner JR, Driver BE. A prospective study of intramuscular droperidol or olanzapine for acute agitation in the emergency department: a natural experiment owing to drug shortages. Ann Emerg Med. 2021;78(2):274-286. doi:10.1016/j.annemergmed.2021.01.005
  13. Page CB, Parker LE, Rashford SJ, et al. Prospective study of the safety and effectiveness of droperidol in elderly patients for pre-hospital acute behavioural disturbance. Emerg Med Australas. 2020;32(5):731-736. doi:10.1111/1742-6723.13496
  14. Page CB, Parker LE, Rashford SJ, et al. A prospective study of the safety and effectiveness of droperidol inchildren for prehospital acute behavioral disturbance. Prehosp Emerg Care. 2018;23:519-526. doi:10.1080/10903127.2018.1542473
Issue
Federal Practitioner - 43(5)
Issue
Federal Practitioner - 43(5)
Page Number
180-185
Page Number
180-185
Publications
Publications
Topics
Article Type
Display Headline

Effectiveness and Safety of Droperidol Use in the VA Greater Los Angeles Healthcare System Emergency Department

Display Headline

Effectiveness and Safety of Droperidol Use in the VA Greater Los Angeles Healthcare System Emergency Department

Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

An Opportunity to Provide High-Quality Training and Care: Use of Telesupervision and Reflection on Practices

Article Type
Changed
Display Headline

An Opportunity to Provide High-Quality Training and Care: Use of Telesupervision and Reflection on Practices

Rural populations experience more health care disparities than urban populations, including a greater proportion of adults aged ≥ 65 years, higher poverty, and a higher prevalence of chronic comorbidities. Reported rates vary by study methodology and over time.1 These disparities are further exacerbated by reduced access to health care practitioners (HCPs), particularly physical and mental health specialty services, and a lack of rural health care facilities.1 HCP training programs are primarily located in urban settings and may heavily influence the geographical location and population focus of newly trained HCPs’ first positions.2 As the largest provider of health professions training, the US Department of Veterans Affairs (VA) can innovate to improve the quality of education and training while supporting rural health care sustainability and health care workforce retention.3,4 

One such innovation is expanding the implementation of telesupervision (ie, clinical supervision delivered via synchronous audio and video formats) for health professions trainees. During the COVID-19 pandemic, the literature documenting telesupervision substantially expanded across health care disciplines. These findings support telesupervision as a feasible alternative to traditional in-person supervision and suggest increased trainee comfort with telehealth use.5,6 The literature also provides insight into considerations for the use of telesupervision, including being more intentional in the development of the supervisory relationship,6-8 and enabling appropriate access to supervisors to support quality patient care and experiential learning.9,10 

This quality improvement examination of telesupervision in 11 rural VA psychology training programs spanned 3 years and included 3197 monthly surveys completed by supervisors and trainees. It supported the use of telesupervision compared with in-person or mixed modality supervision across a wide range of outcomes in upholding patient safety and maintaining the quality of supervision while also expanding trainees’ comfort in implementing telehealth care. The Table summarizes how frequently supervisors observed trainees providing clinical care via live observation, video or tape reviews, or conducting cotherapy. The clinical sessions for most trainees (70.3%) were directly observed by supervisors at least monthly across all methods. We also reviewed differences in Supervisory Working Alliance Inventory (SWAI) scores, which quantify the strength of the working relationship between trainees and supervisors, across 458 rotations by position (trainee vs supervisor) and rurality (rural vs urban sites). Overall, alliance was high with mean scores of 5.5 to 6.7 on a 7-point scale. While trainees tended to report higher alliance (P < .001), there were no differences by rurality (P = .06) or the rurality × position interaction (P = .08), and the marginally significant effects were small, indicating that rurality tended to attenuate position effects (Figure). Additional analyses of modality (in-person, telesupervision, or mixed modalities) indicated no differences. Thus, trainee and supervisor data from this project identified safe, high-quality, and consistent supervisory practices. Finally, additional data highlighted the potential benefits of a mixed-modality supervision, including both in-person supervision and telesupervision.11,12 

The expanded use of telesupervision provides several new opportunities for rural health care clinical supervisors, trainees, and veterans. Clinical supervisors who would otherwise operate as the sole HCP within their discipline or specialty at a remote clinic can increase their professional connection to a main facility and/or larger professional organization by serving as a clinical supervisor within a training program via telesupervision. This creates a greater connection to the larger mission, thereby supporting the clinical supervisor’s potential retention in their work setting.10 

FIGURE. Mean Supervisory Working Alliance Inventory Scores and 95% CIs, based on 458 rotations by position and rurality. 

Telesupervision expands the opportunity for health professions trainees to be clinically supervised by individuals with the cultural knowledge specific to the patient population served (ie, those individuals working within or knowledgeable about the particular rural setting). This supports higher quality training and patient care, even if the trainee’s primary physical location is not colocated with the clinical supervisor. 

Telesupervision can expand the number of clinical supervisors and rotations available within a health care system or clinic, particularly for specialty services (eg, psychological testing, dermatology) that are not otherwise available within specific geographic regions. Thus, telesupervision enables a supervisor with the needed expertise, specialty, or advanced training at one clinic to supervise a trainee located hundreds to thousands of miles away while serving a veteran who may or may not be colocated with either HCP. For example, the supervisor may be located in American Samoa, supervising a trainee physically residing in Hawaii who provides telehealth patient care to a veteran in Saipan. This also enables health care systems serving rural patient populations to bolster their offerings to support future trainee recruitment. 

The more trainees increase their connection to caring for rural veterans, the greater the likelihood they will develop knowledge and contribute to these communities after completing their training. Consequently, telesupervision may be fundamental to improving rural population health, contributing to the sustainability of rural health training programs and workforce retention, increasing access to needed health care in geographical areas of shortage, and allowing trainees to receive supervision from those who are most competent in the specific needs of patients living in rural communities. 

The evolving landscape of telesupervision and associated opportunities underscores the need to bolster overall clinical supervision practices. Clinical supervision is more than assuming liability, cosigning notes, and ensuring that the standard of care is met. The provision of clinical supervision is a distinct competency separate from the delivery of clinical care. However, only a small portion of those providing clinical supervision have had formal training in supervision and the development of supervision competencies.13,14 Thus, an HCP can be a highly proficient clinician while still being deficient in the skills needed to be a competent clinical supervisor, with a lack of training in supervision skills undermining engagement in effective supervision.15 

Research supports the following as essential components of effective clinical supervision: a working alliance between supervisor and supervisee, inclusive of resolution of strains/ruptures, consistent provision of evaluative feedback, consistent supervision meetings, direct observation of clinical work, and opportunities for trainees to see skills modeled through experiential supervision.13 These elements enable investment in the long-term development of the trainee through deep and nuanced feedback provided, the supervisory relationship, access to mentoring, and assistance with articulating case formulations to enable future health care professionals to provide even better care. Engaging in effective supervision requires both the development of supervision competencies and the time allocation needed to uphold these essential elements. Although vital to quality health care, clinical supervision is not consistently reflected in labor mapping or productivity metrics. Consequently, limited dedicated time for supervision (eg, direct observation of trainees’ clinical care, reflection, and preparation to address trainees’ developmental needs) and heavy workloads remain major barriers to effective supervision.14 The continued expansion of technology-assisted supervision highlights the need for HCP duties and associated clinical supervisory skills (whether in person or via telesupervision) to become more integrated into their roles within health care settings. 

Upholding effective supervision practices within telesupervision requires thoughtful implementation. Supervisors should engage in direct observation of clinical work in a manner that enables timely correction of trainees and supplemental clinical care as needed, including interventions that assist trainees. In addition, it is essential that the supervisor provides trainees with access to scheduled, ad hoc, and emergent supervision. Furthermore, the supervisor needs to ensure that, regardless of modality, the supervisor can uphold the competency/learning goal development of the trainee (ie, meet learning needs), effectively deliver and receive constructive feedback, and model critical clinical skills relevant to the clinical training area. Of utmost importance, the supervisory oversight and type of supervision required should match the setting to ensure effective supervision. 

In some clinical settings, telesupervision may be less appropriate for upholding all elements of effective supervision while matching the needs of the clinical intervention and the trainee. Thus, supervisors need to engage in the supervisory modality that enables them to effectively intervene in clinical care according to the oversight needed. For example, a physical health care intervention may require the supervisor to provide hands-on guidance for a skill or procedure, whereas the dynamics of an inpatient mental health care setting may have patient care interactions that are not fully met by the use of telesupervision, such as complex patients’ needs, acuity, and crisis management. As telesupervision research continues to expand to better understand these applied complexities, there will be an evolving knowledge of the nuances in the application of telesupervision that best capture the benefits of telesupervision without compromising the quality of training and patient care. 

CONCLUSIONS 

Clinicians working with HCP trainees have the opportunity to use telesupervision to create a dynamic and rich learning environment while maintaining the quality of training and potentially reducing health disparities experienced by rural veterans. With this opportunity also comes the need to recognize clinical supervision as a competency and an essential role of an HCP. In doing so, a thoughtful approach to supervision will enable the powerful tool of telesupervision to be used to its highest potential in a responsible manner that does not overextend its reach. 

References
  1. National Healthcare Quality and Disparities Report Chartbook on Rural Healthcare. Agency for Healthcare Research and Quality; November 2021. Accessed January 26, 2026. https://www.ahrq.gov/sites/default/files/wysiwyg/research/findings/nhqrdr/chartbooks/2019-qdr-rural-chartbook.pdf
  2. PHYSICIAN WORKFORCE: Caps on Medicare-Funded Graduate Medical Education at Teaching Hospitals. US Government Accountability Office; May 2021. Accessed January 26, 2026. https://www.gao.gov/assets/gao-21-391.pdf
  3. Passion to Learn, Power to Heal. US Dept of Veterans Affairs, Office of Academic Affiliations; 2021. Accessed January 26, 2026. https://content.yudu.com/web/448fx/0A448g9/75thAnniversary2021/html/index.html?origin=reader
  4. US Department of Veterans Affairs. Impact of VACAA (Choice ACT) on training at VA. 2018. Accessed January 26, 2026. https://www.va.gov/OAA/VACAA_Impact.asp
  5. Frye WS, Feldman M, Katzenstein J, et al. Modified training experiences for psychology interns and fellows during COVID-19: use of telepsychology and telesupervision by child and adolescent training programs. J Clin Psychol Med Settings. 2022;29:840-848. doi:10.1007/s10880-021-09839-4
  6. Bernhard PA, Camins JS. Supervision from afar: trainees’ perspectives on telesupervision. Couns Psychol Q. 2021;34:377-386. doi:10.1080/09515070.2020.1770697
  7. Schmittel EM, Lettenberger-Klein C, Oliver T, et al. Intentionality in academic telesupervision: a phenomenological study of faculty telesupervisors’ experiences. Contemp Fam Ther. 2023;45:61-74. doi:10.1007/s10591-021-09601-w
  8. Hames JL, Bell DJ, Perez-Lima LM, et al. Navigating uncharted waters: considerations for training clinics in the rapid transition to telepsychology and telesupervision during COVID-19. J Psychother Integr. 2020;30:348-365. doi:10.1037/int0000224
  9. Hausman C, Vescera K, Bacigalupi R, et al. Remote supervision and training in suicide prevention during the time of the coronavirus pandemic: recommendations for training programs and supervisors. Train Educ Prof Psychol. 2021;15:290-297. doi:10.1037/tep0000379
  10. Shearer EM, Jordan SE, Eliason KD, et al. Perspectives of psychology supervisors and trainees: implications for supervision and telesupervision. J Technol Behav Sci. 2024;9:68-82. doi:10.1007/s41347-024-00387-w
  11. Shearer EM, Jordan SE, Mackintosh M. Strategies to facilitate and assess effective supervision across in-person and virtual modalities. Presented at: Annual Meeting of the American Psychological Association; August 3, 2023; Washington, DC.
  12. Shearer EM, Mackintosh M, Jordan SE, et al. Using technology to enhance the supervisory relationship: A review of the data. Presented at: Annual Meeting of the American Psychological Association; August 8, 2024; Seattle, WA.
  13. Falender CA, Shafranske EP. Clinical Supervision: A Competency-Based Approach. 2nd ed. American Psychological Association; 2021.
  14. Hutman H, Enyedy K, Ellis M, et al. Training public sector clinicians in competency-based clinical supervision: methods, curriculum, and lessons learned. J Contemp Psychother. 2021;51:227-237. doi:10.1007/s10879-021-09499-3
  15. Rothwell C, Kehoe A, Farook SF, et al. Enablers and barriers to effective clinical supervision in the workplace: a rapid evidence review. BMJ Open. 2021;11:e052929. doi:10.1136/bmjopen-2021-052929
Article PDF
Author and Disclosure Information

Shiloh E. Jordan, PhDa,b; Margaret-Anne Mackintosh, PhDb,c

Author affiliations 

aVeterans Affairs Pacific Islands Health Care System, Honolulu, Hawaii 

bVeterans Rural Health Resource Center, Salt Lake City, Utah 

cNational Center for PTSD, Dissemination and Training Division, Veterans Affairs Palo Alto Health Care System, Menlo Park, California 

Author disclosures 

This work was supported by the US Department of Veterans Affairs, Veterans Health Administration, Office of Rural Health NOMAD #PRFY-008768, and support and resources from the National Center for PTSD. 

Disclaimer 

The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies, including the Department of Veterans Affairs. 

Ethics and consent 

The US Department of Veterans Affairs (VA) Office of Research and Development and the VA Portland Health Care System Research Office designated this project as quality improvement and not subject to institutional review board oversight. 

Correspondence: Shiloh Jordan (shiloh.jordan@va.gov) 

Fed Pract. 2026;43(5). Published May 15. doi:10.12788/fp.0692

Issue
Federal Practitioner - 43(5)
Publications
Topics
Page Number
176-179
Sections
Author and Disclosure Information

Shiloh E. Jordan, PhDa,b; Margaret-Anne Mackintosh, PhDb,c

Author affiliations 

aVeterans Affairs Pacific Islands Health Care System, Honolulu, Hawaii 

bVeterans Rural Health Resource Center, Salt Lake City, Utah 

cNational Center for PTSD, Dissemination and Training Division, Veterans Affairs Palo Alto Health Care System, Menlo Park, California 

Author disclosures 

This work was supported by the US Department of Veterans Affairs, Veterans Health Administration, Office of Rural Health NOMAD #PRFY-008768, and support and resources from the National Center for PTSD. 

Disclaimer 

The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies, including the Department of Veterans Affairs. 

Ethics and consent 

The US Department of Veterans Affairs (VA) Office of Research and Development and the VA Portland Health Care System Research Office designated this project as quality improvement and not subject to institutional review board oversight. 

Correspondence: Shiloh Jordan (shiloh.jordan@va.gov) 

Fed Pract. 2026;43(5). Published May 15. doi:10.12788/fp.0692

Author and Disclosure Information

Shiloh E. Jordan, PhDa,b; Margaret-Anne Mackintosh, PhDb,c

Author affiliations 

aVeterans Affairs Pacific Islands Health Care System, Honolulu, Hawaii 

bVeterans Rural Health Resource Center, Salt Lake City, Utah 

cNational Center for PTSD, Dissemination and Training Division, Veterans Affairs Palo Alto Health Care System, Menlo Park, California 

Author disclosures 

This work was supported by the US Department of Veterans Affairs, Veterans Health Administration, Office of Rural Health NOMAD #PRFY-008768, and support and resources from the National Center for PTSD. 

Disclaimer 

The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies, including the Department of Veterans Affairs. 

Ethics and consent 

The US Department of Veterans Affairs (VA) Office of Research and Development and the VA Portland Health Care System Research Office designated this project as quality improvement and not subject to institutional review board oversight. 

Correspondence: Shiloh Jordan (shiloh.jordan@va.gov) 

Fed Pract. 2026;43(5). Published May 15. doi:10.12788/fp.0692

Article PDF
Article PDF

Rural populations experience more health care disparities than urban populations, including a greater proportion of adults aged ≥ 65 years, higher poverty, and a higher prevalence of chronic comorbidities. Reported rates vary by study methodology and over time.1 These disparities are further exacerbated by reduced access to health care practitioners (HCPs), particularly physical and mental health specialty services, and a lack of rural health care facilities.1 HCP training programs are primarily located in urban settings and may heavily influence the geographical location and population focus of newly trained HCPs’ first positions.2 As the largest provider of health professions training, the US Department of Veterans Affairs (VA) can innovate to improve the quality of education and training while supporting rural health care sustainability and health care workforce retention.3,4 

One such innovation is expanding the implementation of telesupervision (ie, clinical supervision delivered via synchronous audio and video formats) for health professions trainees. During the COVID-19 pandemic, the literature documenting telesupervision substantially expanded across health care disciplines. These findings support telesupervision as a feasible alternative to traditional in-person supervision and suggest increased trainee comfort with telehealth use.5,6 The literature also provides insight into considerations for the use of telesupervision, including being more intentional in the development of the supervisory relationship,6-8 and enabling appropriate access to supervisors to support quality patient care and experiential learning.9,10 

This quality improvement examination of telesupervision in 11 rural VA psychology training programs spanned 3 years and included 3197 monthly surveys completed by supervisors and trainees. It supported the use of telesupervision compared with in-person or mixed modality supervision across a wide range of outcomes in upholding patient safety and maintaining the quality of supervision while also expanding trainees’ comfort in implementing telehealth care. The Table summarizes how frequently supervisors observed trainees providing clinical care via live observation, video or tape reviews, or conducting cotherapy. The clinical sessions for most trainees (70.3%) were directly observed by supervisors at least monthly across all methods. We also reviewed differences in Supervisory Working Alliance Inventory (SWAI) scores, which quantify the strength of the working relationship between trainees and supervisors, across 458 rotations by position (trainee vs supervisor) and rurality (rural vs urban sites). Overall, alliance was high with mean scores of 5.5 to 6.7 on a 7-point scale. While trainees tended to report higher alliance (P < .001), there were no differences by rurality (P = .06) or the rurality × position interaction (P = .08), and the marginally significant effects were small, indicating that rurality tended to attenuate position effects (Figure). Additional analyses of modality (in-person, telesupervision, or mixed modalities) indicated no differences. Thus, trainee and supervisor data from this project identified safe, high-quality, and consistent supervisory practices. Finally, additional data highlighted the potential benefits of a mixed-modality supervision, including both in-person supervision and telesupervision.11,12 

The expanded use of telesupervision provides several new opportunities for rural health care clinical supervisors, trainees, and veterans. Clinical supervisors who would otherwise operate as the sole HCP within their discipline or specialty at a remote clinic can increase their professional connection to a main facility and/or larger professional organization by serving as a clinical supervisor within a training program via telesupervision. This creates a greater connection to the larger mission, thereby supporting the clinical supervisor’s potential retention in their work setting.10 

FIGURE. Mean Supervisory Working Alliance Inventory Scores and 95% CIs, based on 458 rotations by position and rurality. 

Telesupervision expands the opportunity for health professions trainees to be clinically supervised by individuals with the cultural knowledge specific to the patient population served (ie, those individuals working within or knowledgeable about the particular rural setting). This supports higher quality training and patient care, even if the trainee’s primary physical location is not colocated with the clinical supervisor. 

Telesupervision can expand the number of clinical supervisors and rotations available within a health care system or clinic, particularly for specialty services (eg, psychological testing, dermatology) that are not otherwise available within specific geographic regions. Thus, telesupervision enables a supervisor with the needed expertise, specialty, or advanced training at one clinic to supervise a trainee located hundreds to thousands of miles away while serving a veteran who may or may not be colocated with either HCP. For example, the supervisor may be located in American Samoa, supervising a trainee physically residing in Hawaii who provides telehealth patient care to a veteran in Saipan. This also enables health care systems serving rural patient populations to bolster their offerings to support future trainee recruitment. 

The more trainees increase their connection to caring for rural veterans, the greater the likelihood they will develop knowledge and contribute to these communities after completing their training. Consequently, telesupervision may be fundamental to improving rural population health, contributing to the sustainability of rural health training programs and workforce retention, increasing access to needed health care in geographical areas of shortage, and allowing trainees to receive supervision from those who are most competent in the specific needs of patients living in rural communities. 

The evolving landscape of telesupervision and associated opportunities underscores the need to bolster overall clinical supervision practices. Clinical supervision is more than assuming liability, cosigning notes, and ensuring that the standard of care is met. The provision of clinical supervision is a distinct competency separate from the delivery of clinical care. However, only a small portion of those providing clinical supervision have had formal training in supervision and the development of supervision competencies.13,14 Thus, an HCP can be a highly proficient clinician while still being deficient in the skills needed to be a competent clinical supervisor, with a lack of training in supervision skills undermining engagement in effective supervision.15 

Research supports the following as essential components of effective clinical supervision: a working alliance between supervisor and supervisee, inclusive of resolution of strains/ruptures, consistent provision of evaluative feedback, consistent supervision meetings, direct observation of clinical work, and opportunities for trainees to see skills modeled through experiential supervision.13 These elements enable investment in the long-term development of the trainee through deep and nuanced feedback provided, the supervisory relationship, access to mentoring, and assistance with articulating case formulations to enable future health care professionals to provide even better care. Engaging in effective supervision requires both the development of supervision competencies and the time allocation needed to uphold these essential elements. Although vital to quality health care, clinical supervision is not consistently reflected in labor mapping or productivity metrics. Consequently, limited dedicated time for supervision (eg, direct observation of trainees’ clinical care, reflection, and preparation to address trainees’ developmental needs) and heavy workloads remain major barriers to effective supervision.14 The continued expansion of technology-assisted supervision highlights the need for HCP duties and associated clinical supervisory skills (whether in person or via telesupervision) to become more integrated into their roles within health care settings. 

Upholding effective supervision practices within telesupervision requires thoughtful implementation. Supervisors should engage in direct observation of clinical work in a manner that enables timely correction of trainees and supplemental clinical care as needed, including interventions that assist trainees. In addition, it is essential that the supervisor provides trainees with access to scheduled, ad hoc, and emergent supervision. Furthermore, the supervisor needs to ensure that, regardless of modality, the supervisor can uphold the competency/learning goal development of the trainee (ie, meet learning needs), effectively deliver and receive constructive feedback, and model critical clinical skills relevant to the clinical training area. Of utmost importance, the supervisory oversight and type of supervision required should match the setting to ensure effective supervision. 

In some clinical settings, telesupervision may be less appropriate for upholding all elements of effective supervision while matching the needs of the clinical intervention and the trainee. Thus, supervisors need to engage in the supervisory modality that enables them to effectively intervene in clinical care according to the oversight needed. For example, a physical health care intervention may require the supervisor to provide hands-on guidance for a skill or procedure, whereas the dynamics of an inpatient mental health care setting may have patient care interactions that are not fully met by the use of telesupervision, such as complex patients’ needs, acuity, and crisis management. As telesupervision research continues to expand to better understand these applied complexities, there will be an evolving knowledge of the nuances in the application of telesupervision that best capture the benefits of telesupervision without compromising the quality of training and patient care. 

CONCLUSIONS 

Clinicians working with HCP trainees have the opportunity to use telesupervision to create a dynamic and rich learning environment while maintaining the quality of training and potentially reducing health disparities experienced by rural veterans. With this opportunity also comes the need to recognize clinical supervision as a competency and an essential role of an HCP. In doing so, a thoughtful approach to supervision will enable the powerful tool of telesupervision to be used to its highest potential in a responsible manner that does not overextend its reach. 

Rural populations experience more health care disparities than urban populations, including a greater proportion of adults aged ≥ 65 years, higher poverty, and a higher prevalence of chronic comorbidities. Reported rates vary by study methodology and over time.1 These disparities are further exacerbated by reduced access to health care practitioners (HCPs), particularly physical and mental health specialty services, and a lack of rural health care facilities.1 HCP training programs are primarily located in urban settings and may heavily influence the geographical location and population focus of newly trained HCPs’ first positions.2 As the largest provider of health professions training, the US Department of Veterans Affairs (VA) can innovate to improve the quality of education and training while supporting rural health care sustainability and health care workforce retention.3,4 

One such innovation is expanding the implementation of telesupervision (ie, clinical supervision delivered via synchronous audio and video formats) for health professions trainees. During the COVID-19 pandemic, the literature documenting telesupervision substantially expanded across health care disciplines. These findings support telesupervision as a feasible alternative to traditional in-person supervision and suggest increased trainee comfort with telehealth use.5,6 The literature also provides insight into considerations for the use of telesupervision, including being more intentional in the development of the supervisory relationship,6-8 and enabling appropriate access to supervisors to support quality patient care and experiential learning.9,10 

This quality improvement examination of telesupervision in 11 rural VA psychology training programs spanned 3 years and included 3197 monthly surveys completed by supervisors and trainees. It supported the use of telesupervision compared with in-person or mixed modality supervision across a wide range of outcomes in upholding patient safety and maintaining the quality of supervision while also expanding trainees’ comfort in implementing telehealth care. The Table summarizes how frequently supervisors observed trainees providing clinical care via live observation, video or tape reviews, or conducting cotherapy. The clinical sessions for most trainees (70.3%) were directly observed by supervisors at least monthly across all methods. We also reviewed differences in Supervisory Working Alliance Inventory (SWAI) scores, which quantify the strength of the working relationship between trainees and supervisors, across 458 rotations by position (trainee vs supervisor) and rurality (rural vs urban sites). Overall, alliance was high with mean scores of 5.5 to 6.7 on a 7-point scale. While trainees tended to report higher alliance (P < .001), there were no differences by rurality (P = .06) or the rurality × position interaction (P = .08), and the marginally significant effects were small, indicating that rurality tended to attenuate position effects (Figure). Additional analyses of modality (in-person, telesupervision, or mixed modalities) indicated no differences. Thus, trainee and supervisor data from this project identified safe, high-quality, and consistent supervisory practices. Finally, additional data highlighted the potential benefits of a mixed-modality supervision, including both in-person supervision and telesupervision.11,12 

The expanded use of telesupervision provides several new opportunities for rural health care clinical supervisors, trainees, and veterans. Clinical supervisors who would otherwise operate as the sole HCP within their discipline or specialty at a remote clinic can increase their professional connection to a main facility and/or larger professional organization by serving as a clinical supervisor within a training program via telesupervision. This creates a greater connection to the larger mission, thereby supporting the clinical supervisor’s potential retention in their work setting.10 

FIGURE. Mean Supervisory Working Alliance Inventory Scores and 95% CIs, based on 458 rotations by position and rurality. 

Telesupervision expands the opportunity for health professions trainees to be clinically supervised by individuals with the cultural knowledge specific to the patient population served (ie, those individuals working within or knowledgeable about the particular rural setting). This supports higher quality training and patient care, even if the trainee’s primary physical location is not colocated with the clinical supervisor. 

Telesupervision can expand the number of clinical supervisors and rotations available within a health care system or clinic, particularly for specialty services (eg, psychological testing, dermatology) that are not otherwise available within specific geographic regions. Thus, telesupervision enables a supervisor with the needed expertise, specialty, or advanced training at one clinic to supervise a trainee located hundreds to thousands of miles away while serving a veteran who may or may not be colocated with either HCP. For example, the supervisor may be located in American Samoa, supervising a trainee physically residing in Hawaii who provides telehealth patient care to a veteran in Saipan. This also enables health care systems serving rural patient populations to bolster their offerings to support future trainee recruitment. 

The more trainees increase their connection to caring for rural veterans, the greater the likelihood they will develop knowledge and contribute to these communities after completing their training. Consequently, telesupervision may be fundamental to improving rural population health, contributing to the sustainability of rural health training programs and workforce retention, increasing access to needed health care in geographical areas of shortage, and allowing trainees to receive supervision from those who are most competent in the specific needs of patients living in rural communities. 

The evolving landscape of telesupervision and associated opportunities underscores the need to bolster overall clinical supervision practices. Clinical supervision is more than assuming liability, cosigning notes, and ensuring that the standard of care is met. The provision of clinical supervision is a distinct competency separate from the delivery of clinical care. However, only a small portion of those providing clinical supervision have had formal training in supervision and the development of supervision competencies.13,14 Thus, an HCP can be a highly proficient clinician while still being deficient in the skills needed to be a competent clinical supervisor, with a lack of training in supervision skills undermining engagement in effective supervision.15 

Research supports the following as essential components of effective clinical supervision: a working alliance between supervisor and supervisee, inclusive of resolution of strains/ruptures, consistent provision of evaluative feedback, consistent supervision meetings, direct observation of clinical work, and opportunities for trainees to see skills modeled through experiential supervision.13 These elements enable investment in the long-term development of the trainee through deep and nuanced feedback provided, the supervisory relationship, access to mentoring, and assistance with articulating case formulations to enable future health care professionals to provide even better care. Engaging in effective supervision requires both the development of supervision competencies and the time allocation needed to uphold these essential elements. Although vital to quality health care, clinical supervision is not consistently reflected in labor mapping or productivity metrics. Consequently, limited dedicated time for supervision (eg, direct observation of trainees’ clinical care, reflection, and preparation to address trainees’ developmental needs) and heavy workloads remain major barriers to effective supervision.14 The continued expansion of technology-assisted supervision highlights the need for HCP duties and associated clinical supervisory skills (whether in person or via telesupervision) to become more integrated into their roles within health care settings. 

Upholding effective supervision practices within telesupervision requires thoughtful implementation. Supervisors should engage in direct observation of clinical work in a manner that enables timely correction of trainees and supplemental clinical care as needed, including interventions that assist trainees. In addition, it is essential that the supervisor provides trainees with access to scheduled, ad hoc, and emergent supervision. Furthermore, the supervisor needs to ensure that, regardless of modality, the supervisor can uphold the competency/learning goal development of the trainee (ie, meet learning needs), effectively deliver and receive constructive feedback, and model critical clinical skills relevant to the clinical training area. Of utmost importance, the supervisory oversight and type of supervision required should match the setting to ensure effective supervision. 

In some clinical settings, telesupervision may be less appropriate for upholding all elements of effective supervision while matching the needs of the clinical intervention and the trainee. Thus, supervisors need to engage in the supervisory modality that enables them to effectively intervene in clinical care according to the oversight needed. For example, a physical health care intervention may require the supervisor to provide hands-on guidance for a skill or procedure, whereas the dynamics of an inpatient mental health care setting may have patient care interactions that are not fully met by the use of telesupervision, such as complex patients’ needs, acuity, and crisis management. As telesupervision research continues to expand to better understand these applied complexities, there will be an evolving knowledge of the nuances in the application of telesupervision that best capture the benefits of telesupervision without compromising the quality of training and patient care. 

CONCLUSIONS 

Clinicians working with HCP trainees have the opportunity to use telesupervision to create a dynamic and rich learning environment while maintaining the quality of training and potentially reducing health disparities experienced by rural veterans. With this opportunity also comes the need to recognize clinical supervision as a competency and an essential role of an HCP. In doing so, a thoughtful approach to supervision will enable the powerful tool of telesupervision to be used to its highest potential in a responsible manner that does not overextend its reach. 

References
  1. National Healthcare Quality and Disparities Report Chartbook on Rural Healthcare. Agency for Healthcare Research and Quality; November 2021. Accessed January 26, 2026. https://www.ahrq.gov/sites/default/files/wysiwyg/research/findings/nhqrdr/chartbooks/2019-qdr-rural-chartbook.pdf
  2. PHYSICIAN WORKFORCE: Caps on Medicare-Funded Graduate Medical Education at Teaching Hospitals. US Government Accountability Office; May 2021. Accessed January 26, 2026. https://www.gao.gov/assets/gao-21-391.pdf
  3. Passion to Learn, Power to Heal. US Dept of Veterans Affairs, Office of Academic Affiliations; 2021. Accessed January 26, 2026. https://content.yudu.com/web/448fx/0A448g9/75thAnniversary2021/html/index.html?origin=reader
  4. US Department of Veterans Affairs. Impact of VACAA (Choice ACT) on training at VA. 2018. Accessed January 26, 2026. https://www.va.gov/OAA/VACAA_Impact.asp
  5. Frye WS, Feldman M, Katzenstein J, et al. Modified training experiences for psychology interns and fellows during COVID-19: use of telepsychology and telesupervision by child and adolescent training programs. J Clin Psychol Med Settings. 2022;29:840-848. doi:10.1007/s10880-021-09839-4
  6. Bernhard PA, Camins JS. Supervision from afar: trainees’ perspectives on telesupervision. Couns Psychol Q. 2021;34:377-386. doi:10.1080/09515070.2020.1770697
  7. Schmittel EM, Lettenberger-Klein C, Oliver T, et al. Intentionality in academic telesupervision: a phenomenological study of faculty telesupervisors’ experiences. Contemp Fam Ther. 2023;45:61-74. doi:10.1007/s10591-021-09601-w
  8. Hames JL, Bell DJ, Perez-Lima LM, et al. Navigating uncharted waters: considerations for training clinics in the rapid transition to telepsychology and telesupervision during COVID-19. J Psychother Integr. 2020;30:348-365. doi:10.1037/int0000224
  9. Hausman C, Vescera K, Bacigalupi R, et al. Remote supervision and training in suicide prevention during the time of the coronavirus pandemic: recommendations for training programs and supervisors. Train Educ Prof Psychol. 2021;15:290-297. doi:10.1037/tep0000379
  10. Shearer EM, Jordan SE, Eliason KD, et al. Perspectives of psychology supervisors and trainees: implications for supervision and telesupervision. J Technol Behav Sci. 2024;9:68-82. doi:10.1007/s41347-024-00387-w
  11. Shearer EM, Jordan SE, Mackintosh M. Strategies to facilitate and assess effective supervision across in-person and virtual modalities. Presented at: Annual Meeting of the American Psychological Association; August 3, 2023; Washington, DC.
  12. Shearer EM, Mackintosh M, Jordan SE, et al. Using technology to enhance the supervisory relationship: A review of the data. Presented at: Annual Meeting of the American Psychological Association; August 8, 2024; Seattle, WA.
  13. Falender CA, Shafranske EP. Clinical Supervision: A Competency-Based Approach. 2nd ed. American Psychological Association; 2021.
  14. Hutman H, Enyedy K, Ellis M, et al. Training public sector clinicians in competency-based clinical supervision: methods, curriculum, and lessons learned. J Contemp Psychother. 2021;51:227-237. doi:10.1007/s10879-021-09499-3
  15. Rothwell C, Kehoe A, Farook SF, et al. Enablers and barriers to effective clinical supervision in the workplace: a rapid evidence review. BMJ Open. 2021;11:e052929. doi:10.1136/bmjopen-2021-052929
References
  1. National Healthcare Quality and Disparities Report Chartbook on Rural Healthcare. Agency for Healthcare Research and Quality; November 2021. Accessed January 26, 2026. https://www.ahrq.gov/sites/default/files/wysiwyg/research/findings/nhqrdr/chartbooks/2019-qdr-rural-chartbook.pdf
  2. PHYSICIAN WORKFORCE: Caps on Medicare-Funded Graduate Medical Education at Teaching Hospitals. US Government Accountability Office; May 2021. Accessed January 26, 2026. https://www.gao.gov/assets/gao-21-391.pdf
  3. Passion to Learn, Power to Heal. US Dept of Veterans Affairs, Office of Academic Affiliations; 2021. Accessed January 26, 2026. https://content.yudu.com/web/448fx/0A448g9/75thAnniversary2021/html/index.html?origin=reader
  4. US Department of Veterans Affairs. Impact of VACAA (Choice ACT) on training at VA. 2018. Accessed January 26, 2026. https://www.va.gov/OAA/VACAA_Impact.asp
  5. Frye WS, Feldman M, Katzenstein J, et al. Modified training experiences for psychology interns and fellows during COVID-19: use of telepsychology and telesupervision by child and adolescent training programs. J Clin Psychol Med Settings. 2022;29:840-848. doi:10.1007/s10880-021-09839-4
  6. Bernhard PA, Camins JS. Supervision from afar: trainees’ perspectives on telesupervision. Couns Psychol Q. 2021;34:377-386. doi:10.1080/09515070.2020.1770697
  7. Schmittel EM, Lettenberger-Klein C, Oliver T, et al. Intentionality in academic telesupervision: a phenomenological study of faculty telesupervisors’ experiences. Contemp Fam Ther. 2023;45:61-74. doi:10.1007/s10591-021-09601-w
  8. Hames JL, Bell DJ, Perez-Lima LM, et al. Navigating uncharted waters: considerations for training clinics in the rapid transition to telepsychology and telesupervision during COVID-19. J Psychother Integr. 2020;30:348-365. doi:10.1037/int0000224
  9. Hausman C, Vescera K, Bacigalupi R, et al. Remote supervision and training in suicide prevention during the time of the coronavirus pandemic: recommendations for training programs and supervisors. Train Educ Prof Psychol. 2021;15:290-297. doi:10.1037/tep0000379
  10. Shearer EM, Jordan SE, Eliason KD, et al. Perspectives of psychology supervisors and trainees: implications for supervision and telesupervision. J Technol Behav Sci. 2024;9:68-82. doi:10.1007/s41347-024-00387-w
  11. Shearer EM, Jordan SE, Mackintosh M. Strategies to facilitate and assess effective supervision across in-person and virtual modalities. Presented at: Annual Meeting of the American Psychological Association; August 3, 2023; Washington, DC.
  12. Shearer EM, Mackintosh M, Jordan SE, et al. Using technology to enhance the supervisory relationship: A review of the data. Presented at: Annual Meeting of the American Psychological Association; August 8, 2024; Seattle, WA.
  13. Falender CA, Shafranske EP. Clinical Supervision: A Competency-Based Approach. 2nd ed. American Psychological Association; 2021.
  14. Hutman H, Enyedy K, Ellis M, et al. Training public sector clinicians in competency-based clinical supervision: methods, curriculum, and lessons learned. J Contemp Psychother. 2021;51:227-237. doi:10.1007/s10879-021-09499-3
  15. Rothwell C, Kehoe A, Farook SF, et al. Enablers and barriers to effective clinical supervision in the workplace: a rapid evidence review. BMJ Open. 2021;11:e052929. doi:10.1136/bmjopen-2021-052929
Issue
Federal Practitioner - 43(5)
Issue
Federal Practitioner - 43(5)
Page Number
176-179
Page Number
176-179
Publications
Publications
Topics
Article Type
Display Headline

An Opportunity to Provide High-Quality Training and Care: Use of Telesupervision and Reflection on Practices

Display Headline

An Opportunity to Provide High-Quality Training and Care: Use of Telesupervision and Reflection on Practices

Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

Hypochlorous Acid: A Multipurpose New Addition to the Military Med Bag?

Article Type
Changed
Display Headline

Hypochlorous Acid: A Multipurpose New Addition to the Military Med Bag?

Exogenously, hypochlorous acid (HOCl) is a powerful oxidizing agent formed from chlorine dissolved in water. Within the body, it is part of the immune response, created by activated leukocytes, which form HOCl from hydrogen peroxide and chloride. HOCl has been used as a disinfectant in wound care due to its antimicrobial properties via inhibition of DNA synthesis, protein synthesis, and decreased adenosine triphosphate production. It specifically targets bacteria by blocking bacterial cell wall synthesis and decreasing DNA replication.1 

During the COVID-19 pandemic, HOCl was recommended by the US Environmental Protection Agency as a disinfectant.2 HOCl can be purchased from a supplier, though its major limitation is its shelf life. The main environmental factors affecting its stability are sunlight exposure, temperatures > 25 °C, and air exposure. HOCl is stable and most potent when the pH falls between 3.5 and 5.5.3 It is best stored in a cool, dark environment to maintain efficacy for 2 weeks. Rossi-Fedele et al found that when exposed to sunlight, chlorine reduction starts on day 4, whereas solutions kept in dark storage remained more stable, with this process starting after day 14.4 

HOCl can also be made on-site via a machine, which ranges in price from a portable version costing < $200 to a large commercial option that can cost $7000 to $25,000. HOCl is produced by mixing noniodinated salt and water, and using electrolysis, which generally takes less than 10 minutes before it is ready for use.2 Given the cost and nonreusable nature of disinfecting wipes, HOCl may be more worthwhile for economic and disposal purposes in the long term. 

Different concentrations of HOCl are readily available commercially. Because topical application of 1% HOCl may cause skin irritation, solutions with lower concentrations have been developed including Vashe (0.03% HOCl; SteadMed), PhaseOne (0.025% HOCl solution; IHT), OCuSOFT (0.02% HOCl; OCuSOFT), Bruder (0.02% HOCl; Bruder Healthcare), Acuicyn (0.01% HOCl solution in dilute saline; Sonoma Pharmaceuticals), and Avenova (0.01% HOCl solution; NovaBay Pharmaceuticals).5 

Aside from its surface utility, HOCl has been researched for its beneficial effects on skin. HOCl has been shown to be helpful intraoperatively and postoperatively in improving adverse effects (AEs) after hair restoration, including erythema and pruritus, and in optimizing healing by reducing inflammation, likely due to its antimicrobial properties and ability to promote oxygenation.6 Bucko et al demonstrated that Microcyn scar gel (with HOCl) was a superior nonirritating, nontoxic method of not only improving scar appearance (vascularity, scar height, and pliability) but also reducing scar symptoms of pain and pruritus in comparison to 100% silicone scar gel (traditional application used to improve scarring).7 Zhang et al demonstrated that HOCl consistently improved symptom relief of blepharitis, including meibomian gland, eyelash, and eyelid redness, irritation, and appearance in comparison as well as were better tolerated in comparison to traditional recommendations of eyelid compresses and wash (tea tree oil, diluted baby shampoo, and topical antibiotics).8 In children with moderate to severe atopic dermatitis, Majewski et al compared a traditional bleach bath with a body wash containing hypochlorite (NaOCl; hypochlorous acid in alkaline aqueous solution). The body wash proved to be more convenient (showering vs 10-minute bath) and significantly improved symptoms while reducing the need for topical corticosteroids (common treatment modality for atopic dermatitis).9 

The skin is the body’s primary defense against both dermatologic and respiratory infections. The face is especially vulnerable to microbes via airborne or environmental transmission, mechanical irritation, and touch. In the military environment, personal protective equipment (PPE) or uniform items may increase the risk of dermatologic conditions such as allergic or irritant dermatitis, infection, and friction blisters. 

In a literature review of 312 dermatologic articles published between 2002 and 2022, Singal and Lipner found that among deployed soldiers serving in hot and dry climates, dermatitis and eczematous conditions were the most common, whereas bacterial and fungal conditions were most common in hot and humid settings. In the nondeployed setting, dermatitis and eczematous, acne, and fungal infections were the most common skin conditions. This is reflected by the unique circumstances that service members face at home and while deployed, when they may be more vulnerable to developing new or worsening chronic skin conditions depending on the environment (access to shelter, humid vs dry environments), and decreased access or time for hygiene (shared quarters at home in barracks or on deployment). Occupation-related conditions also play a large role in military dermatologic conditions.10 

Dever et al noted the unique risks and exposures in the environment itself (plants, arthropods) as well as uniform items (protective gear) that carry an increased risk of friction irritation and dermatitis. Occupational exposures commonly associated with irritant contact dermatitis include alcohols, oils, fuel, disinfectants, and solvents. Chemicals in military uniforms themselves (eg, formaldehyde resins, disperse dyes, and chromate-containing dyes) also have the potential to cause allergic contact dermatitis, which can be challenging to address given the emphasis on uniformity and standards.11 PPE also may exacerbate rosacea and acne. 

Some pathologies are associated specifically with bacteria, such as Cutibacterium acnes, as seen in acne vulgaris. Colonization of bacteria on the face may create biofilms that are difficult to detect, may be resistant to antibiotic therapy, and are implicated in other dermatologic conditions, such as persistent wounds, atopic dermatitis, and candidiasis.12 

Biofilm and antibiotic resistance already pose a risk to patient care, but the unique environmental conditions and exposures of military settings can amplify this risk in the military population.13 Using HOCl in austere environments or the field for wound care may help reduce microbial load and the subsequent need for systemic antibiotics which carry the risk of gastrointestinal AEs and resistance.1 

An optimized healing rate would support operational objectives by enabling service members to remain on full duty and avoid medications, which may prevent them from special duty, such as aviation. Sakarya et al found that HOCl solution enhanced wound healing in contrast with povidone-iodine (PI), while a study by Dharap et al discussed how HOCl provided major improvement in ulcer wound size (and infection), as well as significant reduction of inflammation.13 

Anagnostopoulos et al studied the efficacy of 0.01% HOCl vs other disinfectants (5% PI, 4% chlorhexidine gluconate [CHG] and 70% isopropyl alcohol [IPA]) against common skin organisms, including methicillin-susceptible Staphylococcus aureus and methicillin-susceptible Staphylococcus epidermidis. The study found that HOCl had at least equal if not greater efficacy to PI, CHG, and IPA depending on the bacterial strain, demonstrating immediate bactericidal effects.14 

Furthermore, HOCl has been shown to be useful in suturing and wound closure by reducing microbial load when soaked gauze is placed in wound beds prior to closure, while not harming surrounding tissue.15 This would be especially advantageous for military health care when specialist follow-up would be delayed or to prevent infection risk while en route to higher care. Aside from its disinfectant strength, it’s also well tolerated. HOCl studies on human tissue demonstrate its efficacy to prevent irritation and AEs while also preventing infection and promoting wound healing. 

Gozukucuk and Cakiroglu studied the use of HOCl as a skin disinfectant before neonatal circumcision and demonstrated fewer adverse effects compared with the more commonly used PI. Neonates treated with PI prior to circumcision resulted in greater postoperative edema and increased duration of wound healing compared with infants treated with HOCl.16 Furthermore, studies have shown that PI can lead to irritant dermatitis or chemical burns if not properly dried or if it becomes pooled because of occlusion dressings.17 

Aside from its indicated use for infection or wound care, anti-inflammatory properties of HOCl also may be beneficial for off-label use in preventing flareups of chronic conditions as well as for treating symptoms while awaiting specialist evaluation. This might be the case during US-based training exercises, in remote locations without nearby dermatologists, or during virtual care because of internet constraints. For chronic conditions such as rosacea or atopic dermatitis, which research has shown are related to mast cell activation and degranulation and cytokine release, HOCl has been shown to reduce histamine, neutrophil-generated leukotrienes, in addition to interleukin-6 and interleukin-2 to improve symptoms by reducing inflammation.18 

Limitations of HOCl to explore would be extending its shelf life, exploring its various forms (eg, spray, topical) and storage limitations, and training of the machine and materials needed to be made in-house if not purchased. There are also no official guidelines for clinicians to recommend HOCl to patients, and research should be expanded on its use in humans, though it generally is well tolerated without AEs. HOCl has the potential to be a potent, nontoxic, inexpensive tool in med bags or at austere clinics to help maintain a sterile space for procedures, prevent infection while rendering care, and help with exacerbations or prevent flare-ups of chronic conditions such as psoriasis, acne, and atopic dermatitis while specialist care is pending. 

References
  1. Natarelli N, et al. Hypochlorous acid: applications in dermatology. J Integr Dermatol. December 22, 2022. Accessed March 2, 2026. https://www.jintegrativederm.org/article/56663-hypochlorous-acid-applications-in-dermatology
  2. Block MS, Rowan BG. Hypochlorous acid: a review. J Oral Maxillofac Surg. 2020;78:1461-1466. doi:10.1016/j.joms.2020.06.029
  3. Menta N, Vidal SI, Friedman A. Hypochlorous acid: a blast from the past. J Drugs Dermatol. 2024;23:909-910.
  4. Rossi-Fedele G, Dogramaci E, Steier L, et al. Some factors influencing the stability of Sterilox®, a super-oxidised water. Br Dent J. 2011;210:E23. doi:10.1038/sj.bdj.2011.143
  5. Tran AQ, Topilow N, Rong A, et al. Comparison of skin antiseptic agents and the role of 0.01% hypochlorous acid. Aesthet Surg J. 2021;41:1170-1175. doi:10.1093/asj/sjaa322
  6. Stough D. Topical stabilized super-oxidized hypochlorous acid for wound healing in hair restoration surgery: a real-time usage-controlled trial evaluating safety, efficacy, and tolerability. J Drugs Dermatol. 2023;22:1191-1196. doi:10.36849/JDD.7172
  7. Bucko AD, Draelos Z, Dubois JC, Jones TM. A doubleblind, randomized study to compare Microcyn scar management hydrogel, K103163, and Kelo-cote scar gel for hypertrophic or keloid scars. Dermatologist. 2015;23:113-122.
  8. Zhang H, Wu Y, Wan X, et al. Effect of hypochlorous acid on blepharitis through ultrasonic atomization: a randomized clinical trial. J Clin Med. 2023;12(3):1164. doi:10.3390/jcm12031164
  9. Majewski S, Bhattacharya T, Asztalos M, et al. Sodium hypochlorite body wash in the management of Staphylococcus aureus-colonized moderate-to-severe atopic dermatitis in infants, children, and adolescents. Pediatr Dermatol. 2019;36:442-447. doi:10.1111/pde.13842
  10. Singal A, Lipner SR. A review of skin disease in military soldiers: challenges and potential solutions. Ann Med. 2023;55:2267425. doi:10.1080/07853890.2023.2267425
  11. Dever TT, Walters M, Jacob S. Contact dermatitis in military personnel. Dermatitis. 2011;22:313-319. doi:10.2310/6620.2011.11024
  12. Nowbuth AA, Armstrong J, Cloete T, et al. A potential benefit of hypochlorous acid-facial sanitisation: a review. Preprints. 2021. doi:10.20944/preprints202107.0129.v2
  13. Gold MH, Andriessen A, Bhatia AC, et al. Topical stabilized hypochlorous acid: the future gold standard for wound care and scar management in dermatologic and plastic surgery procedures. J Cosmet Dermatol. 2020;19:270-277. doi:10.1111/jocd.13280
  14. Anagnostopoulos AG, Rong A, Miller D, et al. 0.01% hypochlorous acid as an alternative skin antiseptic: an in vitro comparison. Dermatol Surg. 2018;44:1489-1493. doi:10.1097/DSS.0000000000001594
  15. Odom EB, Mundschenk MB, Hard KA, et al. The utility of hypochlorous acid wound therapy in wound bed preparation and skin graft salvage. Plast Reconstr Surg. 2019;143:677e-678e. doi:10.1097/PRS.0000000000005359
  16. Gozukucuk A, Cakiroglu B. Comparison of hypochlorous acid and povidone-iodine as a disinfectant in neonatal circumcision. J Pediatr Urol. 2022;18:341.e1-341.e5. doi:10.1016/j.jpurol.2022.03.011
  17. Borrego L, Hernández N, Hernández Z, et al. Povidoneiodine-induced postsurgical irritant contact dermatitis localized outside of the surgical incision area: report of 27 cases and a literature review. Int J Dermatol. 2016;55:540- 545. doi:10.1111/ijd.12957
  18. Del Rosso JQ, Bhatia N. Status report on topical hypochlorous acid: clinical relevance of specific formulations, potential modes of action, and study outcomes. J Clin Aesthet Dermatol. 2018;11:36-39.
Article PDF
Author and Disclosure Information

Adriana Campo, DOa

Author affiliations 

aNaval Health Clinic Cherry Point, North Carolina 

Author disclosures 

The authors report no actual or potential conflicts of interest with regard to this article. 

Disclaimer 

The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations— including indications, contraindications, warnings, and adverse effects— before administering pharmacologic therapy to patients. 

Correspondence: Adriana Campo (adcampo13@gmail.com) 

Fed Pract. 2026;43(5). Published online May 20. doi:10.12788/fp.0702

Issue
Federal Practitioner - 43(5)
Publications
Topics
Page Number
172-175
Sections
Author and Disclosure Information

Adriana Campo, DOa

Author affiliations 

aNaval Health Clinic Cherry Point, North Carolina 

Author disclosures 

The authors report no actual or potential conflicts of interest with regard to this article. 

Disclaimer 

The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations— including indications, contraindications, warnings, and adverse effects— before administering pharmacologic therapy to patients. 

Correspondence: Adriana Campo (adcampo13@gmail.com) 

Fed Pract. 2026;43(5). Published online May 20. doi:10.12788/fp.0702

Author and Disclosure Information

Adriana Campo, DOa

Author affiliations 

aNaval Health Clinic Cherry Point, North Carolina 

Author disclosures 

The authors report no actual or potential conflicts of interest with regard to this article. 

Disclaimer 

The opinions expressed herein are those of the authors and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies. This article may discuss unlabeled or investigational use of certain drugs. Please review the complete prescribing information for specific drugs or drug combinations— including indications, contraindications, warnings, and adverse effects— before administering pharmacologic therapy to patients. 

Correspondence: Adriana Campo (adcampo13@gmail.com) 

Fed Pract. 2026;43(5). Published online May 20. doi:10.12788/fp.0702

Article PDF
Article PDF

Exogenously, hypochlorous acid (HOCl) is a powerful oxidizing agent formed from chlorine dissolved in water. Within the body, it is part of the immune response, created by activated leukocytes, which form HOCl from hydrogen peroxide and chloride. HOCl has been used as a disinfectant in wound care due to its antimicrobial properties via inhibition of DNA synthesis, protein synthesis, and decreased adenosine triphosphate production. It specifically targets bacteria by blocking bacterial cell wall synthesis and decreasing DNA replication.1 

During the COVID-19 pandemic, HOCl was recommended by the US Environmental Protection Agency as a disinfectant.2 HOCl can be purchased from a supplier, though its major limitation is its shelf life. The main environmental factors affecting its stability are sunlight exposure, temperatures > 25 °C, and air exposure. HOCl is stable and most potent when the pH falls between 3.5 and 5.5.3 It is best stored in a cool, dark environment to maintain efficacy for 2 weeks. Rossi-Fedele et al found that when exposed to sunlight, chlorine reduction starts on day 4, whereas solutions kept in dark storage remained more stable, with this process starting after day 14.4 

HOCl can also be made on-site via a machine, which ranges in price from a portable version costing < $200 to a large commercial option that can cost $7000 to $25,000. HOCl is produced by mixing noniodinated salt and water, and using electrolysis, which generally takes less than 10 minutes before it is ready for use.2 Given the cost and nonreusable nature of disinfecting wipes, HOCl may be more worthwhile for economic and disposal purposes in the long term. 

Different concentrations of HOCl are readily available commercially. Because topical application of 1% HOCl may cause skin irritation, solutions with lower concentrations have been developed including Vashe (0.03% HOCl; SteadMed), PhaseOne (0.025% HOCl solution; IHT), OCuSOFT (0.02% HOCl; OCuSOFT), Bruder (0.02% HOCl; Bruder Healthcare), Acuicyn (0.01% HOCl solution in dilute saline; Sonoma Pharmaceuticals), and Avenova (0.01% HOCl solution; NovaBay Pharmaceuticals).5 

Aside from its surface utility, HOCl has been researched for its beneficial effects on skin. HOCl has been shown to be helpful intraoperatively and postoperatively in improving adverse effects (AEs) after hair restoration, including erythema and pruritus, and in optimizing healing by reducing inflammation, likely due to its antimicrobial properties and ability to promote oxygenation.6 Bucko et al demonstrated that Microcyn scar gel (with HOCl) was a superior nonirritating, nontoxic method of not only improving scar appearance (vascularity, scar height, and pliability) but also reducing scar symptoms of pain and pruritus in comparison to 100% silicone scar gel (traditional application used to improve scarring).7 Zhang et al demonstrated that HOCl consistently improved symptom relief of blepharitis, including meibomian gland, eyelash, and eyelid redness, irritation, and appearance in comparison as well as were better tolerated in comparison to traditional recommendations of eyelid compresses and wash (tea tree oil, diluted baby shampoo, and topical antibiotics).8 In children with moderate to severe atopic dermatitis, Majewski et al compared a traditional bleach bath with a body wash containing hypochlorite (NaOCl; hypochlorous acid in alkaline aqueous solution). The body wash proved to be more convenient (showering vs 10-minute bath) and significantly improved symptoms while reducing the need for topical corticosteroids (common treatment modality for atopic dermatitis).9 

The skin is the body’s primary defense against both dermatologic and respiratory infections. The face is especially vulnerable to microbes via airborne or environmental transmission, mechanical irritation, and touch. In the military environment, personal protective equipment (PPE) or uniform items may increase the risk of dermatologic conditions such as allergic or irritant dermatitis, infection, and friction blisters. 

In a literature review of 312 dermatologic articles published between 2002 and 2022, Singal and Lipner found that among deployed soldiers serving in hot and dry climates, dermatitis and eczematous conditions were the most common, whereas bacterial and fungal conditions were most common in hot and humid settings. In the nondeployed setting, dermatitis and eczematous, acne, and fungal infections were the most common skin conditions. This is reflected by the unique circumstances that service members face at home and while deployed, when they may be more vulnerable to developing new or worsening chronic skin conditions depending on the environment (access to shelter, humid vs dry environments), and decreased access or time for hygiene (shared quarters at home in barracks or on deployment). Occupation-related conditions also play a large role in military dermatologic conditions.10 

Dever et al noted the unique risks and exposures in the environment itself (plants, arthropods) as well as uniform items (protective gear) that carry an increased risk of friction irritation and dermatitis. Occupational exposures commonly associated with irritant contact dermatitis include alcohols, oils, fuel, disinfectants, and solvents. Chemicals in military uniforms themselves (eg, formaldehyde resins, disperse dyes, and chromate-containing dyes) also have the potential to cause allergic contact dermatitis, which can be challenging to address given the emphasis on uniformity and standards.11 PPE also may exacerbate rosacea and acne. 

Some pathologies are associated specifically with bacteria, such as Cutibacterium acnes, as seen in acne vulgaris. Colonization of bacteria on the face may create biofilms that are difficult to detect, may be resistant to antibiotic therapy, and are implicated in other dermatologic conditions, such as persistent wounds, atopic dermatitis, and candidiasis.12 

Biofilm and antibiotic resistance already pose a risk to patient care, but the unique environmental conditions and exposures of military settings can amplify this risk in the military population.13 Using HOCl in austere environments or the field for wound care may help reduce microbial load and the subsequent need for systemic antibiotics which carry the risk of gastrointestinal AEs and resistance.1 

An optimized healing rate would support operational objectives by enabling service members to remain on full duty and avoid medications, which may prevent them from special duty, such as aviation. Sakarya et al found that HOCl solution enhanced wound healing in contrast with povidone-iodine (PI), while a study by Dharap et al discussed how HOCl provided major improvement in ulcer wound size (and infection), as well as significant reduction of inflammation.13 

Anagnostopoulos et al studied the efficacy of 0.01% HOCl vs other disinfectants (5% PI, 4% chlorhexidine gluconate [CHG] and 70% isopropyl alcohol [IPA]) against common skin organisms, including methicillin-susceptible Staphylococcus aureus and methicillin-susceptible Staphylococcus epidermidis. The study found that HOCl had at least equal if not greater efficacy to PI, CHG, and IPA depending on the bacterial strain, demonstrating immediate bactericidal effects.14 

Furthermore, HOCl has been shown to be useful in suturing and wound closure by reducing microbial load when soaked gauze is placed in wound beds prior to closure, while not harming surrounding tissue.15 This would be especially advantageous for military health care when specialist follow-up would be delayed or to prevent infection risk while en route to higher care. Aside from its disinfectant strength, it’s also well tolerated. HOCl studies on human tissue demonstrate its efficacy to prevent irritation and AEs while also preventing infection and promoting wound healing. 

Gozukucuk and Cakiroglu studied the use of HOCl as a skin disinfectant before neonatal circumcision and demonstrated fewer adverse effects compared with the more commonly used PI. Neonates treated with PI prior to circumcision resulted in greater postoperative edema and increased duration of wound healing compared with infants treated with HOCl.16 Furthermore, studies have shown that PI can lead to irritant dermatitis or chemical burns if not properly dried or if it becomes pooled because of occlusion dressings.17 

Aside from its indicated use for infection or wound care, anti-inflammatory properties of HOCl also may be beneficial for off-label use in preventing flareups of chronic conditions as well as for treating symptoms while awaiting specialist evaluation. This might be the case during US-based training exercises, in remote locations without nearby dermatologists, or during virtual care because of internet constraints. For chronic conditions such as rosacea or atopic dermatitis, which research has shown are related to mast cell activation and degranulation and cytokine release, HOCl has been shown to reduce histamine, neutrophil-generated leukotrienes, in addition to interleukin-6 and interleukin-2 to improve symptoms by reducing inflammation.18 

Limitations of HOCl to explore would be extending its shelf life, exploring its various forms (eg, spray, topical) and storage limitations, and training of the machine and materials needed to be made in-house if not purchased. There are also no official guidelines for clinicians to recommend HOCl to patients, and research should be expanded on its use in humans, though it generally is well tolerated without AEs. HOCl has the potential to be a potent, nontoxic, inexpensive tool in med bags or at austere clinics to help maintain a sterile space for procedures, prevent infection while rendering care, and help with exacerbations or prevent flare-ups of chronic conditions such as psoriasis, acne, and atopic dermatitis while specialist care is pending. 

Exogenously, hypochlorous acid (HOCl) is a powerful oxidizing agent formed from chlorine dissolved in water. Within the body, it is part of the immune response, created by activated leukocytes, which form HOCl from hydrogen peroxide and chloride. HOCl has been used as a disinfectant in wound care due to its antimicrobial properties via inhibition of DNA synthesis, protein synthesis, and decreased adenosine triphosphate production. It specifically targets bacteria by blocking bacterial cell wall synthesis and decreasing DNA replication.1 

During the COVID-19 pandemic, HOCl was recommended by the US Environmental Protection Agency as a disinfectant.2 HOCl can be purchased from a supplier, though its major limitation is its shelf life. The main environmental factors affecting its stability are sunlight exposure, temperatures > 25 °C, and air exposure. HOCl is stable and most potent when the pH falls between 3.5 and 5.5.3 It is best stored in a cool, dark environment to maintain efficacy for 2 weeks. Rossi-Fedele et al found that when exposed to sunlight, chlorine reduction starts on day 4, whereas solutions kept in dark storage remained more stable, with this process starting after day 14.4 

HOCl can also be made on-site via a machine, which ranges in price from a portable version costing < $200 to a large commercial option that can cost $7000 to $25,000. HOCl is produced by mixing noniodinated salt and water, and using electrolysis, which generally takes less than 10 minutes before it is ready for use.2 Given the cost and nonreusable nature of disinfecting wipes, HOCl may be more worthwhile for economic and disposal purposes in the long term. 

Different concentrations of HOCl are readily available commercially. Because topical application of 1% HOCl may cause skin irritation, solutions with lower concentrations have been developed including Vashe (0.03% HOCl; SteadMed), PhaseOne (0.025% HOCl solution; IHT), OCuSOFT (0.02% HOCl; OCuSOFT), Bruder (0.02% HOCl; Bruder Healthcare), Acuicyn (0.01% HOCl solution in dilute saline; Sonoma Pharmaceuticals), and Avenova (0.01% HOCl solution; NovaBay Pharmaceuticals).5 

Aside from its surface utility, HOCl has been researched for its beneficial effects on skin. HOCl has been shown to be helpful intraoperatively and postoperatively in improving adverse effects (AEs) after hair restoration, including erythema and pruritus, and in optimizing healing by reducing inflammation, likely due to its antimicrobial properties and ability to promote oxygenation.6 Bucko et al demonstrated that Microcyn scar gel (with HOCl) was a superior nonirritating, nontoxic method of not only improving scar appearance (vascularity, scar height, and pliability) but also reducing scar symptoms of pain and pruritus in comparison to 100% silicone scar gel (traditional application used to improve scarring).7 Zhang et al demonstrated that HOCl consistently improved symptom relief of blepharitis, including meibomian gland, eyelash, and eyelid redness, irritation, and appearance in comparison as well as were better tolerated in comparison to traditional recommendations of eyelid compresses and wash (tea tree oil, diluted baby shampoo, and topical antibiotics).8 In children with moderate to severe atopic dermatitis, Majewski et al compared a traditional bleach bath with a body wash containing hypochlorite (NaOCl; hypochlorous acid in alkaline aqueous solution). The body wash proved to be more convenient (showering vs 10-minute bath) and significantly improved symptoms while reducing the need for topical corticosteroids (common treatment modality for atopic dermatitis).9 

The skin is the body’s primary defense against both dermatologic and respiratory infections. The face is especially vulnerable to microbes via airborne or environmental transmission, mechanical irritation, and touch. In the military environment, personal protective equipment (PPE) or uniform items may increase the risk of dermatologic conditions such as allergic or irritant dermatitis, infection, and friction blisters. 

In a literature review of 312 dermatologic articles published between 2002 and 2022, Singal and Lipner found that among deployed soldiers serving in hot and dry climates, dermatitis and eczematous conditions were the most common, whereas bacterial and fungal conditions were most common in hot and humid settings. In the nondeployed setting, dermatitis and eczematous, acne, and fungal infections were the most common skin conditions. This is reflected by the unique circumstances that service members face at home and while deployed, when they may be more vulnerable to developing new or worsening chronic skin conditions depending on the environment (access to shelter, humid vs dry environments), and decreased access or time for hygiene (shared quarters at home in barracks or on deployment). Occupation-related conditions also play a large role in military dermatologic conditions.10 

Dever et al noted the unique risks and exposures in the environment itself (plants, arthropods) as well as uniform items (protective gear) that carry an increased risk of friction irritation and dermatitis. Occupational exposures commonly associated with irritant contact dermatitis include alcohols, oils, fuel, disinfectants, and solvents. Chemicals in military uniforms themselves (eg, formaldehyde resins, disperse dyes, and chromate-containing dyes) also have the potential to cause allergic contact dermatitis, which can be challenging to address given the emphasis on uniformity and standards.11 PPE also may exacerbate rosacea and acne. 

Some pathologies are associated specifically with bacteria, such as Cutibacterium acnes, as seen in acne vulgaris. Colonization of bacteria on the face may create biofilms that are difficult to detect, may be resistant to antibiotic therapy, and are implicated in other dermatologic conditions, such as persistent wounds, atopic dermatitis, and candidiasis.12 

Biofilm and antibiotic resistance already pose a risk to patient care, but the unique environmental conditions and exposures of military settings can amplify this risk in the military population.13 Using HOCl in austere environments or the field for wound care may help reduce microbial load and the subsequent need for systemic antibiotics which carry the risk of gastrointestinal AEs and resistance.1 

An optimized healing rate would support operational objectives by enabling service members to remain on full duty and avoid medications, which may prevent them from special duty, such as aviation. Sakarya et al found that HOCl solution enhanced wound healing in contrast with povidone-iodine (PI), while a study by Dharap et al discussed how HOCl provided major improvement in ulcer wound size (and infection), as well as significant reduction of inflammation.13 

Anagnostopoulos et al studied the efficacy of 0.01% HOCl vs other disinfectants (5% PI, 4% chlorhexidine gluconate [CHG] and 70% isopropyl alcohol [IPA]) against common skin organisms, including methicillin-susceptible Staphylococcus aureus and methicillin-susceptible Staphylococcus epidermidis. The study found that HOCl had at least equal if not greater efficacy to PI, CHG, and IPA depending on the bacterial strain, demonstrating immediate bactericidal effects.14 

Furthermore, HOCl has been shown to be useful in suturing and wound closure by reducing microbial load when soaked gauze is placed in wound beds prior to closure, while not harming surrounding tissue.15 This would be especially advantageous for military health care when specialist follow-up would be delayed or to prevent infection risk while en route to higher care. Aside from its disinfectant strength, it’s also well tolerated. HOCl studies on human tissue demonstrate its efficacy to prevent irritation and AEs while also preventing infection and promoting wound healing. 

Gozukucuk and Cakiroglu studied the use of HOCl as a skin disinfectant before neonatal circumcision and demonstrated fewer adverse effects compared with the more commonly used PI. Neonates treated with PI prior to circumcision resulted in greater postoperative edema and increased duration of wound healing compared with infants treated with HOCl.16 Furthermore, studies have shown that PI can lead to irritant dermatitis or chemical burns if not properly dried or if it becomes pooled because of occlusion dressings.17 

Aside from its indicated use for infection or wound care, anti-inflammatory properties of HOCl also may be beneficial for off-label use in preventing flareups of chronic conditions as well as for treating symptoms while awaiting specialist evaluation. This might be the case during US-based training exercises, in remote locations without nearby dermatologists, or during virtual care because of internet constraints. For chronic conditions such as rosacea or atopic dermatitis, which research has shown are related to mast cell activation and degranulation and cytokine release, HOCl has been shown to reduce histamine, neutrophil-generated leukotrienes, in addition to interleukin-6 and interleukin-2 to improve symptoms by reducing inflammation.18 

Limitations of HOCl to explore would be extending its shelf life, exploring its various forms (eg, spray, topical) and storage limitations, and training of the machine and materials needed to be made in-house if not purchased. There are also no official guidelines for clinicians to recommend HOCl to patients, and research should be expanded on its use in humans, though it generally is well tolerated without AEs. HOCl has the potential to be a potent, nontoxic, inexpensive tool in med bags or at austere clinics to help maintain a sterile space for procedures, prevent infection while rendering care, and help with exacerbations or prevent flare-ups of chronic conditions such as psoriasis, acne, and atopic dermatitis while specialist care is pending. 

References
  1. Natarelli N, et al. Hypochlorous acid: applications in dermatology. J Integr Dermatol. December 22, 2022. Accessed March 2, 2026. https://www.jintegrativederm.org/article/56663-hypochlorous-acid-applications-in-dermatology
  2. Block MS, Rowan BG. Hypochlorous acid: a review. J Oral Maxillofac Surg. 2020;78:1461-1466. doi:10.1016/j.joms.2020.06.029
  3. Menta N, Vidal SI, Friedman A. Hypochlorous acid: a blast from the past. J Drugs Dermatol. 2024;23:909-910.
  4. Rossi-Fedele G, Dogramaci E, Steier L, et al. Some factors influencing the stability of Sterilox®, a super-oxidised water. Br Dent J. 2011;210:E23. doi:10.1038/sj.bdj.2011.143
  5. Tran AQ, Topilow N, Rong A, et al. Comparison of skin antiseptic agents and the role of 0.01% hypochlorous acid. Aesthet Surg J. 2021;41:1170-1175. doi:10.1093/asj/sjaa322
  6. Stough D. Topical stabilized super-oxidized hypochlorous acid for wound healing in hair restoration surgery: a real-time usage-controlled trial evaluating safety, efficacy, and tolerability. J Drugs Dermatol. 2023;22:1191-1196. doi:10.36849/JDD.7172
  7. Bucko AD, Draelos Z, Dubois JC, Jones TM. A doubleblind, randomized study to compare Microcyn scar management hydrogel, K103163, and Kelo-cote scar gel for hypertrophic or keloid scars. Dermatologist. 2015;23:113-122.
  8. Zhang H, Wu Y, Wan X, et al. Effect of hypochlorous acid on blepharitis through ultrasonic atomization: a randomized clinical trial. J Clin Med. 2023;12(3):1164. doi:10.3390/jcm12031164
  9. Majewski S, Bhattacharya T, Asztalos M, et al. Sodium hypochlorite body wash in the management of Staphylococcus aureus-colonized moderate-to-severe atopic dermatitis in infants, children, and adolescents. Pediatr Dermatol. 2019;36:442-447. doi:10.1111/pde.13842
  10. Singal A, Lipner SR. A review of skin disease in military soldiers: challenges and potential solutions. Ann Med. 2023;55:2267425. doi:10.1080/07853890.2023.2267425
  11. Dever TT, Walters M, Jacob S. Contact dermatitis in military personnel. Dermatitis. 2011;22:313-319. doi:10.2310/6620.2011.11024
  12. Nowbuth AA, Armstrong J, Cloete T, et al. A potential benefit of hypochlorous acid-facial sanitisation: a review. Preprints. 2021. doi:10.20944/preprints202107.0129.v2
  13. Gold MH, Andriessen A, Bhatia AC, et al. Topical stabilized hypochlorous acid: the future gold standard for wound care and scar management in dermatologic and plastic surgery procedures. J Cosmet Dermatol. 2020;19:270-277. doi:10.1111/jocd.13280
  14. Anagnostopoulos AG, Rong A, Miller D, et al. 0.01% hypochlorous acid as an alternative skin antiseptic: an in vitro comparison. Dermatol Surg. 2018;44:1489-1493. doi:10.1097/DSS.0000000000001594
  15. Odom EB, Mundschenk MB, Hard KA, et al. The utility of hypochlorous acid wound therapy in wound bed preparation and skin graft salvage. Plast Reconstr Surg. 2019;143:677e-678e. doi:10.1097/PRS.0000000000005359
  16. Gozukucuk A, Cakiroglu B. Comparison of hypochlorous acid and povidone-iodine as a disinfectant in neonatal circumcision. J Pediatr Urol. 2022;18:341.e1-341.e5. doi:10.1016/j.jpurol.2022.03.011
  17. Borrego L, Hernández N, Hernández Z, et al. Povidoneiodine-induced postsurgical irritant contact dermatitis localized outside of the surgical incision area: report of 27 cases and a literature review. Int J Dermatol. 2016;55:540- 545. doi:10.1111/ijd.12957
  18. Del Rosso JQ, Bhatia N. Status report on topical hypochlorous acid: clinical relevance of specific formulations, potential modes of action, and study outcomes. J Clin Aesthet Dermatol. 2018;11:36-39.
References
  1. Natarelli N, et al. Hypochlorous acid: applications in dermatology. J Integr Dermatol. December 22, 2022. Accessed March 2, 2026. https://www.jintegrativederm.org/article/56663-hypochlorous-acid-applications-in-dermatology
  2. Block MS, Rowan BG. Hypochlorous acid: a review. J Oral Maxillofac Surg. 2020;78:1461-1466. doi:10.1016/j.joms.2020.06.029
  3. Menta N, Vidal SI, Friedman A. Hypochlorous acid: a blast from the past. J Drugs Dermatol. 2024;23:909-910.
  4. Rossi-Fedele G, Dogramaci E, Steier L, et al. Some factors influencing the stability of Sterilox®, a super-oxidised water. Br Dent J. 2011;210:E23. doi:10.1038/sj.bdj.2011.143
  5. Tran AQ, Topilow N, Rong A, et al. Comparison of skin antiseptic agents and the role of 0.01% hypochlorous acid. Aesthet Surg J. 2021;41:1170-1175. doi:10.1093/asj/sjaa322
  6. Stough D. Topical stabilized super-oxidized hypochlorous acid for wound healing in hair restoration surgery: a real-time usage-controlled trial evaluating safety, efficacy, and tolerability. J Drugs Dermatol. 2023;22:1191-1196. doi:10.36849/JDD.7172
  7. Bucko AD, Draelos Z, Dubois JC, Jones TM. A doubleblind, randomized study to compare Microcyn scar management hydrogel, K103163, and Kelo-cote scar gel for hypertrophic or keloid scars. Dermatologist. 2015;23:113-122.
  8. Zhang H, Wu Y, Wan X, et al. Effect of hypochlorous acid on blepharitis through ultrasonic atomization: a randomized clinical trial. J Clin Med. 2023;12(3):1164. doi:10.3390/jcm12031164
  9. Majewski S, Bhattacharya T, Asztalos M, et al. Sodium hypochlorite body wash in the management of Staphylococcus aureus-colonized moderate-to-severe atopic dermatitis in infants, children, and adolescents. Pediatr Dermatol. 2019;36:442-447. doi:10.1111/pde.13842
  10. Singal A, Lipner SR. A review of skin disease in military soldiers: challenges and potential solutions. Ann Med. 2023;55:2267425. doi:10.1080/07853890.2023.2267425
  11. Dever TT, Walters M, Jacob S. Contact dermatitis in military personnel. Dermatitis. 2011;22:313-319. doi:10.2310/6620.2011.11024
  12. Nowbuth AA, Armstrong J, Cloete T, et al. A potential benefit of hypochlorous acid-facial sanitisation: a review. Preprints. 2021. doi:10.20944/preprints202107.0129.v2
  13. Gold MH, Andriessen A, Bhatia AC, et al. Topical stabilized hypochlorous acid: the future gold standard for wound care and scar management in dermatologic and plastic surgery procedures. J Cosmet Dermatol. 2020;19:270-277. doi:10.1111/jocd.13280
  14. Anagnostopoulos AG, Rong A, Miller D, et al. 0.01% hypochlorous acid as an alternative skin antiseptic: an in vitro comparison. Dermatol Surg. 2018;44:1489-1493. doi:10.1097/DSS.0000000000001594
  15. Odom EB, Mundschenk MB, Hard KA, et al. The utility of hypochlorous acid wound therapy in wound bed preparation and skin graft salvage. Plast Reconstr Surg. 2019;143:677e-678e. doi:10.1097/PRS.0000000000005359
  16. Gozukucuk A, Cakiroglu B. Comparison of hypochlorous acid and povidone-iodine as a disinfectant in neonatal circumcision. J Pediatr Urol. 2022;18:341.e1-341.e5. doi:10.1016/j.jpurol.2022.03.011
  17. Borrego L, Hernández N, Hernández Z, et al. Povidoneiodine-induced postsurgical irritant contact dermatitis localized outside of the surgical incision area: report of 27 cases and a literature review. Int J Dermatol. 2016;55:540- 545. doi:10.1111/ijd.12957
  18. Del Rosso JQ, Bhatia N. Status report on topical hypochlorous acid: clinical relevance of specific formulations, potential modes of action, and study outcomes. J Clin Aesthet Dermatol. 2018;11:36-39.
Issue
Federal Practitioner - 43(5)
Issue
Federal Practitioner - 43(5)
Page Number
172-175
Page Number
172-175
Publications
Publications
Topics
Article Type
Display Headline

Hypochlorous Acid: A Multipurpose New Addition to the Military Med Bag?

Display Headline

Hypochlorous Acid: A Multipurpose New Addition to the Military Med Bag?

Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

Divine Calling and Human Rank: The Locus of Authority for Military Chaplains

Article Type
Changed
Display Headline

Divine Calling and Human Rank: The Locus of Authority for Military Chaplains

Render unto Caesar the things that are Caesar’s, and to God the things that are God’s.
Matthew 22:21

While in my 20s, I taught religious education at a church on the Army base where I was born and had the honor of working with military chaplains. During my US Department of Veterans Affairs career, I closely collaborated with chaplains—many of whom were veterans—on patient care and ethics consultations. Some were quite proud of their rank and interested in climbing the ladder of promotion. A few made sure you knew what they wore or had worn on their uniform, while most were incredibly humble and sheepish when soldiers saluted them. Those visible responses to rank may be hidden if chaplains will no longer be permitted to wear insignia indicating their grade. 

Department of War Secretary Peter Hegseth, a combat veteran who has championed a “combative” form of Christianity, announced in April 2026 that chaplains would no longer wear their rank on their uniform.1 Details of how this shift will be translated into regulation, policy, and actions were not provided. Secretary Hegseth did not remove the actual rank of members of the chaplain corps and they would retain their rank, attendant pay, benefits, responsibilities, and privileges. However, instead of bearing the insignia of their military station, under this new policy only the symbol of their religious profession would identify them. Currently, both a military officer’s rank and religious symbol are displayed.2 

Useful insight can be gained from an historical perspective, which demonstrates that the concerns and contention about the issue of chaplain’s wearing rank are not new. There have been chaplains in the US Army since 1775.3 Army chaplains initially wore only a religious symbol on their clothing. In April 1914, chaplain leaders successful argued that chaplains deserved the privileges, respect, and prospect for promotion that rank symbolized and where authorized to display their position. Four years later, General Jack Pershing cabled the then Secretary of War opposing the new policy: “Believe the work of chaplains would be facilitated if they were not given military rank ... Many of our principal ministers believe that their relations would be closer if they did not have military titles and did not wear insignia.”4 Interestingly, Secretary Hegseth articulated the same concern: “A chaplain is first and foremost a chaplain and an officer second. This change is a visual representation of that fact.”5 

Hegseth has stated that in recent years the military chaplain corps had drifted too far in the direction of providing spiritual counseling and psychological support. This contravenes the current competencies especially for company-grade military chaplains who primarily minister to the moral distress and spiritual needs of service members.4 The removal of rank is thus best understood as part of Secretary Hegseth’s broader plan to remake the chaplain corps into his vision of religious ministry in the military.5 

Secretary Hegseth proffered several arguments for the necessity of removing rank in part to reorient the chaplain corps to what he calls a more fundamental mission. The first was theological: chaplains need to prioritize their “divine calling” rather than any human distinction. Chaplain theologians and ethicists have expressed similar concerns that in wearing rank, military chaplains become servants of the state and not of God. Adam Tietje articulates the corruptive influence this shift in the source of legitimacy has on the military chaplain’s spiritual mission: 

This undermines the ability of chaplains to provide care and counsel to both soldiers and leaders that is not muddied with the interests of the military. Chaplains without rank are better positioned to hear and advocate for their soldier’s matters of conscience as well as bear witness to the moral claims of their respective religious communities especially about war itself.3 

The second argument is pastoral. Hegseth contends that service members of lower rank would feel more comfortable and secure approaching chaplains with no outward sign of their higher position. Chaplain interactions with military personnel carry a degree of confidentiality higher than that of either doctors or lawyers. Chaplains, as they were in the past, remain divided on this important consideration.4,5 

The third argument is ethical in nature. Secretary Hegseth contends that excluding any manifestation of military rank, “speaks to the difficult balance of the duality” of the role.6 It seems he is proposing that chaplains displaying only the image of their faith commitment symbolically resolves the inherent moral conflict between serving human masters as a military officer, and the divine as a minister.7 Military chaplains and health care professionals are all too familiar with the dilemma of having 2 masters and the challenge of negotiating legally and ethically overlapping roles.8-10 

This may seem to some like a minor change in chaplain etiquette to some, but to others it signals a significant ethical and political change with potential import beyond chaplaincy. One military commentator has suggested the move sets a dangerous precedent that could eventually be applied to both health care professionals and the judge advocate corps.11 At this point this is only speculation and its slippery slope arguments are logically suspect without evidence. Yet at least 1 study suggests that the influence of military physician’s rank on patient care may lead to inequities in the care delivered to patients with lower grade.12 

It is commanders who are the decision-makers in the military. Chaplains who are field grade officers serve as trusted staff advisors in moral, ethical, and spiritual matters.4 Some chaplains fear that without rank leaders at all levels will not have adequate trust and sufficient respect to heed their crucial counsel especially regarding high-stakes strategic decisions in wartime.8 The more serious concern is with a major shift in the locus of authority to determine the professional identity of chaplains, that could in theory be expanded to impact military health care practitioners, and attorneys. The independent expert judgment of these professionals regarding what is necessary to fulfil their respective roles in providing spiritual ministry, medical care, and legal is critical to uphold the highest values of the US military.11 Chaplains have long struggled with what they owe to the Caesar and to God: how the Secretary’s recent decision will shape that rendering is uncertain. What is certain is that military chaplains of all faiths and in every branch of the armed services will continue to minister to their brothers and sisters in arms with courage and compassion. 

References
  1. Baker R, Graham R. Pete Hegseth and his ‘battle cry’ for a new christian crusade. The New York Times. December 6, 2024. Accessed April 24, 2026. https://www.nytimes.com/2024/12/05/us/hegseth-church-crusades.html   
  2. Sampson E. Hegseth removes rank insignia from military chaplains. Military Times. March 25, 2026. Accessed April 24, 2026. https://www.militarytimes.com/news/pentagon-congress/2026/03/25/hegseth-removes-rank-insignia-from-military-chaplains/  
  3. Tietje A. A seductive confusion of authority: military chaplains and the wearing of rank. J Church State. 2020;62:506-524.
  4. Morris JT. Military chaplaincy in the USA: an unfolding of roles and functions. In: Weiss H, Federschmidt KH, Louw DJ, et al, eds. Care, Healing, and Human Well-Being Within Interreligious Discourses. African Sun Media; 2021:319-333.
  5. Cox M. Hegseth’s push for chaplain’s to shed remove rank sparks debate. Air and Space Forces Magazine. March 27, 2026. Accessed April 29, 2026. https://www.airandspaceforces.com/chaplains-ordered-to-shed-rank-ret-af-leaders-question-move/  
  6. Mitchell E. Hegseth: Military chaplains will no longer display rank. The Hill. March 25, 2026. Accessed April 24, 2026. https://thehill.com/policy/defense/5800026-pete-hegseth-military-chaplains-faith-insignia/  
  7. Banks AM. Hegseth’s removal of the top Army chaplain raises ‘troubling questions’ from Black denomination. Religious News Service. April 9, 2026. Accessed April 24, 2026. https://religionnews.com/2026/04/09/army-chaplains-chiefs-firing-prompts-serious-concern-from-black-baptist-denomination/  
  8. Burchard WW. Role conflicts of military chaplains. Amer Sociolog Rev. 1954;19:528-535 https://www.jstor.org/stable/2087790  
  9. Sturtz DL. Commitment. Mil Med. 2001;166:741-744.
  10. Carver D. New Department of War policy: military chaplains no longer wear rank insignia. North American Mission Board. April 8, 2026. Accessed April 24, 2026. https://www.namb.net/resource/new-department-of-war-policy-military-chaplains-no-longer-wear-rank-insignia/  
  11. Petri D. If chaplains are ‘officers second,’ which staff corps officers are next? Military Times. April 1, 2026. Accessed April 24, 2026. https://www.militarytimes.com/opinion/2026/04/01/if-chaplains-are-officers-second-which-staff-corps-officers-are-next/   
  12. Schwab SD, Singh M. How power shapes behavior: evidence from physicians. Science. 2024; 384:802-807.
Article PDF
Author and Disclosure Information

Disclaimer 

The opinions expressed herein are those of the author and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies. 

Cynthia M.A. Geppert is Editor-in-Chief. 

Correspondence: 

Cynthia Geppert (fedprac@mdedge.com) 

Fed Pract. 2026;43(5). Published online May 15. doi:10.12788/fp.0733

Issue
Federal Practitioner - 43(5)
Publications
Topics
Page Number
170-171
Sections
Author and Disclosure Information

Disclaimer 

The opinions expressed herein are those of the author and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies. 

Cynthia M.A. Geppert is Editor-in-Chief. 

Correspondence: 

Cynthia Geppert (fedprac@mdedge.com) 

Fed Pract. 2026;43(5). Published online May 15. doi:10.12788/fp.0733

Author and Disclosure Information

Disclaimer 

The opinions expressed herein are those of the author and do not necessarily reflect those of Federal Practitioner, Frontline Medical Communications Inc., the US Government, or any of its agencies. 

Cynthia M.A. Geppert is Editor-in-Chief. 

Correspondence: 

Cynthia Geppert (fedprac@mdedge.com) 

Fed Pract. 2026;43(5). Published online May 15. doi:10.12788/fp.0733

Article PDF
Article PDF

Render unto Caesar the things that are Caesar’s, and to God the things that are God’s.
Matthew 22:21

While in my 20s, I taught religious education at a church on the Army base where I was born and had the honor of working with military chaplains. During my US Department of Veterans Affairs career, I closely collaborated with chaplains—many of whom were veterans—on patient care and ethics consultations. Some were quite proud of their rank and interested in climbing the ladder of promotion. A few made sure you knew what they wore or had worn on their uniform, while most were incredibly humble and sheepish when soldiers saluted them. Those visible responses to rank may be hidden if chaplains will no longer be permitted to wear insignia indicating their grade. 

Department of War Secretary Peter Hegseth, a combat veteran who has championed a “combative” form of Christianity, announced in April 2026 that chaplains would no longer wear their rank on their uniform.1 Details of how this shift will be translated into regulation, policy, and actions were not provided. Secretary Hegseth did not remove the actual rank of members of the chaplain corps and they would retain their rank, attendant pay, benefits, responsibilities, and privileges. However, instead of bearing the insignia of their military station, under this new policy only the symbol of their religious profession would identify them. Currently, both a military officer’s rank and religious symbol are displayed.2 

Useful insight can be gained from an historical perspective, which demonstrates that the concerns and contention about the issue of chaplain’s wearing rank are not new. There have been chaplains in the US Army since 1775.3 Army chaplains initially wore only a religious symbol on their clothing. In April 1914, chaplain leaders successful argued that chaplains deserved the privileges, respect, and prospect for promotion that rank symbolized and where authorized to display their position. Four years later, General Jack Pershing cabled the then Secretary of War opposing the new policy: “Believe the work of chaplains would be facilitated if they were not given military rank ... Many of our principal ministers believe that their relations would be closer if they did not have military titles and did not wear insignia.”4 Interestingly, Secretary Hegseth articulated the same concern: “A chaplain is first and foremost a chaplain and an officer second. This change is a visual representation of that fact.”5 

Hegseth has stated that in recent years the military chaplain corps had drifted too far in the direction of providing spiritual counseling and psychological support. This contravenes the current competencies especially for company-grade military chaplains who primarily minister to the moral distress and spiritual needs of service members.4 The removal of rank is thus best understood as part of Secretary Hegseth’s broader plan to remake the chaplain corps into his vision of religious ministry in the military.5 

Secretary Hegseth proffered several arguments for the necessity of removing rank in part to reorient the chaplain corps to what he calls a more fundamental mission. The first was theological: chaplains need to prioritize their “divine calling” rather than any human distinction. Chaplain theologians and ethicists have expressed similar concerns that in wearing rank, military chaplains become servants of the state and not of God. Adam Tietje articulates the corruptive influence this shift in the source of legitimacy has on the military chaplain’s spiritual mission: 

This undermines the ability of chaplains to provide care and counsel to both soldiers and leaders that is not muddied with the interests of the military. Chaplains without rank are better positioned to hear and advocate for their soldier’s matters of conscience as well as bear witness to the moral claims of their respective religious communities especially about war itself.3 

The second argument is pastoral. Hegseth contends that service members of lower rank would feel more comfortable and secure approaching chaplains with no outward sign of their higher position. Chaplain interactions with military personnel carry a degree of confidentiality higher than that of either doctors or lawyers. Chaplains, as they were in the past, remain divided on this important consideration.4,5 

The third argument is ethical in nature. Secretary Hegseth contends that excluding any manifestation of military rank, “speaks to the difficult balance of the duality” of the role.6 It seems he is proposing that chaplains displaying only the image of their faith commitment symbolically resolves the inherent moral conflict between serving human masters as a military officer, and the divine as a minister.7 Military chaplains and health care professionals are all too familiar with the dilemma of having 2 masters and the challenge of negotiating legally and ethically overlapping roles.8-10 

This may seem to some like a minor change in chaplain etiquette to some, but to others it signals a significant ethical and political change with potential import beyond chaplaincy. One military commentator has suggested the move sets a dangerous precedent that could eventually be applied to both health care professionals and the judge advocate corps.11 At this point this is only speculation and its slippery slope arguments are logically suspect without evidence. Yet at least 1 study suggests that the influence of military physician’s rank on patient care may lead to inequities in the care delivered to patients with lower grade.12 

It is commanders who are the decision-makers in the military. Chaplains who are field grade officers serve as trusted staff advisors in moral, ethical, and spiritual matters.4 Some chaplains fear that without rank leaders at all levels will not have adequate trust and sufficient respect to heed their crucial counsel especially regarding high-stakes strategic decisions in wartime.8 The more serious concern is with a major shift in the locus of authority to determine the professional identity of chaplains, that could in theory be expanded to impact military health care practitioners, and attorneys. The independent expert judgment of these professionals regarding what is necessary to fulfil their respective roles in providing spiritual ministry, medical care, and legal is critical to uphold the highest values of the US military.11 Chaplains have long struggled with what they owe to the Caesar and to God: how the Secretary’s recent decision will shape that rendering is uncertain. What is certain is that military chaplains of all faiths and in every branch of the armed services will continue to minister to their brothers and sisters in arms with courage and compassion. 

Render unto Caesar the things that are Caesar’s, and to God the things that are God’s.
Matthew 22:21

While in my 20s, I taught religious education at a church on the Army base where I was born and had the honor of working with military chaplains. During my US Department of Veterans Affairs career, I closely collaborated with chaplains—many of whom were veterans—on patient care and ethics consultations. Some were quite proud of their rank and interested in climbing the ladder of promotion. A few made sure you knew what they wore or had worn on their uniform, while most were incredibly humble and sheepish when soldiers saluted them. Those visible responses to rank may be hidden if chaplains will no longer be permitted to wear insignia indicating their grade. 

Department of War Secretary Peter Hegseth, a combat veteran who has championed a “combative” form of Christianity, announced in April 2026 that chaplains would no longer wear their rank on their uniform.1 Details of how this shift will be translated into regulation, policy, and actions were not provided. Secretary Hegseth did not remove the actual rank of members of the chaplain corps and they would retain their rank, attendant pay, benefits, responsibilities, and privileges. However, instead of bearing the insignia of their military station, under this new policy only the symbol of their religious profession would identify them. Currently, both a military officer’s rank and religious symbol are displayed.2 

Useful insight can be gained from an historical perspective, which demonstrates that the concerns and contention about the issue of chaplain’s wearing rank are not new. There have been chaplains in the US Army since 1775.3 Army chaplains initially wore only a religious symbol on their clothing. In April 1914, chaplain leaders successful argued that chaplains deserved the privileges, respect, and prospect for promotion that rank symbolized and where authorized to display their position. Four years later, General Jack Pershing cabled the then Secretary of War opposing the new policy: “Believe the work of chaplains would be facilitated if they were not given military rank ... Many of our principal ministers believe that their relations would be closer if they did not have military titles and did not wear insignia.”4 Interestingly, Secretary Hegseth articulated the same concern: “A chaplain is first and foremost a chaplain and an officer second. This change is a visual representation of that fact.”5 

Hegseth has stated that in recent years the military chaplain corps had drifted too far in the direction of providing spiritual counseling and psychological support. This contravenes the current competencies especially for company-grade military chaplains who primarily minister to the moral distress and spiritual needs of service members.4 The removal of rank is thus best understood as part of Secretary Hegseth’s broader plan to remake the chaplain corps into his vision of religious ministry in the military.5 

Secretary Hegseth proffered several arguments for the necessity of removing rank in part to reorient the chaplain corps to what he calls a more fundamental mission. The first was theological: chaplains need to prioritize their “divine calling” rather than any human distinction. Chaplain theologians and ethicists have expressed similar concerns that in wearing rank, military chaplains become servants of the state and not of God. Adam Tietje articulates the corruptive influence this shift in the source of legitimacy has on the military chaplain’s spiritual mission: 

This undermines the ability of chaplains to provide care and counsel to both soldiers and leaders that is not muddied with the interests of the military. Chaplains without rank are better positioned to hear and advocate for their soldier’s matters of conscience as well as bear witness to the moral claims of their respective religious communities especially about war itself.3 

The second argument is pastoral. Hegseth contends that service members of lower rank would feel more comfortable and secure approaching chaplains with no outward sign of their higher position. Chaplain interactions with military personnel carry a degree of confidentiality higher than that of either doctors or lawyers. Chaplains, as they were in the past, remain divided on this important consideration.4,5 

The third argument is ethical in nature. Secretary Hegseth contends that excluding any manifestation of military rank, “speaks to the difficult balance of the duality” of the role.6 It seems he is proposing that chaplains displaying only the image of their faith commitment symbolically resolves the inherent moral conflict between serving human masters as a military officer, and the divine as a minister.7 Military chaplains and health care professionals are all too familiar with the dilemma of having 2 masters and the challenge of negotiating legally and ethically overlapping roles.8-10 

This may seem to some like a minor change in chaplain etiquette to some, but to others it signals a significant ethical and political change with potential import beyond chaplaincy. One military commentator has suggested the move sets a dangerous precedent that could eventually be applied to both health care professionals and the judge advocate corps.11 At this point this is only speculation and its slippery slope arguments are logically suspect without evidence. Yet at least 1 study suggests that the influence of military physician’s rank on patient care may lead to inequities in the care delivered to patients with lower grade.12 

It is commanders who are the decision-makers in the military. Chaplains who are field grade officers serve as trusted staff advisors in moral, ethical, and spiritual matters.4 Some chaplains fear that without rank leaders at all levels will not have adequate trust and sufficient respect to heed their crucial counsel especially regarding high-stakes strategic decisions in wartime.8 The more serious concern is with a major shift in the locus of authority to determine the professional identity of chaplains, that could in theory be expanded to impact military health care practitioners, and attorneys. The independent expert judgment of these professionals regarding what is necessary to fulfil their respective roles in providing spiritual ministry, medical care, and legal is critical to uphold the highest values of the US military.11 Chaplains have long struggled with what they owe to the Caesar and to God: how the Secretary’s recent decision will shape that rendering is uncertain. What is certain is that military chaplains of all faiths and in every branch of the armed services will continue to minister to their brothers and sisters in arms with courage and compassion. 

References
  1. Baker R, Graham R. Pete Hegseth and his ‘battle cry’ for a new christian crusade. The New York Times. December 6, 2024. Accessed April 24, 2026. https://www.nytimes.com/2024/12/05/us/hegseth-church-crusades.html   
  2. Sampson E. Hegseth removes rank insignia from military chaplains. Military Times. March 25, 2026. Accessed April 24, 2026. https://www.militarytimes.com/news/pentagon-congress/2026/03/25/hegseth-removes-rank-insignia-from-military-chaplains/  
  3. Tietje A. A seductive confusion of authority: military chaplains and the wearing of rank. J Church State. 2020;62:506-524.
  4. Morris JT. Military chaplaincy in the USA: an unfolding of roles and functions. In: Weiss H, Federschmidt KH, Louw DJ, et al, eds. Care, Healing, and Human Well-Being Within Interreligious Discourses. African Sun Media; 2021:319-333.
  5. Cox M. Hegseth’s push for chaplain’s to shed remove rank sparks debate. Air and Space Forces Magazine. March 27, 2026. Accessed April 29, 2026. https://www.airandspaceforces.com/chaplains-ordered-to-shed-rank-ret-af-leaders-question-move/  
  6. Mitchell E. Hegseth: Military chaplains will no longer display rank. The Hill. March 25, 2026. Accessed April 24, 2026. https://thehill.com/policy/defense/5800026-pete-hegseth-military-chaplains-faith-insignia/  
  7. Banks AM. Hegseth’s removal of the top Army chaplain raises ‘troubling questions’ from Black denomination. Religious News Service. April 9, 2026. Accessed April 24, 2026. https://religionnews.com/2026/04/09/army-chaplains-chiefs-firing-prompts-serious-concern-from-black-baptist-denomination/  
  8. Burchard WW. Role conflicts of military chaplains. Amer Sociolog Rev. 1954;19:528-535 https://www.jstor.org/stable/2087790  
  9. Sturtz DL. Commitment. Mil Med. 2001;166:741-744.
  10. Carver D. New Department of War policy: military chaplains no longer wear rank insignia. North American Mission Board. April 8, 2026. Accessed April 24, 2026. https://www.namb.net/resource/new-department-of-war-policy-military-chaplains-no-longer-wear-rank-insignia/  
  11. Petri D. If chaplains are ‘officers second,’ which staff corps officers are next? Military Times. April 1, 2026. Accessed April 24, 2026. https://www.militarytimes.com/opinion/2026/04/01/if-chaplains-are-officers-second-which-staff-corps-officers-are-next/   
  12. Schwab SD, Singh M. How power shapes behavior: evidence from physicians. Science. 2024; 384:802-807.
References
  1. Baker R, Graham R. Pete Hegseth and his ‘battle cry’ for a new christian crusade. The New York Times. December 6, 2024. Accessed April 24, 2026. https://www.nytimes.com/2024/12/05/us/hegseth-church-crusades.html   
  2. Sampson E. Hegseth removes rank insignia from military chaplains. Military Times. March 25, 2026. Accessed April 24, 2026. https://www.militarytimes.com/news/pentagon-congress/2026/03/25/hegseth-removes-rank-insignia-from-military-chaplains/  
  3. Tietje A. A seductive confusion of authority: military chaplains and the wearing of rank. J Church State. 2020;62:506-524.
  4. Morris JT. Military chaplaincy in the USA: an unfolding of roles and functions. In: Weiss H, Federschmidt KH, Louw DJ, et al, eds. Care, Healing, and Human Well-Being Within Interreligious Discourses. African Sun Media; 2021:319-333.
  5. Cox M. Hegseth’s push for chaplain’s to shed remove rank sparks debate. Air and Space Forces Magazine. March 27, 2026. Accessed April 29, 2026. https://www.airandspaceforces.com/chaplains-ordered-to-shed-rank-ret-af-leaders-question-move/  
  6. Mitchell E. Hegseth: Military chaplains will no longer display rank. The Hill. March 25, 2026. Accessed April 24, 2026. https://thehill.com/policy/defense/5800026-pete-hegseth-military-chaplains-faith-insignia/  
  7. Banks AM. Hegseth’s removal of the top Army chaplain raises ‘troubling questions’ from Black denomination. Religious News Service. April 9, 2026. Accessed April 24, 2026. https://religionnews.com/2026/04/09/army-chaplains-chiefs-firing-prompts-serious-concern-from-black-baptist-denomination/  
  8. Burchard WW. Role conflicts of military chaplains. Amer Sociolog Rev. 1954;19:528-535 https://www.jstor.org/stable/2087790  
  9. Sturtz DL. Commitment. Mil Med. 2001;166:741-744.
  10. Carver D. New Department of War policy: military chaplains no longer wear rank insignia. North American Mission Board. April 8, 2026. Accessed April 24, 2026. https://www.namb.net/resource/new-department-of-war-policy-military-chaplains-no-longer-wear-rank-insignia/  
  11. Petri D. If chaplains are ‘officers second,’ which staff corps officers are next? Military Times. April 1, 2026. Accessed April 24, 2026. https://www.militarytimes.com/opinion/2026/04/01/if-chaplains-are-officers-second-which-staff-corps-officers-are-next/   
  12. Schwab SD, Singh M. How power shapes behavior: evidence from physicians. Science. 2024; 384:802-807.
Issue
Federal Practitioner - 43(5)
Issue
Federal Practitioner - 43(5)
Page Number
170-171
Page Number
170-171
Publications
Publications
Topics
Article Type
Display Headline

Divine Calling and Human Rank: The Locus of Authority for Military Chaplains

Display Headline

Divine Calling and Human Rank: The Locus of Authority for Military Chaplains

Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

The Effect of GLP-1 Receptor Agonists on Hidradenitis Suppurativa: A Comprehensive Systematic Review

Article Type
Changed
Display Headline

The Effect of GLP-1 Receptor Agonists on Hidradenitis Suppurativa: A Comprehensive Systematic Review

Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory skin disorder affecting apocrine gland–bearing areas such as the axillae, inguinal regions, and anogenital area.1 It manifests with painful nodules, abscesses, sinus tract formation, and scarring.2 The disease strongly impacts patients’ quality of life due to pain, malodor, and psychosocial burden.3

The exact etiology of HS is multifactorial, involving genetic predisposition, mechanical stress, hormonal influences, dysbiosis, and immune dysregulation.4 Obesity and metabolic syndrome are highly prevalent among patients with HS and are considered exacerbating factors.5 Adipose tissue contributes to systemic inflammation through the secretion of proinflammatory cytokines such as tumor necrosis factor (TNF) α and interleukins (ILs).6

Management of HS includes lifestyle modifications, medical therapy, and surgical interventions. Medical treatments encompass antibiotics, retinoids, hormonal therapy, immunosuppressants, and immunomodulators such as anti-TNF and anti–IL-17 agents.7 Despite available therapies, many patients have suboptimal responses or experience adverse effects and dramatic reductions in their quality of life.3

Glucagonlike peptide 1 receptor agonists (GLP-1 RAs) are incretin-based therapies used in type 2 diabetes and obesity management.8 They enhance insulin secretion, suppress glucagon release, delay gastric emptying, and promote satiety.9 Beyond glycemic control, GLP-1 RAs exhibit anti-inflammatory properties and cardiovascular benefits.10

Given the high prevalence of obesity and metabolic syndrome in patients with HS as well as the anti-inflammatory effects of GLP-1 RAs, these agents may offer therapeutic benefits in HS.11 We conducted a systematic review to evaluate the existing evidence on the efficacy and safety of GLP-1 RAs in the treatment of HS.

Methods

A systematic review was conducted via a PubMed search of articles indexed for MEDLINE in October 2024, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines12 using the terms hidradenitis suppurativa OR acne inversa AND GLP-1 receptor agonist OR glucagon-like peptide-1 receptor agonist OR liraglutide OR semaglutide OR exenatide OR dulaglutide. No filters were applied to limit the search by language or publication date.

Inclusion criteria were clinical trials, observational studies (cohort, case control, cross-sectional), and case reports/series involving patients diagnosed with HS treated with GLP-1 RAs. Outcomes of interest included clinical improvement in HS severity (eg, lesion count, pain assessment, HS-specific scores), safety, and adverse events. Exclusion criteria included animal studies or in vitro experiments, reviews, editorials, and opinion pieces without original patient data; studies not in English; and studies not reporting clinical outcomes related to HS.

Two independent reviewers (N.R.K. and S.K.C.) screened the titles and abstracts for relevance. Full-text articles of potentially eligible studies were retrieved for detailed evaluation. Data extracted included study design, patient demographics, intervention details, outcomes, and adverse events. Discrepancies were resolved through discussion.

Results

The initial search yielded 11 articles (Figure). After screening titles and abstracts, 9 articles were selected for full-text review. Of these, 3 articles met the inclusion criteria. These studies included 3 case reports. Interventions involved liraglutide (2 reports)13,14 and semaglutide15 (1 report)(Table). The patient population consisted of adult patients with HS with comorbid diabetes, obesity, and/or metabolic syndrome.

Kassira-Figure
FIGURE. PRISMA flow diagram of systematic review of the literature on glucagonlike peptide-1 receptor agonists and hidradenitis suppurativa.
CT117004019_e-Table

Jennings et al13 reported a 31-year-old obese woman with a history of smoking and Hurley stage 2 HS, a Hidradenitis Suppurativa Physician’s Global Assessment score of 4, a Dermatology Life Quality Index score of 24, and a body mass index of 45.3. She was treated with liraglutide monotherapy, starting with 0.6 mg subcutaneously once daily then titrating weekly to 1.8 mg subcutaneously. After 4 weeks, outcomes showed a reduction in Hidradenitis Suppurativa Physician’s Global Assessment (score=1) and Dermatology Life Quality Index (score=14) scores, and the patient lost 4.5 kg from baseline. The patient’s Hurley stage decreased from 2 to 1. After another 4 weeks, the patient’s weight decreased by a further 2 kg and HS remained controlled. No adverse events were recorded.

Khandalavala14 reported a single case of a 19-year-old woman with severe HS, obesity, and metabolic syndrome of 8 years’ duration treated with liraglutide. The patient had a weight of 215 lb with a body mass index of 37. With a combination of metformin 2000 mg/d, liraglutide 0.6 mg/d subcutaneously increased to 1.8 mg/d over 2 months, levonorgestrel-ethinyl estradiol (no dosage listed), dapsone 100 mg/d, and finasteride 5 mg/d, there was a marked reduction in nodules and abscesses after 6 months, with a weight loss of 40 lb (19% body weight). No adverse events were reported.

Mainville et al15 described a 59-year-old woman with refractory HS who showed improvement with a combination of intravenous ertapenem 1 g/d for 6 weeks, minocycline 100 mg/d for 3 months, metformin 500 mg three times daily for 2 months, doxycycline 100 mg/d to bridge to adalimumab (160 mg subcutaneously starting dose then 80 mg subcutaneously), and semaglutide (no dosage listed). After semaglutide was introduced, the patient lost 10 kg. The only adverse event was diarrhea.

Comment

The limited but growing body of evidence suggests that GLP-1 RAs may be beneficial in managing HS, particularly in patients with comorbid obesity. Treatment with liraglutide or semaglutide was associated with marked improvements in clinical severity scores, lesion counts, pain reduction, and quality of life.

As adjunct therapy, GLP-1 RAs could serve alongside standard HS treatments such as antibiotics and biologics. Addressing obesity, a known risk factor and disease modifier in HS, may lead to better disease control. The therapeutic benefits of GLP-1 RAs in HS are attributed to weight loss, which reduces adipose tissue and systemic inflammation.16 The anti-inflammatory effects of GLP-1 RAs involve the reduction of proinflammatory cytokines such as IL-6 and TNF-α.17 Metabolic improvements, including enhanced insulin sensitivity and lipid profile, also may contribute to disease modulation.17

Limitations—Because our analysis was limited to 3 case reports, the strength of the evidence is limited. These case reports also lack the standardized use of the Hidradenitis Suppurativa Clinical Response scoring system that generally is found in randomized controlled trials (RCTs). The lack of RCTs precludes definitive conclusions about efficacy. Future directions include the need for well-designed RCTs with large sample sizes to confirm findings, assessment of long-term safety and tolerability in patients with HS, and further research into the molecular mechanisms by which GLP-1 RAs affect HS pathophysiology. Of note, it is imperative to be aware of the medication shortage for all GLP-1 RAs when prescribing these medications for patients with HS.

Conclusion

Glucagonlike peptide 1 RAs show promise as a therapeutic option for HS, especially in patients with obesity and metabolic disturbances. The observed benefits likely result from weight loss and anti-inflammatory effects. Other drugs targeting glucose-dependent insulinotropic polypeptide and glucagon also are being studied thoroughly as options for managing HS. Although preliminary results are encouraging, robust clinical trials are needed to establish efficacy, optimal dosing, and safety in this patient population.

References
  1. Vinkel C, Thomsen SF. Hidradenitis suppurativa: causes, features, and current treatments. J Clin Aesthet Dermatol. 2018;11:17-23.
  2. Napolitano M, Megna M, Timoshchuk EA, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol. 2017;10:105-115. doi:10.2147/CCID.S111019
  3. Chernyshov PV, Finlay AY, Tomas-Aragones L, et al. Quality of life in hidradenitis suppurativa: an update. Int J Environ Res Public Health. 2021;18:6131. doi:10.3390/ijerph18116131
  4. Seyed Jafari SM, Hunger RE, Schlapbach C. Hidradenitis suppurativa: current understanding of pathogenic mechanisms and suggestion for treatment algorithm. Front Med (Lausanne). 2020;7:68. doi:10.3389/fmed.2020.00068
  5. Alotaibi HM. Incidence, risk factors, and prognosis of hidradenitis suppurativa across the globe: insights from the literature. Clin Cosmet Investig Dermatol. 2023;16:545-552. doi:10.2147/CCID.S402453
  6. Vossen ARJV, van der Zee HH, Prens EP. Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model. Front Immunol. 2018;9:2965. doi:10.3389/fimmu.2018.02965
  7. Orenstein LAV, Nguyen TV, Damiani G, et al. Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice. Dermatology. 2020;236:393-412. doi:10.1159/000507323
  8. Brown E, Cuthbertson DJ, Wilding JP. Newer GLP-1 receptor agonists and obesity-diabetes. Peptides. 2018;100:61-67. doi:10.1016/j.peptides.2017.12.009
  9. Cornell S. A review of GLP‐1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once‐weekly agents. J Clin Pharm Ther. 2020;45(suppl 1):17-27. doi:10.1111/jcpt.13230
  10. Lee YS, Jun HS. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators Inflamm. 2016;2016:3094642. doi:10.1155/2016/3094642
  11. Mintoff D, Benhadou F, Pace NP, et al. Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects. Int J Dermatol. 2022;61:1175-1186. doi:10.1111/ijd.15910
  12. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
  13. Jennings L, Nestor L, Molloy O, et al. The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide. Br J Dermatol. 2017;177:858-859. doi:10.1111/bjd.15233
  14. Khandalavala BN. A disease-modifying approach for advanced hidradenitis suppurativa (regimen with metformin, liraglutide, dapsone, and finasteride): a case report. Case Rep Dermatol. 2017;9:70-78. doi:10.1159/000473873
  15. Mainville L, MacHaalany J, Veillette H. Hidradenitis suppurativa patient requiring cardiac procedure with inguinal access: case management with ertapenem. SAGE Open Med Case Rep. 2024;12:2050313X241274819. doi:10.1177/2050313X241274819
  16. Hamed K, Alosaimi MN, Ali BA, et al. Glucagon-like peptide-1 (GLP-1) receptor agonists: exploring their impact on diabetes, obesity, and cardiovascular health through a comprehensive literature review. Cureus. 2024;16:E68390. doi:10.7759/cureus.68390
  17. Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024;15:20420188231222367. doi:10.1177/20420188231222367
Article PDF
Author and Disclosure Information

Dr. Kassira is from Southwest Healthcare MEC, Temecula, California. Dr. Carley is from Sharp Rees-Stealy Medical Group, Santee, California.

The authors have no relevant financial disclosures to report.

Correspondence: Sama K. Carley, MD, Sharp Rees-Stealy Medical Group, 8701 Cuyamaca St, 3rd Floor Dermatology, Santee, CA 92071 (sama.carley@sharp.com).

Cutis. 2026 April;117(4):E19-E22. doi:10.12788/cutis.1385

Issue
Cutis - 117(4)
Publications
Topics
Page Number
E19-E22
Sections
Author and Disclosure Information

Dr. Kassira is from Southwest Healthcare MEC, Temecula, California. Dr. Carley is from Sharp Rees-Stealy Medical Group, Santee, California.

The authors have no relevant financial disclosures to report.

Correspondence: Sama K. Carley, MD, Sharp Rees-Stealy Medical Group, 8701 Cuyamaca St, 3rd Floor Dermatology, Santee, CA 92071 (sama.carley@sharp.com).

Cutis. 2026 April;117(4):E19-E22. doi:10.12788/cutis.1385

Author and Disclosure Information

Dr. Kassira is from Southwest Healthcare MEC, Temecula, California. Dr. Carley is from Sharp Rees-Stealy Medical Group, Santee, California.

The authors have no relevant financial disclosures to report.

Correspondence: Sama K. Carley, MD, Sharp Rees-Stealy Medical Group, 8701 Cuyamaca St, 3rd Floor Dermatology, Santee, CA 92071 (sama.carley@sharp.com).

Cutis. 2026 April;117(4):E19-E22. doi:10.12788/cutis.1385

Article PDF
Article PDF

Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory skin disorder affecting apocrine gland–bearing areas such as the axillae, inguinal regions, and anogenital area.1 It manifests with painful nodules, abscesses, sinus tract formation, and scarring.2 The disease strongly impacts patients’ quality of life due to pain, malodor, and psychosocial burden.3

The exact etiology of HS is multifactorial, involving genetic predisposition, mechanical stress, hormonal influences, dysbiosis, and immune dysregulation.4 Obesity and metabolic syndrome are highly prevalent among patients with HS and are considered exacerbating factors.5 Adipose tissue contributes to systemic inflammation through the secretion of proinflammatory cytokines such as tumor necrosis factor (TNF) α and interleukins (ILs).6

Management of HS includes lifestyle modifications, medical therapy, and surgical interventions. Medical treatments encompass antibiotics, retinoids, hormonal therapy, immunosuppressants, and immunomodulators such as anti-TNF and anti–IL-17 agents.7 Despite available therapies, many patients have suboptimal responses or experience adverse effects and dramatic reductions in their quality of life.3

Glucagonlike peptide 1 receptor agonists (GLP-1 RAs) are incretin-based therapies used in type 2 diabetes and obesity management.8 They enhance insulin secretion, suppress glucagon release, delay gastric emptying, and promote satiety.9 Beyond glycemic control, GLP-1 RAs exhibit anti-inflammatory properties and cardiovascular benefits.10

Given the high prevalence of obesity and metabolic syndrome in patients with HS as well as the anti-inflammatory effects of GLP-1 RAs, these agents may offer therapeutic benefits in HS.11 We conducted a systematic review to evaluate the existing evidence on the efficacy and safety of GLP-1 RAs in the treatment of HS.

Methods

A systematic review was conducted via a PubMed search of articles indexed for MEDLINE in October 2024, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines12 using the terms hidradenitis suppurativa OR acne inversa AND GLP-1 receptor agonist OR glucagon-like peptide-1 receptor agonist OR liraglutide OR semaglutide OR exenatide OR dulaglutide. No filters were applied to limit the search by language or publication date.

Inclusion criteria were clinical trials, observational studies (cohort, case control, cross-sectional), and case reports/series involving patients diagnosed with HS treated with GLP-1 RAs. Outcomes of interest included clinical improvement in HS severity (eg, lesion count, pain assessment, HS-specific scores), safety, and adverse events. Exclusion criteria included animal studies or in vitro experiments, reviews, editorials, and opinion pieces without original patient data; studies not in English; and studies not reporting clinical outcomes related to HS.

Two independent reviewers (N.R.K. and S.K.C.) screened the titles and abstracts for relevance. Full-text articles of potentially eligible studies were retrieved for detailed evaluation. Data extracted included study design, patient demographics, intervention details, outcomes, and adverse events. Discrepancies were resolved through discussion.

Results

The initial search yielded 11 articles (Figure). After screening titles and abstracts, 9 articles were selected for full-text review. Of these, 3 articles met the inclusion criteria. These studies included 3 case reports. Interventions involved liraglutide (2 reports)13,14 and semaglutide15 (1 report)(Table). The patient population consisted of adult patients with HS with comorbid diabetes, obesity, and/or metabolic syndrome.

Kassira-Figure
FIGURE. PRISMA flow diagram of systematic review of the literature on glucagonlike peptide-1 receptor agonists and hidradenitis suppurativa.
CT117004019_e-Table

Jennings et al13 reported a 31-year-old obese woman with a history of smoking and Hurley stage 2 HS, a Hidradenitis Suppurativa Physician’s Global Assessment score of 4, a Dermatology Life Quality Index score of 24, and a body mass index of 45.3. She was treated with liraglutide monotherapy, starting with 0.6 mg subcutaneously once daily then titrating weekly to 1.8 mg subcutaneously. After 4 weeks, outcomes showed a reduction in Hidradenitis Suppurativa Physician’s Global Assessment (score=1) and Dermatology Life Quality Index (score=14) scores, and the patient lost 4.5 kg from baseline. The patient’s Hurley stage decreased from 2 to 1. After another 4 weeks, the patient’s weight decreased by a further 2 kg and HS remained controlled. No adverse events were recorded.

Khandalavala14 reported a single case of a 19-year-old woman with severe HS, obesity, and metabolic syndrome of 8 years’ duration treated with liraglutide. The patient had a weight of 215 lb with a body mass index of 37. With a combination of metformin 2000 mg/d, liraglutide 0.6 mg/d subcutaneously increased to 1.8 mg/d over 2 months, levonorgestrel-ethinyl estradiol (no dosage listed), dapsone 100 mg/d, and finasteride 5 mg/d, there was a marked reduction in nodules and abscesses after 6 months, with a weight loss of 40 lb (19% body weight). No adverse events were reported.

Mainville et al15 described a 59-year-old woman with refractory HS who showed improvement with a combination of intravenous ertapenem 1 g/d for 6 weeks, minocycline 100 mg/d for 3 months, metformin 500 mg three times daily for 2 months, doxycycline 100 mg/d to bridge to adalimumab (160 mg subcutaneously starting dose then 80 mg subcutaneously), and semaglutide (no dosage listed). After semaglutide was introduced, the patient lost 10 kg. The only adverse event was diarrhea.

Comment

The limited but growing body of evidence suggests that GLP-1 RAs may be beneficial in managing HS, particularly in patients with comorbid obesity. Treatment with liraglutide or semaglutide was associated with marked improvements in clinical severity scores, lesion counts, pain reduction, and quality of life.

As adjunct therapy, GLP-1 RAs could serve alongside standard HS treatments such as antibiotics and biologics. Addressing obesity, a known risk factor and disease modifier in HS, may lead to better disease control. The therapeutic benefits of GLP-1 RAs in HS are attributed to weight loss, which reduces adipose tissue and systemic inflammation.16 The anti-inflammatory effects of GLP-1 RAs involve the reduction of proinflammatory cytokines such as IL-6 and TNF-α.17 Metabolic improvements, including enhanced insulin sensitivity and lipid profile, also may contribute to disease modulation.17

Limitations—Because our analysis was limited to 3 case reports, the strength of the evidence is limited. These case reports also lack the standardized use of the Hidradenitis Suppurativa Clinical Response scoring system that generally is found in randomized controlled trials (RCTs). The lack of RCTs precludes definitive conclusions about efficacy. Future directions include the need for well-designed RCTs with large sample sizes to confirm findings, assessment of long-term safety and tolerability in patients with HS, and further research into the molecular mechanisms by which GLP-1 RAs affect HS pathophysiology. Of note, it is imperative to be aware of the medication shortage for all GLP-1 RAs when prescribing these medications for patients with HS.

Conclusion

Glucagonlike peptide 1 RAs show promise as a therapeutic option for HS, especially in patients with obesity and metabolic disturbances. The observed benefits likely result from weight loss and anti-inflammatory effects. Other drugs targeting glucose-dependent insulinotropic polypeptide and glucagon also are being studied thoroughly as options for managing HS. Although preliminary results are encouraging, robust clinical trials are needed to establish efficacy, optimal dosing, and safety in this patient population.

Hidradenitis suppurativa (HS) is a chronic relapsing inflammatory skin disorder affecting apocrine gland–bearing areas such as the axillae, inguinal regions, and anogenital area.1 It manifests with painful nodules, abscesses, sinus tract formation, and scarring.2 The disease strongly impacts patients’ quality of life due to pain, malodor, and psychosocial burden.3

The exact etiology of HS is multifactorial, involving genetic predisposition, mechanical stress, hormonal influences, dysbiosis, and immune dysregulation.4 Obesity and metabolic syndrome are highly prevalent among patients with HS and are considered exacerbating factors.5 Adipose tissue contributes to systemic inflammation through the secretion of proinflammatory cytokines such as tumor necrosis factor (TNF) α and interleukins (ILs).6

Management of HS includes lifestyle modifications, medical therapy, and surgical interventions. Medical treatments encompass antibiotics, retinoids, hormonal therapy, immunosuppressants, and immunomodulators such as anti-TNF and anti–IL-17 agents.7 Despite available therapies, many patients have suboptimal responses or experience adverse effects and dramatic reductions in their quality of life.3

Glucagonlike peptide 1 receptor agonists (GLP-1 RAs) are incretin-based therapies used in type 2 diabetes and obesity management.8 They enhance insulin secretion, suppress glucagon release, delay gastric emptying, and promote satiety.9 Beyond glycemic control, GLP-1 RAs exhibit anti-inflammatory properties and cardiovascular benefits.10

Given the high prevalence of obesity and metabolic syndrome in patients with HS as well as the anti-inflammatory effects of GLP-1 RAs, these agents may offer therapeutic benefits in HS.11 We conducted a systematic review to evaluate the existing evidence on the efficacy and safety of GLP-1 RAs in the treatment of HS.

Methods

A systematic review was conducted via a PubMed search of articles indexed for MEDLINE in October 2024, following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines12 using the terms hidradenitis suppurativa OR acne inversa AND GLP-1 receptor agonist OR glucagon-like peptide-1 receptor agonist OR liraglutide OR semaglutide OR exenatide OR dulaglutide. No filters were applied to limit the search by language or publication date.

Inclusion criteria were clinical trials, observational studies (cohort, case control, cross-sectional), and case reports/series involving patients diagnosed with HS treated with GLP-1 RAs. Outcomes of interest included clinical improvement in HS severity (eg, lesion count, pain assessment, HS-specific scores), safety, and adverse events. Exclusion criteria included animal studies or in vitro experiments, reviews, editorials, and opinion pieces without original patient data; studies not in English; and studies not reporting clinical outcomes related to HS.

Two independent reviewers (N.R.K. and S.K.C.) screened the titles and abstracts for relevance. Full-text articles of potentially eligible studies were retrieved for detailed evaluation. Data extracted included study design, patient demographics, intervention details, outcomes, and adverse events. Discrepancies were resolved through discussion.

Results

The initial search yielded 11 articles (Figure). After screening titles and abstracts, 9 articles were selected for full-text review. Of these, 3 articles met the inclusion criteria. These studies included 3 case reports. Interventions involved liraglutide (2 reports)13,14 and semaglutide15 (1 report)(Table). The patient population consisted of adult patients with HS with comorbid diabetes, obesity, and/or metabolic syndrome.

Kassira-Figure
FIGURE. PRISMA flow diagram of systematic review of the literature on glucagonlike peptide-1 receptor agonists and hidradenitis suppurativa.
CT117004019_e-Table

Jennings et al13 reported a 31-year-old obese woman with a history of smoking and Hurley stage 2 HS, a Hidradenitis Suppurativa Physician’s Global Assessment score of 4, a Dermatology Life Quality Index score of 24, and a body mass index of 45.3. She was treated with liraglutide monotherapy, starting with 0.6 mg subcutaneously once daily then titrating weekly to 1.8 mg subcutaneously. After 4 weeks, outcomes showed a reduction in Hidradenitis Suppurativa Physician’s Global Assessment (score=1) and Dermatology Life Quality Index (score=14) scores, and the patient lost 4.5 kg from baseline. The patient’s Hurley stage decreased from 2 to 1. After another 4 weeks, the patient’s weight decreased by a further 2 kg and HS remained controlled. No adverse events were recorded.

Khandalavala14 reported a single case of a 19-year-old woman with severe HS, obesity, and metabolic syndrome of 8 years’ duration treated with liraglutide. The patient had a weight of 215 lb with a body mass index of 37. With a combination of metformin 2000 mg/d, liraglutide 0.6 mg/d subcutaneously increased to 1.8 mg/d over 2 months, levonorgestrel-ethinyl estradiol (no dosage listed), dapsone 100 mg/d, and finasteride 5 mg/d, there was a marked reduction in nodules and abscesses after 6 months, with a weight loss of 40 lb (19% body weight). No adverse events were reported.

Mainville et al15 described a 59-year-old woman with refractory HS who showed improvement with a combination of intravenous ertapenem 1 g/d for 6 weeks, minocycline 100 mg/d for 3 months, metformin 500 mg three times daily for 2 months, doxycycline 100 mg/d to bridge to adalimumab (160 mg subcutaneously starting dose then 80 mg subcutaneously), and semaglutide (no dosage listed). After semaglutide was introduced, the patient lost 10 kg. The only adverse event was diarrhea.

Comment

The limited but growing body of evidence suggests that GLP-1 RAs may be beneficial in managing HS, particularly in patients with comorbid obesity. Treatment with liraglutide or semaglutide was associated with marked improvements in clinical severity scores, lesion counts, pain reduction, and quality of life.

As adjunct therapy, GLP-1 RAs could serve alongside standard HS treatments such as antibiotics and biologics. Addressing obesity, a known risk factor and disease modifier in HS, may lead to better disease control. The therapeutic benefits of GLP-1 RAs in HS are attributed to weight loss, which reduces adipose tissue and systemic inflammation.16 The anti-inflammatory effects of GLP-1 RAs involve the reduction of proinflammatory cytokines such as IL-6 and TNF-α.17 Metabolic improvements, including enhanced insulin sensitivity and lipid profile, also may contribute to disease modulation.17

Limitations—Because our analysis was limited to 3 case reports, the strength of the evidence is limited. These case reports also lack the standardized use of the Hidradenitis Suppurativa Clinical Response scoring system that generally is found in randomized controlled trials (RCTs). The lack of RCTs precludes definitive conclusions about efficacy. Future directions include the need for well-designed RCTs with large sample sizes to confirm findings, assessment of long-term safety and tolerability in patients with HS, and further research into the molecular mechanisms by which GLP-1 RAs affect HS pathophysiology. Of note, it is imperative to be aware of the medication shortage for all GLP-1 RAs when prescribing these medications for patients with HS.

Conclusion

Glucagonlike peptide 1 RAs show promise as a therapeutic option for HS, especially in patients with obesity and metabolic disturbances. The observed benefits likely result from weight loss and anti-inflammatory effects. Other drugs targeting glucose-dependent insulinotropic polypeptide and glucagon also are being studied thoroughly as options for managing HS. Although preliminary results are encouraging, robust clinical trials are needed to establish efficacy, optimal dosing, and safety in this patient population.

References
  1. Vinkel C, Thomsen SF. Hidradenitis suppurativa: causes, features, and current treatments. J Clin Aesthet Dermatol. 2018;11:17-23.
  2. Napolitano M, Megna M, Timoshchuk EA, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol. 2017;10:105-115. doi:10.2147/CCID.S111019
  3. Chernyshov PV, Finlay AY, Tomas-Aragones L, et al. Quality of life in hidradenitis suppurativa: an update. Int J Environ Res Public Health. 2021;18:6131. doi:10.3390/ijerph18116131
  4. Seyed Jafari SM, Hunger RE, Schlapbach C. Hidradenitis suppurativa: current understanding of pathogenic mechanisms and suggestion for treatment algorithm. Front Med (Lausanne). 2020;7:68. doi:10.3389/fmed.2020.00068
  5. Alotaibi HM. Incidence, risk factors, and prognosis of hidradenitis suppurativa across the globe: insights from the literature. Clin Cosmet Investig Dermatol. 2023;16:545-552. doi:10.2147/CCID.S402453
  6. Vossen ARJV, van der Zee HH, Prens EP. Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model. Front Immunol. 2018;9:2965. doi:10.3389/fimmu.2018.02965
  7. Orenstein LAV, Nguyen TV, Damiani G, et al. Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice. Dermatology. 2020;236:393-412. doi:10.1159/000507323
  8. Brown E, Cuthbertson DJ, Wilding JP. Newer GLP-1 receptor agonists and obesity-diabetes. Peptides. 2018;100:61-67. doi:10.1016/j.peptides.2017.12.009
  9. Cornell S. A review of GLP‐1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once‐weekly agents. J Clin Pharm Ther. 2020;45(suppl 1):17-27. doi:10.1111/jcpt.13230
  10. Lee YS, Jun HS. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators Inflamm. 2016;2016:3094642. doi:10.1155/2016/3094642
  11. Mintoff D, Benhadou F, Pace NP, et al. Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects. Int J Dermatol. 2022;61:1175-1186. doi:10.1111/ijd.15910
  12. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
  13. Jennings L, Nestor L, Molloy O, et al. The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide. Br J Dermatol. 2017;177:858-859. doi:10.1111/bjd.15233
  14. Khandalavala BN. A disease-modifying approach for advanced hidradenitis suppurativa (regimen with metformin, liraglutide, dapsone, and finasteride): a case report. Case Rep Dermatol. 2017;9:70-78. doi:10.1159/000473873
  15. Mainville L, MacHaalany J, Veillette H. Hidradenitis suppurativa patient requiring cardiac procedure with inguinal access: case management with ertapenem. SAGE Open Med Case Rep. 2024;12:2050313X241274819. doi:10.1177/2050313X241274819
  16. Hamed K, Alosaimi MN, Ali BA, et al. Glucagon-like peptide-1 (GLP-1) receptor agonists: exploring their impact on diabetes, obesity, and cardiovascular health through a comprehensive literature review. Cureus. 2024;16:E68390. doi:10.7759/cureus.68390
  17. Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024;15:20420188231222367. doi:10.1177/20420188231222367
References
  1. Vinkel C, Thomsen SF. Hidradenitis suppurativa: causes, features, and current treatments. J Clin Aesthet Dermatol. 2018;11:17-23.
  2. Napolitano M, Megna M, Timoshchuk EA, et al. Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clin Cosmet Investig Dermatol. 2017;10:105-115. doi:10.2147/CCID.S111019
  3. Chernyshov PV, Finlay AY, Tomas-Aragones L, et al. Quality of life in hidradenitis suppurativa: an update. Int J Environ Res Public Health. 2021;18:6131. doi:10.3390/ijerph18116131
  4. Seyed Jafari SM, Hunger RE, Schlapbach C. Hidradenitis suppurativa: current understanding of pathogenic mechanisms and suggestion for treatment algorithm. Front Med (Lausanne). 2020;7:68. doi:10.3389/fmed.2020.00068
  5. Alotaibi HM. Incidence, risk factors, and prognosis of hidradenitis suppurativa across the globe: insights from the literature. Clin Cosmet Investig Dermatol. 2023;16:545-552. doi:10.2147/CCID.S402453
  6. Vossen ARJV, van der Zee HH, Prens EP. Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model. Front Immunol. 2018;9:2965. doi:10.3389/fimmu.2018.02965
  7. Orenstein LAV, Nguyen TV, Damiani G, et al. Medical and surgical management of hidradenitis suppurativa: a review of international treatment guidelines and implementation in general dermatology practice. Dermatology. 2020;236:393-412. doi:10.1159/000507323
  8. Brown E, Cuthbertson DJ, Wilding JP. Newer GLP-1 receptor agonists and obesity-diabetes. Peptides. 2018;100:61-67. doi:10.1016/j.peptides.2017.12.009
  9. Cornell S. A review of GLP‐1 receptor agonists in type 2 diabetes: a focus on the mechanism of action of once‐weekly agents. J Clin Pharm Ther. 2020;45(suppl 1):17-27. doi:10.1111/jcpt.13230
  10. Lee YS, Jun HS. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators Inflamm. 2016;2016:3094642. doi:10.1155/2016/3094642
  11. Mintoff D, Benhadou F, Pace NP, et al. Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects. Int J Dermatol. 2022;61:1175-1186. doi:10.1111/ijd.15910
  12. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
  13. Jennings L, Nestor L, Molloy O, et al. The treatment of hidradenitis suppurativa with the glucagon-like peptide-1 agonist liraglutide. Br J Dermatol. 2017;177:858-859. doi:10.1111/bjd.15233
  14. Khandalavala BN. A disease-modifying approach for advanced hidradenitis suppurativa (regimen with metformin, liraglutide, dapsone, and finasteride): a case report. Case Rep Dermatol. 2017;9:70-78. doi:10.1159/000473873
  15. Mainville L, MacHaalany J, Veillette H. Hidradenitis suppurativa patient requiring cardiac procedure with inguinal access: case management with ertapenem. SAGE Open Med Case Rep. 2024;12:2050313X241274819. doi:10.1177/2050313X241274819
  16. Hamed K, Alosaimi MN, Ali BA, et al. Glucagon-like peptide-1 (GLP-1) receptor agonists: exploring their impact on diabetes, obesity, and cardiovascular health through a comprehensive literature review. Cureus. 2024;16:E68390. doi:10.7759/cureus.68390
  17. Alharbi SH. Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications. Ther Adv Endocrinol Metab. 2024;15:20420188231222367. doi:10.1177/20420188231222367
Issue
Cutis - 117(4)
Issue
Cutis - 117(4)
Page Number
E19-E22
Page Number
E19-E22
Publications
Publications
Topics
Article Type
Display Headline

The Effect of GLP-1 Receptor Agonists on Hidradenitis Suppurativa: A Comprehensive Systematic Review

Display Headline

The Effect of GLP-1 Receptor Agonists on Hidradenitis Suppurativa: A Comprehensive Systematic Review

Sections
Inside the Article

Practice Points

  • Glucagonlike peptide 1 receptor agonists (GLP-1 RAs) can be used adjunctively to manage hidradenitis suppurativa (HS) symptoms.
  • The anti-inflammatory properties of GLP-1 RAs as well as their tendency to cause weight loss and manage metabolic syndrome improve the outcome of HS.
  • Although current evidence is limited to case reports, these agents can be successfully integrated with existing protocols (biologics, antibiotics, or metformin); however, clinicians should monitor for gastrointestinal adverse effects.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

Hypergammaglobulinemic Purpura of Waldenström With Primary and Autoimmune Associations

Article Type
Changed
Display Headline

Hypergammaglobulinemic Purpura of Waldenström With Primary and Autoimmune Associations

Hypergammaglobulinemic purpura of Waldenström (HGPW) is a rare chronic skin condition characterized by recurrent petechiae and purpura on the lower legs, elevated erythrocyte sedimentation rate (ESR), polyclonal hypergammaglobulinemia, and elevated titers of IgG and IgA rheumatoid factor (RF).1,2 This condition can be a primary (idiopathic) syndrome or secondary to an autoimmune connective tissue disease. We report 2 cases of patients with episodic skin eruptions that were consistent with HGPW.

Patient 1

A 41-year-old woman presented to our clinic with a rash on the legs of 20 years’ duration. She had first been evaluated at an outside dermatology clinic 5 years prior, and a biopsy performed at the time led to a diagnosis of leukocytoclastic vasculitis (LCV). The rash affected her ability to work, as her job involved standing for prolonged periods of time. If she stood for more than 2 hours, she experienced leg pain and worsening of the rash. The rash also was exacerbated by nonsteroidal anti-inflammatory drugs but improved with multiple days of rest. She had been on dapsone 75 mg daily, but the dose was reduced to 50 mg daily after elevated liver enzymes were noted. This regimen had improved her rash for 4 years until she experienced breakthrough symptoms, leading to her re-evaluation. Prior outside therapies included systemic steroids with limited response, then oral dapsone.

Upon our initial evaluation, laboratory tests were notable for an elevated ESR of 43 mm/h. Results of antinuclear antibody (ANA), anti–double-stranded DNA, extractable nuclear antigen, RF, HIV, cryoglobulin, hepatitis panel, serum protein electrophoresis, complete blood count, basic metabolic panel, urinalysis, and thyroid-stimulating hormone testing were within reference range. Physical examination revealed scattered pinpoint violaceous papules on the lower extremities. Photographs on the patient’s phone from 2 months prior showed a more robust manifestation with diffuse palpable purpura on the lower extremities.

At 3-year follow-up, laboratory evaluation including ESR, IgA, IgG, IgM, serum protein electrophoresis with reflex immunofixation, and Mycoplasma pneumoniae IgM/IgG showed elevated ESR (29 mm/h) and IgG (1654 mg), with otherwise unremarkable results. Because of the extended period of time since the previous biopsy, a repeat biopsy with hematoxylin and eosin staining and direct immunofluorescence was performed. Biopsy from the left calf demonstrated a perivascular and interstitial infiltrate with lymphocytes and neutrophils with nuclear debris and hemorrhage (Figure 1). Direct immunofluorescence was positive for IgA, C3, and fibrin within vessel walls (Figure 2).

Colwell-1
FIGURE 1. Punch biopsy from patient 1 demonstrated a perivascula and interstitial infiltrate with lymphocytes and neutrophils with nuclear debris and hemorrhage (H&E, original magnification ×200).
Colwell-2
FIGURE 2. Direct immunofluorescence from patient 1 showing IgA within vessel walls.

Overall the features of recurrent dependent palpable purpura and the pathology findings were consistent with evolving LCV. Given the chronic nature of her symptoms; flares with prolonged standing; presence of polyclonol hypergammaglobulinemia; and negative evaluation for underling autoimmune disease, infection, and malignancy, the clinicopathologic correlation was most consistent with primary HGPW. The patient was treated with colchicine 0.6 mg twice daily and continued on dapsone 50 mg daily. The colchicine was reduced to once daily due to diarrhea. Nonetheless, the patient had less frequent and less intense flares. On follow-up examination 4 months later, she was satisfied with her current level of control and did not wish to escalate her treatment.

Patient 2

A 53-year-old woman with a 1-year history of sicca symptoms presented for evaluation of a transient rash on the legs and feet of 2 months’ duration. At that time, the heels began to feel swollen. The rash was painful on the feet and caused calf myalgias. She did not endorse pruritus or pain elsewhere. The rash was not associated with prolonged standing, walking, or wearing tight socks. She had no fevers, chills, or joint pain. Flares would come and go within a week.

Laboratory evaluation was notable for an ANA of 1:1280 (reference range, 1:80) with positive anti-Ro/SS-A and anti-La/SS-B. Rheumatology evaluation confirmed the diagnosis of Sjögren syndrome. Physical examination revealed minimal petechiae on the heel of the left foot. Photographs from the previous month provided by the patient revealed linear petechiae of the lower extremities with postinflammatory hyperpigmentation (Figure 3). An additional photograph from the prior week revealed more diffuse erythematous plaques without secondary changes on the feet up to the ankles (Figure 4).

Colwell-3
FIGURE 3. Patient 2 had linear petechiae with surrounding postinflammatory hyperpigmentation on the leg.
Colwell-4
FIGURE 4. Patient 2 had petechiae with more widespread involvement of both legs during a separate flare.

The patient experienced a recurrence of the rash within a month and had an expedited visit for biopsies, which demonstrated mixed inflammation with neutrophils, nuclear debris, hemorrhage, and C3 and fibrin immunoreactants within vessel walls. As with patient 1, the features were consistent with LCV.

In the context of Sjögren syndrome and elevated IgG and RF, the patient’s symptoms were consistent with secondary HGPW. Rheumatology prescribed hydroxychloroquine 400 mg daily alternating every other day with 300 mg and 0.6 mg of colchicine. The rash cleared within approximately 1 month.

Comment

Also known as benign hypergammaglobulinemic purpura, HGPW is a rare purpuric eruption that is exacerbated with prolonged standing and increased hydrostatic pressure.3 First described in 1943, HGPW is characterized by recurrent petechiae, purpuric macules, or palpable purpura, depending on the degree of inflammation.1,4,5 It typically is distributed on the bilateral lower extremities or trunk. Chronic postinflammatory hyperpigmentation with hemosiderin deposition also can be observed. The lesions last for up to 1 week at a time and are frequently asymmetrically distributed.2

Patient 1 demonstrated the typical clinical manifestations and laboratory findings of HGPW. The eruption often is asymptomatic, and patients report that the skin worsens with prolonged immobilization, walking, and wearing of tight clothing.2,6-8 Increased hydrostatic pressure is thought to cause the erythrocyte extravasation, resulting in the purpuric lesions. However, patient 2 was less typical, presenting with prominent skin pain and myalgias. Some patients experience discomfort, burning dysesthesia, pruritus, and swelling of the affected area.1 Hypergammaglobulinemic purpura of Waldenström is a chronic condition. Recurrent episodes can occur yearly or as frequently as multiple times per week.8

Women are most commonly diagnosed with HGPW, but many cases have been reported in children.9,10 In spite of the “condition being considered largely benign,” women with a diagnosis of HGPW require preconception counseling due to risks for congenital heart block, neonatal lupus, intrauterine growth restriction, intrauterine demise, and preterm birth.7,9,11,12

The etiology of the rash remains undefined. It is hypothesized that it develops due to underlying immune dysregulation with associated immune complex formation and deposition in the blood vessel wall.1 Small circulating immune complexes containing IgG or IgA RF are a specific finding in patients with HGPW. These highly soluble autoantibodies are hypothesized to influence the rapid appearance and disappearance of lesions.1

The role of hypergammaglobulinemia in the pathogenesis of HGPW is unknown.13 Serum IgG levels do not correlate with the appearance and regression of lesions.13 Additionally, hypergammaglobulinemia can be found in autoimmune connective tissue diseases such as Sjögren syndrome without resulting cutaneous vasculitis.13

Characteristic laboratory abnormalities include polyclonal hypergammaglobulinemia, elevated ESR, and elevated IgA and IgG RF. Positive ANA and anti-Ro/SS-A and anti-La/SS-B indicate a potential to develop autoimmune connective tissue diseases, including Sjögren syndrome, systemic lupus erythematosus, and rheumatoid arthritis.1,14 Additional recommended workup includes complete blood counts, metabolic panel, complement levels, urinalysis, and urine protein/creatinine ratio.9 Repeat monitoring for antibodies, inflammatory markers, immunoglobulins, and RF should be completed 3 months after initial evaluation. Patients with symptoms of systemic disease should have laboratory evaluation repeated.

Erythrocyte sedimentation rate abnormalities are a defining feature of HGPW. Erythrocyte sedimentation rate is an inexpensive and commonly ordered inflammatory marker that measures settling of erythrocytes within 1 hour and can be elevated by plasma proteins such as gamma globulins. Erythrocyte sedimentation rate is nonspecific and is not sensitive as a general screening test. It can be elevated by autoimmune connective tissue disease, infection, and malignancy.15 Notably, ESR is not specific to inflammation. Confounding factors include red blood cell abnormalities, physiologic factors, and the quantity of plasma proteins such as fibrinogen.16 These positively charged plasma proteins neutralize the negative surface charge of erythrocytes, resulting in erythrocytes that are prone to rouleaux formation.17

The utility of the ESR is to expedite the diagnostic process and indicate the need for further workup.16 Patients with mild to moderate elevation in ESR without an identified etiology should have repeat testing to confirm the validity of the laboratory value. Patients with an ESR higher than 100 mm/h are more likely have an infectious cause, collagen vascular disease, or underlying malignancy.15 Elevation of ESR in HGPW is likely a result of increased immunoglobulins and acute phase proteins.17

The histopathology of HGPW is nonspecific and may show LCV or erythrocyte extravasation with mild perivascular lymphocytic infiltrates.1,9 Direct immunofluorescence testing may show immune-complex deposition.5 For patients with evidence of LCV, the biopsy of a fresh but well-developed lesion is important in confirming the presence of vasculitis.1 Incorrect sampling may lead to underreporting of LCV with HGPW.3

Associated underlying conditions include Sjögren syndrome, systemic lupus erythematosus, rheumatoid arthritis, hepatitis C, and hematologic malignancies.1,3 Our patients demonstrated primary and secondary causes of HGPW. Patient 1’s case was not associated with any autoimmune disease but demonstrated chronic recurrence. Patient 2’s case was secondary to Sjögren syndrome.

In patients with suspected HGPW, differential diagnoses to consider include IgA vasculitis, cutaneous small vessel vasculitis, pigmented purpuric dermatoses, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, and scurvy.1,4

For patients with primary disease, treatment is focused on symptom management with compression stockings and avoidance of triggers. Compression stockings may exacerbate purpura but can provide symptom relief in some individuals.14 Patients with frequent or painful episodes can benefit from systemic treatment. In patients with an underlying disease, systemic therapies include prednisone, hydroxychloroquine, indomethacin, colchicine, chlorambucil, mycophenolate mofetil, rituximab, and plasmapheresis. Dapsone, a treatment for LCV, has been reported to be beneficial in patients with a neutrophilic infiltrate.18

Hypergammaglobulinemic purpura of Waldenström requires a thorough evaluation due to its association with underlying systemic disease. Patients without evidence of systemic disease should receive long-term monitoring and coordination of care with rheumatology, as systemic manifestations can develop years after the initial cutaneous manifestation. Dermatologists should consider HGPW in the differential diagnosis for cutaneous vasculitides.

References
  1. Piette WW. Purpura: mechanisms and differential diagnosis.In: Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. Elsevier Health Sciences; 2018:376-389.
  2. Finder KA, McCollough ML, Dixon SL, et al. Hypergammaglobulinemic purpura of Waldenström. J Am Acad Dermatol. 1990;23(4 Pt 1):669-676. doi:10.1016/0190-9622(90)70271-i
  3. Mathis J, Zirwas M, Elkins CT, et al. Persistent and progressive purpura in a patient with an elevated rheumatoid factor and polyclonal gammopathy (hypergammaglobulinemic purpura of Waldenström). J Am Acad Dermatol. 2015;72:374-376. doi:10.1016/j.jaad.2013.02.020
  4. 4. Alexandrescu DT, Levi M. The vascular purpuras. In: Kaushansky K, Prchal JT, Burns LJ, et al, eds. Williams Hematology. 10th ed. McGraw Hill; 2021:1-34.
  5. Lewin JM, Hunt R, Fischer M, et al. Hypergammaglobulinemic purpura of Waldenström. Dermatol Online J. 2012;18:2.
  6. Habib GS, Stimmer MM, Quismorio FP. Hypergammaglobulinemic purpura of Waldenstrom associated with systemic lupus erythematosus: report of a case and review of the literature. Lupus. 1995;4:19-22. doi:10.1177/096120339500400105
  7. Maeda-Tanaka M, Haruta S, Sado T, et al. Juvenile-onset hypergammaglobulinemic purpura and fetal congenital heart block.J Dermatol. 2006;33:714-718. doi:10.1111/j.1346-8138.2006.00166.x
  8. Malaviya AN, Kaushik P, Budhiraja S, et al. Hypergammaglobulinemic purpura of Waldenström: report of 3 cases with a short review. Clin Exp Rheumatol. 2000;18:518-522.
  9. Theisen E, Lee DE, Pei S, et al. Hypergammaglobulinemic purpura of Waldenström in children. Pediatr Dermatol. 2020;37:467-475. doi:10.1111/pde.14120
  10. Martini A, Ravelli A, Viola S, et al. Hypergammaglobulinemic purpura in childhood. Report of two cases and review of the literature. Helv Paediatr Acta. 1988;43:225-231.
  11. Jolly EC, Hunt BJ, Ellis S, et al. “Benign” hypergammaglobulinemic purpura is not benign in pregnancy. Clin Rheumatol. 2009;28(Suppl 1):S11-S15. doi:10.1007/s10067-008-1038-2
  12. Cheung VY, Bocking AD, Hollomby D, et al. Waldenström hypergammaglobulinemic purpura and pregnancy. Obstet Gynecol. 1993;82(4 Pt 2 Suppl):685-687.
  13. Kimura K, Miyabe C, Miyata R, et al. Hypergammaglobulinemic purpura: does hypergammaglobulinemia cause purpura? J Dermatol. 2021;48:e556-e557. doi:10.1111/1346-8138.16122
  14. Frankel A, Ingraffea A, Massé M, et al. Hypergammaglobulinemic purpura of Waldenström. Cutis. 2010;86:23-24.
  15. Brigden ML. Clinical utility of the erythrocyte sedimentation rate. Am Fam Physician. 1999;60:1443-1450.
  16. Solberg BL, Olson RJ. Clinical utility of the erythrocyte sedimentation rate: a case study. Clin Lab Sci. 2014;27:72-77.
  17. Tishkowski K, Gupta V. Erythrocyte sedimentation rate. In: StatPearls. StatPearls Publishing; May 9, 2021.
  18. Cheah J, Fields T. Hypergammaglobulinemic purpura of Waldenström. October 2018. Accessed November 14, 2021. https://www.hss.edu/files/HSS-Grand-Rounds-Complex-Cases-Vol7-Issue3.pdf
Article PDF
Author and Disclosure Information

Dr. Colwell is from Marshfield Clinic Health System, Marshfield, Wisconsin. Drs. Endo, Bennett, and Keenan are from the School of Medicine and Public Health, University of Wisconsin, Madison.

The authors have no relevant financial disclosures to report.

Correspondence: Thomas Keenan, MD, PhD (tkeenan@dermatology.wisc.edu).

Cutis. 2026 April;117(4):E15-E18. doi:10.12788/cutis.1380

Issue
Cutis - 117(4)
Publications
Topics
Page Number
E15-E18
Sections
Author and Disclosure Information

Dr. Colwell is from Marshfield Clinic Health System, Marshfield, Wisconsin. Drs. Endo, Bennett, and Keenan are from the School of Medicine and Public Health, University of Wisconsin, Madison.

The authors have no relevant financial disclosures to report.

Correspondence: Thomas Keenan, MD, PhD (tkeenan@dermatology.wisc.edu).

Cutis. 2026 April;117(4):E15-E18. doi:10.12788/cutis.1380

Author and Disclosure Information

Dr. Colwell is from Marshfield Clinic Health System, Marshfield, Wisconsin. Drs. Endo, Bennett, and Keenan are from the School of Medicine and Public Health, University of Wisconsin, Madison.

The authors have no relevant financial disclosures to report.

Correspondence: Thomas Keenan, MD, PhD (tkeenan@dermatology.wisc.edu).

Cutis. 2026 April;117(4):E15-E18. doi:10.12788/cutis.1380

Article PDF
Article PDF

Hypergammaglobulinemic purpura of Waldenström (HGPW) is a rare chronic skin condition characterized by recurrent petechiae and purpura on the lower legs, elevated erythrocyte sedimentation rate (ESR), polyclonal hypergammaglobulinemia, and elevated titers of IgG and IgA rheumatoid factor (RF).1,2 This condition can be a primary (idiopathic) syndrome or secondary to an autoimmune connective tissue disease. We report 2 cases of patients with episodic skin eruptions that were consistent with HGPW.

Patient 1

A 41-year-old woman presented to our clinic with a rash on the legs of 20 years’ duration. She had first been evaluated at an outside dermatology clinic 5 years prior, and a biopsy performed at the time led to a diagnosis of leukocytoclastic vasculitis (LCV). The rash affected her ability to work, as her job involved standing for prolonged periods of time. If she stood for more than 2 hours, she experienced leg pain and worsening of the rash. The rash also was exacerbated by nonsteroidal anti-inflammatory drugs but improved with multiple days of rest. She had been on dapsone 75 mg daily, but the dose was reduced to 50 mg daily after elevated liver enzymes were noted. This regimen had improved her rash for 4 years until she experienced breakthrough symptoms, leading to her re-evaluation. Prior outside therapies included systemic steroids with limited response, then oral dapsone.

Upon our initial evaluation, laboratory tests were notable for an elevated ESR of 43 mm/h. Results of antinuclear antibody (ANA), anti–double-stranded DNA, extractable nuclear antigen, RF, HIV, cryoglobulin, hepatitis panel, serum protein electrophoresis, complete blood count, basic metabolic panel, urinalysis, and thyroid-stimulating hormone testing were within reference range. Physical examination revealed scattered pinpoint violaceous papules on the lower extremities. Photographs on the patient’s phone from 2 months prior showed a more robust manifestation with diffuse palpable purpura on the lower extremities.

At 3-year follow-up, laboratory evaluation including ESR, IgA, IgG, IgM, serum protein electrophoresis with reflex immunofixation, and Mycoplasma pneumoniae IgM/IgG showed elevated ESR (29 mm/h) and IgG (1654 mg), with otherwise unremarkable results. Because of the extended period of time since the previous biopsy, a repeat biopsy with hematoxylin and eosin staining and direct immunofluorescence was performed. Biopsy from the left calf demonstrated a perivascular and interstitial infiltrate with lymphocytes and neutrophils with nuclear debris and hemorrhage (Figure 1). Direct immunofluorescence was positive for IgA, C3, and fibrin within vessel walls (Figure 2).

Colwell-1
FIGURE 1. Punch biopsy from patient 1 demonstrated a perivascula and interstitial infiltrate with lymphocytes and neutrophils with nuclear debris and hemorrhage (H&E, original magnification ×200).
Colwell-2
FIGURE 2. Direct immunofluorescence from patient 1 showing IgA within vessel walls.

Overall the features of recurrent dependent palpable purpura and the pathology findings were consistent with evolving LCV. Given the chronic nature of her symptoms; flares with prolonged standing; presence of polyclonol hypergammaglobulinemia; and negative evaluation for underling autoimmune disease, infection, and malignancy, the clinicopathologic correlation was most consistent with primary HGPW. The patient was treated with colchicine 0.6 mg twice daily and continued on dapsone 50 mg daily. The colchicine was reduced to once daily due to diarrhea. Nonetheless, the patient had less frequent and less intense flares. On follow-up examination 4 months later, she was satisfied with her current level of control and did not wish to escalate her treatment.

Patient 2

A 53-year-old woman with a 1-year history of sicca symptoms presented for evaluation of a transient rash on the legs and feet of 2 months’ duration. At that time, the heels began to feel swollen. The rash was painful on the feet and caused calf myalgias. She did not endorse pruritus or pain elsewhere. The rash was not associated with prolonged standing, walking, or wearing tight socks. She had no fevers, chills, or joint pain. Flares would come and go within a week.

Laboratory evaluation was notable for an ANA of 1:1280 (reference range, 1:80) with positive anti-Ro/SS-A and anti-La/SS-B. Rheumatology evaluation confirmed the diagnosis of Sjögren syndrome. Physical examination revealed minimal petechiae on the heel of the left foot. Photographs from the previous month provided by the patient revealed linear petechiae of the lower extremities with postinflammatory hyperpigmentation (Figure 3). An additional photograph from the prior week revealed more diffuse erythematous plaques without secondary changes on the feet up to the ankles (Figure 4).

Colwell-3
FIGURE 3. Patient 2 had linear petechiae with surrounding postinflammatory hyperpigmentation on the leg.
Colwell-4
FIGURE 4. Patient 2 had petechiae with more widespread involvement of both legs during a separate flare.

The patient experienced a recurrence of the rash within a month and had an expedited visit for biopsies, which demonstrated mixed inflammation with neutrophils, nuclear debris, hemorrhage, and C3 and fibrin immunoreactants within vessel walls. As with patient 1, the features were consistent with LCV.

In the context of Sjögren syndrome and elevated IgG and RF, the patient’s symptoms were consistent with secondary HGPW. Rheumatology prescribed hydroxychloroquine 400 mg daily alternating every other day with 300 mg and 0.6 mg of colchicine. The rash cleared within approximately 1 month.

Comment

Also known as benign hypergammaglobulinemic purpura, HGPW is a rare purpuric eruption that is exacerbated with prolonged standing and increased hydrostatic pressure.3 First described in 1943, HGPW is characterized by recurrent petechiae, purpuric macules, or palpable purpura, depending on the degree of inflammation.1,4,5 It typically is distributed on the bilateral lower extremities or trunk. Chronic postinflammatory hyperpigmentation with hemosiderin deposition also can be observed. The lesions last for up to 1 week at a time and are frequently asymmetrically distributed.2

Patient 1 demonstrated the typical clinical manifestations and laboratory findings of HGPW. The eruption often is asymptomatic, and patients report that the skin worsens with prolonged immobilization, walking, and wearing of tight clothing.2,6-8 Increased hydrostatic pressure is thought to cause the erythrocyte extravasation, resulting in the purpuric lesions. However, patient 2 was less typical, presenting with prominent skin pain and myalgias. Some patients experience discomfort, burning dysesthesia, pruritus, and swelling of the affected area.1 Hypergammaglobulinemic purpura of Waldenström is a chronic condition. Recurrent episodes can occur yearly or as frequently as multiple times per week.8

Women are most commonly diagnosed with HGPW, but many cases have been reported in children.9,10 In spite of the “condition being considered largely benign,” women with a diagnosis of HGPW require preconception counseling due to risks for congenital heart block, neonatal lupus, intrauterine growth restriction, intrauterine demise, and preterm birth.7,9,11,12

The etiology of the rash remains undefined. It is hypothesized that it develops due to underlying immune dysregulation with associated immune complex formation and deposition in the blood vessel wall.1 Small circulating immune complexes containing IgG or IgA RF are a specific finding in patients with HGPW. These highly soluble autoantibodies are hypothesized to influence the rapid appearance and disappearance of lesions.1

The role of hypergammaglobulinemia in the pathogenesis of HGPW is unknown.13 Serum IgG levels do not correlate with the appearance and regression of lesions.13 Additionally, hypergammaglobulinemia can be found in autoimmune connective tissue diseases such as Sjögren syndrome without resulting cutaneous vasculitis.13

Characteristic laboratory abnormalities include polyclonal hypergammaglobulinemia, elevated ESR, and elevated IgA and IgG RF. Positive ANA and anti-Ro/SS-A and anti-La/SS-B indicate a potential to develop autoimmune connective tissue diseases, including Sjögren syndrome, systemic lupus erythematosus, and rheumatoid arthritis.1,14 Additional recommended workup includes complete blood counts, metabolic panel, complement levels, urinalysis, and urine protein/creatinine ratio.9 Repeat monitoring for antibodies, inflammatory markers, immunoglobulins, and RF should be completed 3 months after initial evaluation. Patients with symptoms of systemic disease should have laboratory evaluation repeated.

Erythrocyte sedimentation rate abnormalities are a defining feature of HGPW. Erythrocyte sedimentation rate is an inexpensive and commonly ordered inflammatory marker that measures settling of erythrocytes within 1 hour and can be elevated by plasma proteins such as gamma globulins. Erythrocyte sedimentation rate is nonspecific and is not sensitive as a general screening test. It can be elevated by autoimmune connective tissue disease, infection, and malignancy.15 Notably, ESR is not specific to inflammation. Confounding factors include red blood cell abnormalities, physiologic factors, and the quantity of plasma proteins such as fibrinogen.16 These positively charged plasma proteins neutralize the negative surface charge of erythrocytes, resulting in erythrocytes that are prone to rouleaux formation.17

The utility of the ESR is to expedite the diagnostic process and indicate the need for further workup.16 Patients with mild to moderate elevation in ESR without an identified etiology should have repeat testing to confirm the validity of the laboratory value. Patients with an ESR higher than 100 mm/h are more likely have an infectious cause, collagen vascular disease, or underlying malignancy.15 Elevation of ESR in HGPW is likely a result of increased immunoglobulins and acute phase proteins.17

The histopathology of HGPW is nonspecific and may show LCV or erythrocyte extravasation with mild perivascular lymphocytic infiltrates.1,9 Direct immunofluorescence testing may show immune-complex deposition.5 For patients with evidence of LCV, the biopsy of a fresh but well-developed lesion is important in confirming the presence of vasculitis.1 Incorrect sampling may lead to underreporting of LCV with HGPW.3

Associated underlying conditions include Sjögren syndrome, systemic lupus erythematosus, rheumatoid arthritis, hepatitis C, and hematologic malignancies.1,3 Our patients demonstrated primary and secondary causes of HGPW. Patient 1’s case was not associated with any autoimmune disease but demonstrated chronic recurrence. Patient 2’s case was secondary to Sjögren syndrome.

In patients with suspected HGPW, differential diagnoses to consider include IgA vasculitis, cutaneous small vessel vasculitis, pigmented purpuric dermatoses, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, and scurvy.1,4

For patients with primary disease, treatment is focused on symptom management with compression stockings and avoidance of triggers. Compression stockings may exacerbate purpura but can provide symptom relief in some individuals.14 Patients with frequent or painful episodes can benefit from systemic treatment. In patients with an underlying disease, systemic therapies include prednisone, hydroxychloroquine, indomethacin, colchicine, chlorambucil, mycophenolate mofetil, rituximab, and plasmapheresis. Dapsone, a treatment for LCV, has been reported to be beneficial in patients with a neutrophilic infiltrate.18

Hypergammaglobulinemic purpura of Waldenström requires a thorough evaluation due to its association with underlying systemic disease. Patients without evidence of systemic disease should receive long-term monitoring and coordination of care with rheumatology, as systemic manifestations can develop years after the initial cutaneous manifestation. Dermatologists should consider HGPW in the differential diagnosis for cutaneous vasculitides.

Hypergammaglobulinemic purpura of Waldenström (HGPW) is a rare chronic skin condition characterized by recurrent petechiae and purpura on the lower legs, elevated erythrocyte sedimentation rate (ESR), polyclonal hypergammaglobulinemia, and elevated titers of IgG and IgA rheumatoid factor (RF).1,2 This condition can be a primary (idiopathic) syndrome or secondary to an autoimmune connective tissue disease. We report 2 cases of patients with episodic skin eruptions that were consistent with HGPW.

Patient 1

A 41-year-old woman presented to our clinic with a rash on the legs of 20 years’ duration. She had first been evaluated at an outside dermatology clinic 5 years prior, and a biopsy performed at the time led to a diagnosis of leukocytoclastic vasculitis (LCV). The rash affected her ability to work, as her job involved standing for prolonged periods of time. If she stood for more than 2 hours, she experienced leg pain and worsening of the rash. The rash also was exacerbated by nonsteroidal anti-inflammatory drugs but improved with multiple days of rest. She had been on dapsone 75 mg daily, but the dose was reduced to 50 mg daily after elevated liver enzymes were noted. This regimen had improved her rash for 4 years until she experienced breakthrough symptoms, leading to her re-evaluation. Prior outside therapies included systemic steroids with limited response, then oral dapsone.

Upon our initial evaluation, laboratory tests were notable for an elevated ESR of 43 mm/h. Results of antinuclear antibody (ANA), anti–double-stranded DNA, extractable nuclear antigen, RF, HIV, cryoglobulin, hepatitis panel, serum protein electrophoresis, complete blood count, basic metabolic panel, urinalysis, and thyroid-stimulating hormone testing were within reference range. Physical examination revealed scattered pinpoint violaceous papules on the lower extremities. Photographs on the patient’s phone from 2 months prior showed a more robust manifestation with diffuse palpable purpura on the lower extremities.

At 3-year follow-up, laboratory evaluation including ESR, IgA, IgG, IgM, serum protein electrophoresis with reflex immunofixation, and Mycoplasma pneumoniae IgM/IgG showed elevated ESR (29 mm/h) and IgG (1654 mg), with otherwise unremarkable results. Because of the extended period of time since the previous biopsy, a repeat biopsy with hematoxylin and eosin staining and direct immunofluorescence was performed. Biopsy from the left calf demonstrated a perivascular and interstitial infiltrate with lymphocytes and neutrophils with nuclear debris and hemorrhage (Figure 1). Direct immunofluorescence was positive for IgA, C3, and fibrin within vessel walls (Figure 2).

Colwell-1
FIGURE 1. Punch biopsy from patient 1 demonstrated a perivascula and interstitial infiltrate with lymphocytes and neutrophils with nuclear debris and hemorrhage (H&E, original magnification ×200).
Colwell-2
FIGURE 2. Direct immunofluorescence from patient 1 showing IgA within vessel walls.

Overall the features of recurrent dependent palpable purpura and the pathology findings were consistent with evolving LCV. Given the chronic nature of her symptoms; flares with prolonged standing; presence of polyclonol hypergammaglobulinemia; and negative evaluation for underling autoimmune disease, infection, and malignancy, the clinicopathologic correlation was most consistent with primary HGPW. The patient was treated with colchicine 0.6 mg twice daily and continued on dapsone 50 mg daily. The colchicine was reduced to once daily due to diarrhea. Nonetheless, the patient had less frequent and less intense flares. On follow-up examination 4 months later, she was satisfied with her current level of control and did not wish to escalate her treatment.

Patient 2

A 53-year-old woman with a 1-year history of sicca symptoms presented for evaluation of a transient rash on the legs and feet of 2 months’ duration. At that time, the heels began to feel swollen. The rash was painful on the feet and caused calf myalgias. She did not endorse pruritus or pain elsewhere. The rash was not associated with prolonged standing, walking, or wearing tight socks. She had no fevers, chills, or joint pain. Flares would come and go within a week.

Laboratory evaluation was notable for an ANA of 1:1280 (reference range, 1:80) with positive anti-Ro/SS-A and anti-La/SS-B. Rheumatology evaluation confirmed the diagnosis of Sjögren syndrome. Physical examination revealed minimal petechiae on the heel of the left foot. Photographs from the previous month provided by the patient revealed linear petechiae of the lower extremities with postinflammatory hyperpigmentation (Figure 3). An additional photograph from the prior week revealed more diffuse erythematous plaques without secondary changes on the feet up to the ankles (Figure 4).

Colwell-3
FIGURE 3. Patient 2 had linear petechiae with surrounding postinflammatory hyperpigmentation on the leg.
Colwell-4
FIGURE 4. Patient 2 had petechiae with more widespread involvement of both legs during a separate flare.

The patient experienced a recurrence of the rash within a month and had an expedited visit for biopsies, which demonstrated mixed inflammation with neutrophils, nuclear debris, hemorrhage, and C3 and fibrin immunoreactants within vessel walls. As with patient 1, the features were consistent with LCV.

In the context of Sjögren syndrome and elevated IgG and RF, the patient’s symptoms were consistent with secondary HGPW. Rheumatology prescribed hydroxychloroquine 400 mg daily alternating every other day with 300 mg and 0.6 mg of colchicine. The rash cleared within approximately 1 month.

Comment

Also known as benign hypergammaglobulinemic purpura, HGPW is a rare purpuric eruption that is exacerbated with prolonged standing and increased hydrostatic pressure.3 First described in 1943, HGPW is characterized by recurrent petechiae, purpuric macules, or palpable purpura, depending on the degree of inflammation.1,4,5 It typically is distributed on the bilateral lower extremities or trunk. Chronic postinflammatory hyperpigmentation with hemosiderin deposition also can be observed. The lesions last for up to 1 week at a time and are frequently asymmetrically distributed.2

Patient 1 demonstrated the typical clinical manifestations and laboratory findings of HGPW. The eruption often is asymptomatic, and patients report that the skin worsens with prolonged immobilization, walking, and wearing of tight clothing.2,6-8 Increased hydrostatic pressure is thought to cause the erythrocyte extravasation, resulting in the purpuric lesions. However, patient 2 was less typical, presenting with prominent skin pain and myalgias. Some patients experience discomfort, burning dysesthesia, pruritus, and swelling of the affected area.1 Hypergammaglobulinemic purpura of Waldenström is a chronic condition. Recurrent episodes can occur yearly or as frequently as multiple times per week.8

Women are most commonly diagnosed with HGPW, but many cases have been reported in children.9,10 In spite of the “condition being considered largely benign,” women with a diagnosis of HGPW require preconception counseling due to risks for congenital heart block, neonatal lupus, intrauterine growth restriction, intrauterine demise, and preterm birth.7,9,11,12

The etiology of the rash remains undefined. It is hypothesized that it develops due to underlying immune dysregulation with associated immune complex formation and deposition in the blood vessel wall.1 Small circulating immune complexes containing IgG or IgA RF are a specific finding in patients with HGPW. These highly soluble autoantibodies are hypothesized to influence the rapid appearance and disappearance of lesions.1

The role of hypergammaglobulinemia in the pathogenesis of HGPW is unknown.13 Serum IgG levels do not correlate with the appearance and regression of lesions.13 Additionally, hypergammaglobulinemia can be found in autoimmune connective tissue diseases such as Sjögren syndrome without resulting cutaneous vasculitis.13

Characteristic laboratory abnormalities include polyclonal hypergammaglobulinemia, elevated ESR, and elevated IgA and IgG RF. Positive ANA and anti-Ro/SS-A and anti-La/SS-B indicate a potential to develop autoimmune connective tissue diseases, including Sjögren syndrome, systemic lupus erythematosus, and rheumatoid arthritis.1,14 Additional recommended workup includes complete blood counts, metabolic panel, complement levels, urinalysis, and urine protein/creatinine ratio.9 Repeat monitoring for antibodies, inflammatory markers, immunoglobulins, and RF should be completed 3 months after initial evaluation. Patients with symptoms of systemic disease should have laboratory evaluation repeated.

Erythrocyte sedimentation rate abnormalities are a defining feature of HGPW. Erythrocyte sedimentation rate is an inexpensive and commonly ordered inflammatory marker that measures settling of erythrocytes within 1 hour and can be elevated by plasma proteins such as gamma globulins. Erythrocyte sedimentation rate is nonspecific and is not sensitive as a general screening test. It can be elevated by autoimmune connective tissue disease, infection, and malignancy.15 Notably, ESR is not specific to inflammation. Confounding factors include red blood cell abnormalities, physiologic factors, and the quantity of plasma proteins such as fibrinogen.16 These positively charged plasma proteins neutralize the negative surface charge of erythrocytes, resulting in erythrocytes that are prone to rouleaux formation.17

The utility of the ESR is to expedite the diagnostic process and indicate the need for further workup.16 Patients with mild to moderate elevation in ESR without an identified etiology should have repeat testing to confirm the validity of the laboratory value. Patients with an ESR higher than 100 mm/h are more likely have an infectious cause, collagen vascular disease, or underlying malignancy.15 Elevation of ESR in HGPW is likely a result of increased immunoglobulins and acute phase proteins.17

The histopathology of HGPW is nonspecific and may show LCV or erythrocyte extravasation with mild perivascular lymphocytic infiltrates.1,9 Direct immunofluorescence testing may show immune-complex deposition.5 For patients with evidence of LCV, the biopsy of a fresh but well-developed lesion is important in confirming the presence of vasculitis.1 Incorrect sampling may lead to underreporting of LCV with HGPW.3

Associated underlying conditions include Sjögren syndrome, systemic lupus erythematosus, rheumatoid arthritis, hepatitis C, and hematologic malignancies.1,3 Our patients demonstrated primary and secondary causes of HGPW. Patient 1’s case was not associated with any autoimmune disease but demonstrated chronic recurrence. Patient 2’s case was secondary to Sjögren syndrome.

In patients with suspected HGPW, differential diagnoses to consider include IgA vasculitis, cutaneous small vessel vasculitis, pigmented purpuric dermatoses, idiopathic thrombocytopenic purpura, thrombotic thrombocytopenic purpura, and scurvy.1,4

For patients with primary disease, treatment is focused on symptom management with compression stockings and avoidance of triggers. Compression stockings may exacerbate purpura but can provide symptom relief in some individuals.14 Patients with frequent or painful episodes can benefit from systemic treatment. In patients with an underlying disease, systemic therapies include prednisone, hydroxychloroquine, indomethacin, colchicine, chlorambucil, mycophenolate mofetil, rituximab, and plasmapheresis. Dapsone, a treatment for LCV, has been reported to be beneficial in patients with a neutrophilic infiltrate.18

Hypergammaglobulinemic purpura of Waldenström requires a thorough evaluation due to its association with underlying systemic disease. Patients without evidence of systemic disease should receive long-term monitoring and coordination of care with rheumatology, as systemic manifestations can develop years after the initial cutaneous manifestation. Dermatologists should consider HGPW in the differential diagnosis for cutaneous vasculitides.

References
  1. Piette WW. Purpura: mechanisms and differential diagnosis.In: Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. Elsevier Health Sciences; 2018:376-389.
  2. Finder KA, McCollough ML, Dixon SL, et al. Hypergammaglobulinemic purpura of Waldenström. J Am Acad Dermatol. 1990;23(4 Pt 1):669-676. doi:10.1016/0190-9622(90)70271-i
  3. Mathis J, Zirwas M, Elkins CT, et al. Persistent and progressive purpura in a patient with an elevated rheumatoid factor and polyclonal gammopathy (hypergammaglobulinemic purpura of Waldenström). J Am Acad Dermatol. 2015;72:374-376. doi:10.1016/j.jaad.2013.02.020
  4. 4. Alexandrescu DT, Levi M. The vascular purpuras. In: Kaushansky K, Prchal JT, Burns LJ, et al, eds. Williams Hematology. 10th ed. McGraw Hill; 2021:1-34.
  5. Lewin JM, Hunt R, Fischer M, et al. Hypergammaglobulinemic purpura of Waldenström. Dermatol Online J. 2012;18:2.
  6. Habib GS, Stimmer MM, Quismorio FP. Hypergammaglobulinemic purpura of Waldenstrom associated with systemic lupus erythematosus: report of a case and review of the literature. Lupus. 1995;4:19-22. doi:10.1177/096120339500400105
  7. Maeda-Tanaka M, Haruta S, Sado T, et al. Juvenile-onset hypergammaglobulinemic purpura and fetal congenital heart block.J Dermatol. 2006;33:714-718. doi:10.1111/j.1346-8138.2006.00166.x
  8. Malaviya AN, Kaushik P, Budhiraja S, et al. Hypergammaglobulinemic purpura of Waldenström: report of 3 cases with a short review. Clin Exp Rheumatol. 2000;18:518-522.
  9. Theisen E, Lee DE, Pei S, et al. Hypergammaglobulinemic purpura of Waldenström in children. Pediatr Dermatol. 2020;37:467-475. doi:10.1111/pde.14120
  10. Martini A, Ravelli A, Viola S, et al. Hypergammaglobulinemic purpura in childhood. Report of two cases and review of the literature. Helv Paediatr Acta. 1988;43:225-231.
  11. Jolly EC, Hunt BJ, Ellis S, et al. “Benign” hypergammaglobulinemic purpura is not benign in pregnancy. Clin Rheumatol. 2009;28(Suppl 1):S11-S15. doi:10.1007/s10067-008-1038-2
  12. Cheung VY, Bocking AD, Hollomby D, et al. Waldenström hypergammaglobulinemic purpura and pregnancy. Obstet Gynecol. 1993;82(4 Pt 2 Suppl):685-687.
  13. Kimura K, Miyabe C, Miyata R, et al. Hypergammaglobulinemic purpura: does hypergammaglobulinemia cause purpura? J Dermatol. 2021;48:e556-e557. doi:10.1111/1346-8138.16122
  14. Frankel A, Ingraffea A, Massé M, et al. Hypergammaglobulinemic purpura of Waldenström. Cutis. 2010;86:23-24.
  15. Brigden ML. Clinical utility of the erythrocyte sedimentation rate. Am Fam Physician. 1999;60:1443-1450.
  16. Solberg BL, Olson RJ. Clinical utility of the erythrocyte sedimentation rate: a case study. Clin Lab Sci. 2014;27:72-77.
  17. Tishkowski K, Gupta V. Erythrocyte sedimentation rate. In: StatPearls. StatPearls Publishing; May 9, 2021.
  18. Cheah J, Fields T. Hypergammaglobulinemic purpura of Waldenström. October 2018. Accessed November 14, 2021. https://www.hss.edu/files/HSS-Grand-Rounds-Complex-Cases-Vol7-Issue3.pdf
References
  1. Piette WW. Purpura: mechanisms and differential diagnosis.In: Bolognia JL, Schaffer JV, Cerroni L, eds. Dermatology. Elsevier Health Sciences; 2018:376-389.
  2. Finder KA, McCollough ML, Dixon SL, et al. Hypergammaglobulinemic purpura of Waldenström. J Am Acad Dermatol. 1990;23(4 Pt 1):669-676. doi:10.1016/0190-9622(90)70271-i
  3. Mathis J, Zirwas M, Elkins CT, et al. Persistent and progressive purpura in a patient with an elevated rheumatoid factor and polyclonal gammopathy (hypergammaglobulinemic purpura of Waldenström). J Am Acad Dermatol. 2015;72:374-376. doi:10.1016/j.jaad.2013.02.020
  4. 4. Alexandrescu DT, Levi M. The vascular purpuras. In: Kaushansky K, Prchal JT, Burns LJ, et al, eds. Williams Hematology. 10th ed. McGraw Hill; 2021:1-34.
  5. Lewin JM, Hunt R, Fischer M, et al. Hypergammaglobulinemic purpura of Waldenström. Dermatol Online J. 2012;18:2.
  6. Habib GS, Stimmer MM, Quismorio FP. Hypergammaglobulinemic purpura of Waldenstrom associated with systemic lupus erythematosus: report of a case and review of the literature. Lupus. 1995;4:19-22. doi:10.1177/096120339500400105
  7. Maeda-Tanaka M, Haruta S, Sado T, et al. Juvenile-onset hypergammaglobulinemic purpura and fetal congenital heart block.J Dermatol. 2006;33:714-718. doi:10.1111/j.1346-8138.2006.00166.x
  8. Malaviya AN, Kaushik P, Budhiraja S, et al. Hypergammaglobulinemic purpura of Waldenström: report of 3 cases with a short review. Clin Exp Rheumatol. 2000;18:518-522.
  9. Theisen E, Lee DE, Pei S, et al. Hypergammaglobulinemic purpura of Waldenström in children. Pediatr Dermatol. 2020;37:467-475. doi:10.1111/pde.14120
  10. Martini A, Ravelli A, Viola S, et al. Hypergammaglobulinemic purpura in childhood. Report of two cases and review of the literature. Helv Paediatr Acta. 1988;43:225-231.
  11. Jolly EC, Hunt BJ, Ellis S, et al. “Benign” hypergammaglobulinemic purpura is not benign in pregnancy. Clin Rheumatol. 2009;28(Suppl 1):S11-S15. doi:10.1007/s10067-008-1038-2
  12. Cheung VY, Bocking AD, Hollomby D, et al. Waldenström hypergammaglobulinemic purpura and pregnancy. Obstet Gynecol. 1993;82(4 Pt 2 Suppl):685-687.
  13. Kimura K, Miyabe C, Miyata R, et al. Hypergammaglobulinemic purpura: does hypergammaglobulinemia cause purpura? J Dermatol. 2021;48:e556-e557. doi:10.1111/1346-8138.16122
  14. Frankel A, Ingraffea A, Massé M, et al. Hypergammaglobulinemic purpura of Waldenström. Cutis. 2010;86:23-24.
  15. Brigden ML. Clinical utility of the erythrocyte sedimentation rate. Am Fam Physician. 1999;60:1443-1450.
  16. Solberg BL, Olson RJ. Clinical utility of the erythrocyte sedimentation rate: a case study. Clin Lab Sci. 2014;27:72-77.
  17. Tishkowski K, Gupta V. Erythrocyte sedimentation rate. In: StatPearls. StatPearls Publishing; May 9, 2021.
  18. Cheah J, Fields T. Hypergammaglobulinemic purpura of Waldenström. October 2018. Accessed November 14, 2021. https://www.hss.edu/files/HSS-Grand-Rounds-Complex-Cases-Vol7-Issue3.pdf
Issue
Cutis - 117(4)
Issue
Cutis - 117(4)
Page Number
E15-E18
Page Number
E15-E18
Publications
Publications
Topics
Article Type
Display Headline

Hypergammaglobulinemic Purpura of Waldenström With Primary and Autoimmune Associations

Display Headline

Hypergammaglobulinemic Purpura of Waldenström With Primary and Autoimmune Associations

Sections
Inside the Article

Practice Points

  • Elevation of the erythrocyte sedimentation rate (ESR) is nonspecific for inflammation and may be observed in the setting of increased immunoglobulin levels.
  • Patients with elevated ESR and clinical evidence of recurrent petechiae and purpura should be screened for monoclonal and polyclonal gammopathies.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

A Solitary Axillary Subcutaneous Mass

Article Type
Changed
Display Headline

A Solitary Axillary Subcutaneous Mass

THE DIAGNOSIS: Cutaneous Rosai-Dorfman Disease

The clinical differential diagnosis in our patient included a broad array of soft-tissue neoplasms ranging from benign entities to sarcomas. Histology was notable for a dense, dermal-based, lymphohistiocytic infiltrate with alternating hypocellular and hypercellular areas imparting a marbled appearance on low-power view (Figure, A). Further immunohistochemical staining revealed large, S100-positive histiocytes containing intact inflammatory cells (emperipolesis), which confirmed a diagnosis of cutaneous Rosai-Dorfman disease (RDD)(Figure, B). Our patient elected to undergo surgical removal of the mass, and he will be monitored for recurrence.

CT117004012_e-Fig_AB
FIGURE. A, A punch biopsy from the lesion in the right axilla demonstrated a dense, dermal inflammatory infiltrate with alternating hypocellular and hypercellular zones (H&E, original magnification ×200 and ×300. B, High-power view showed large pale histiocytes containing intact lymphocytes and plasma cells within the cytoplasm (H&E, original magnification ×400

Rosai-Dorfman disease is a non–Langerhans cell histiocytosis that most commonly affects the lymph nodes but can affect other organs including the skin. Rosai-Dorfman disease initially was documented in the medical literature in 1969 by Rosai and Dorfman1 as benign sinus histiocytosis with massive lymphadenopathy. Classic RDD usually manifests with painless cervical lymphadenopathy in children or young adults along with fever, leukocytosis, anemia, polyclonal hypergammaglobulinemia, and elevated inflammatory markers.2,3 Extranodal involvement has been reported in up to 43% of cases, with common sites including the skin, central nervous system, and gastrointestinal tract.3,4

Cutaneous RDD is a distinct, less common clinical entity that is limited to the skin and shows no nodal involvement or systemic symptoms such as fever, night sweats, or weight loss.5 Cutaneous RDD classically manifests with localized indurated papules and plaques, but it can manifest with tumorlike lesions in the subcutaneous tissues.6 Cutaneous RDD is very rare, with fewer than 200 known case reports in the literature as of 2014; in comparison to classic forms of RDD, cutaneous RDD has a female predominance.7,8 There are few reports of isolated cutaneous disease manifesting as soft-tissue masses, and our case represents a rare case of cutaneous RDD manifesting as a solitary soft-tissue mass in the axilla.9-11 Diagnosis of cutaneous RDD is challenging due to its variable clinical manifestations and nonspecific imaging findings, requiring clinicopathologic correlation.

Imaging of subcutaneous RDD lesions typically shows well-defined, irregularly shaped masses with homogenous enhancement on computed tomography/ magnetic resonance imaging. Additional imaging with positron emission tomography/computed tomography is recommended to examine for organ involvement, as RDD lesions have avid uptake.12,13 Imaging may help differentiate RDD lesions from malignant neoplasms prior to biopsy. Additional workup includes baseline laboratory testing with inflammatory markers and a complete blood count for evaluation of laboratory abnormalities seen in classic RDD, including leukocytosis, anemia, or systemic inflammation.12 Following imaging and laboratory testing, definitive diagnosis of RDD necessitates histopathologic examination.

Although cutaneous RDD is clinically distinct from its classic RDD counterpart, the conditions share the same characteristic histologic features.5 Histology is notable for a dense mixed inflammatory infiltrate comprised of large pale histiocytes exhibiting emperipolesis, lymphocytes, plasma cells, and occasional eosinophils and neutrophils. Histiocytes stain positive for CD68, CD163, and S100 and are negative for Langerhans cell markers CD1a and CD207.6

The etiology of RDD remains poorly understood. Classic RDD has been associated with both sporadic and familial forms, with somatic mutations identified in the mitogen-activated protein kinase/KRAS pathway in up to one-third of cases, and less frequently in the BRAF gene.14,15 Germline mutations in familial cases of RDD have been identified in the SLC29A3 gene; mutations in this gene are associated with a spectrum of syndromes with histiocytosis and lymphadenopathy.14,15 In contrast, molecular drivers have yet to be identified in cutaneous RDD lesions, and the current predominant hypothesis is that cutaneous RDD has a reactive or immunologic pathophysiology. Autoimmune diseases, infections, and lymphomas have been reported to co-occur with both classic and cutaneous RDD.15 While subclinical viral infections such as Epstein-Barr virus and human herpesvirus 6 have been identified in RDD cases, studies have failed to prove their role as pathogenic drivers of the disease.14,16,17 Commonly reported comorbidities include systemic lupus erythematous, diabetes, hemolytic anemia, acute/chronic uveitis (though it is controversial whether these cases represent orbital involvement in systemic RDD), and Crohn disease.7,8,18,19 Immunohistochemical findings have supported that cells within RDD are activated monocytes responding to T-cell cytokine signaling following an infectious or immunologic insult.20,21

Consensus guidelines on treatment for cutaneous RDD recommend either observation for asymptomatic disease or surgical excision for unifocal lesions with consideration of systemic therapy for refractory cutaneous disease.22,23 Most patients with cutaneous RDD have self-limited disease, but long-term follow-up is recommended following surgical excision to monitor for recurrence, especially if there is a residual positive margin.24 Radiation therapy also may have to be utilized for residual or recurrent disease that becomes symptomatic; however, further studies are needed to determine its efficacy in limiting recurrence.4,12,25 Systemic treatment options include immunosuppressive or immunomodulatory agents such as corticosteroids, methotrexate, and rituximab.5 There currently are no guidelines on length of follow-up, but surveillance is recommended initially at 4 months, followed by 6- to 12-month intervals.22

References
  1. Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. a newly recognized benign clinicopathological entity. Arch Pathol. 1969;87:63-70.
  2. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. 1990;7:19-73.
  3. Stefanato CM, Ellerin PS, Bhawan J. Cutaneous sinus histiocytosis (Rosai-Dorfman disease) presenting clinically as vasculitis. J Am Acad Dermatol. 2002;46:775-778.
  4. Dalia S, Sagatys E, Sokol L, et al. Rosai-Dorfman Disease: tumor biology, clinical features, pathology, and treatment. Cancer Control. 2014;21:322-327.
  5. Bruce-Brand C, Schneider JW, Schubert P. Rosai-Dorfman disease: an overview. J Clin Pathol. 2020;73:697.
  6. Bolognia J, Jorizzo J, Schaffer J. Dermatology. 3rd ed. ed. Elsevier Saunders 2012.
  7. Salva KA, Stenstrom M, Breadon JY, et al. Possible association of cutaneous rosai-dorfman disease and chronic crohn disease: a case series report. JAMA Dermatol. 2014;150:177-181.
  8. Brenn T, Calonje E, Granter SR, et al. Cutaneous Rosai-Dorfman disease is a distinct clinical entity. Am J Dermatopathol. 2002; 24:385-391.
  9. Betini N, Munger AM, Rottmann D, et al. Rare presentation of Rosai- Dorfman disease in soft tissue: diagnostic findings and surgical treatment. Case Rep Surg. 2022;2022:8440836.
  10. Cravero JC, Ibrahim S. Recurrent soft tissue rosai dorfman disease of right medial thigh lipoma with lymph node involvement. Fed Pract. 2024;41(suppl 2):S20-S23
  11. Tenny SO, McGinness M, Zhang D, et al. Rosai-Dorfman disease presenting as a breast mass and enlarged axillary lymph node mimicking malignancy: a case report and review of the literature. Breast J. 2011;17:516-520.
  12. Goyal G, Ravindran A, Young JR, et al. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica. 2020;105:348-357.
  13. Li H, Li D, Xia J, et al. Radiological features of Rosai-Dorfman disease: case series and review of the literature. Clin Radiol. 2022;77:E799-E805.
  14. Elbaz Younes I, Sokol L, Zhang L. Rosai-Dorfman disease between proliferation and neoplasia. Cancers. 2022;14:5271.
  15. Ravindran A, Rech KL. How I diagnose Rosai-Dorfman disease. Am J Clin Pathol. 2023;160:1-10.
  16. Kutlubay Z, Bairamov O, Sevim A, et al. Rosai-Dorfman disease: a case report with nodal and cutaneous involvement and review of the literature. Am J Dermatopathol. 2014;36:353-357.
  17. Luppi M, Barozzi P, Garber R, et al. Expression of human herpesvirus 6 antigens in benign and malignant lymphoproliferative diseases. Am J Pathol. 1998;153:815-823.
  18. Wang KH, Chen WY, Liu HN, et al. Cutaneous Rosai-Dorfman disease: clinicopathological profiles, spectrum and evolution of 21 lesions in six patients. Br J Dermatol. 2006;154:277-286.
  19. Vaiselbuh SR, Bryceson YT, Allen CE, et al. Updates on histiocytic disorders. Pediatr Blood Cancer. 2014;61:1329-1335.
  20. Ravindran A, Goyal G, Go RS, et al. Rosai-Dorfman disease displays a unique monocyte-macrophage phenotype characterized by expression of OCT2. Am J Surg Pathol. 2021;45:35-44.
  21. Hoogewerf CJ, van Baar ME, Middelkoop E, et al. Impact of facial burns: relationship between depressive symptoms, self-esteem and scar severity. Gen Hosp Psychiatry. 2014;36:271-276.
  22. Abla O, Jacobsen E, Picarsic J, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018;131:2877-2890.
  23. Al-Khateeb THH. Cutaneous Rosai-Dorfman disease of the face: a comprehensive literature review and case report. J Oral Maxillofacial Surg. 2016;74:528-540.
  24. Cheng SP, Jeng KS, Liu CL. Subcutaneous Rosai–Dorfman disease: is surgical excision justified? J Eur Acad Dermatol Venereol. 2005; 19:747-750.
  25. Garcia RA, DiCarlo EF. Rosai-Dorfman disease of bone and soft tissue. Arch Pathol Lab Med. 2021;146:40-46.
Article PDF
Author and Disclosure Information

From the Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.

The authors have no relevant financial disclosures to report.

Correspondence: Mica C.G. Williams, BA, 15 York St, LMP 5040, New Haven, CT 06510 (mica.williams@yale.edu).

Cutis. 2026 April;117(4):E12-E14. doi:10.12788/cutis.1383

Issue
Cutis - 117(4)
Publications
Topics
Page Number
E12-E14
Sections
Author and Disclosure Information

From the Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.

The authors have no relevant financial disclosures to report.

Correspondence: Mica C.G. Williams, BA, 15 York St, LMP 5040, New Haven, CT 06510 (mica.williams@yale.edu).

Cutis. 2026 April;117(4):E12-E14. doi:10.12788/cutis.1383

Author and Disclosure Information

From the Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut.

The authors have no relevant financial disclosures to report.

Correspondence: Mica C.G. Williams, BA, 15 York St, LMP 5040, New Haven, CT 06510 (mica.williams@yale.edu).

Cutis. 2026 April;117(4):E12-E14. doi:10.12788/cutis.1383

Article PDF
Article PDF

THE DIAGNOSIS: Cutaneous Rosai-Dorfman Disease

The clinical differential diagnosis in our patient included a broad array of soft-tissue neoplasms ranging from benign entities to sarcomas. Histology was notable for a dense, dermal-based, lymphohistiocytic infiltrate with alternating hypocellular and hypercellular areas imparting a marbled appearance on low-power view (Figure, A). Further immunohistochemical staining revealed large, S100-positive histiocytes containing intact inflammatory cells (emperipolesis), which confirmed a diagnosis of cutaneous Rosai-Dorfman disease (RDD)(Figure, B). Our patient elected to undergo surgical removal of the mass, and he will be monitored for recurrence.

CT117004012_e-Fig_AB
FIGURE. A, A punch biopsy from the lesion in the right axilla demonstrated a dense, dermal inflammatory infiltrate with alternating hypocellular and hypercellular zones (H&E, original magnification ×200 and ×300. B, High-power view showed large pale histiocytes containing intact lymphocytes and plasma cells within the cytoplasm (H&E, original magnification ×400

Rosai-Dorfman disease is a non–Langerhans cell histiocytosis that most commonly affects the lymph nodes but can affect other organs including the skin. Rosai-Dorfman disease initially was documented in the medical literature in 1969 by Rosai and Dorfman1 as benign sinus histiocytosis with massive lymphadenopathy. Classic RDD usually manifests with painless cervical lymphadenopathy in children or young adults along with fever, leukocytosis, anemia, polyclonal hypergammaglobulinemia, and elevated inflammatory markers.2,3 Extranodal involvement has been reported in up to 43% of cases, with common sites including the skin, central nervous system, and gastrointestinal tract.3,4

Cutaneous RDD is a distinct, less common clinical entity that is limited to the skin and shows no nodal involvement or systemic symptoms such as fever, night sweats, or weight loss.5 Cutaneous RDD classically manifests with localized indurated papules and plaques, but it can manifest with tumorlike lesions in the subcutaneous tissues.6 Cutaneous RDD is very rare, with fewer than 200 known case reports in the literature as of 2014; in comparison to classic forms of RDD, cutaneous RDD has a female predominance.7,8 There are few reports of isolated cutaneous disease manifesting as soft-tissue masses, and our case represents a rare case of cutaneous RDD manifesting as a solitary soft-tissue mass in the axilla.9-11 Diagnosis of cutaneous RDD is challenging due to its variable clinical manifestations and nonspecific imaging findings, requiring clinicopathologic correlation.

Imaging of subcutaneous RDD lesions typically shows well-defined, irregularly shaped masses with homogenous enhancement on computed tomography/ magnetic resonance imaging. Additional imaging with positron emission tomography/computed tomography is recommended to examine for organ involvement, as RDD lesions have avid uptake.12,13 Imaging may help differentiate RDD lesions from malignant neoplasms prior to biopsy. Additional workup includes baseline laboratory testing with inflammatory markers and a complete blood count for evaluation of laboratory abnormalities seen in classic RDD, including leukocytosis, anemia, or systemic inflammation.12 Following imaging and laboratory testing, definitive diagnosis of RDD necessitates histopathologic examination.

Although cutaneous RDD is clinically distinct from its classic RDD counterpart, the conditions share the same characteristic histologic features.5 Histology is notable for a dense mixed inflammatory infiltrate comprised of large pale histiocytes exhibiting emperipolesis, lymphocytes, plasma cells, and occasional eosinophils and neutrophils. Histiocytes stain positive for CD68, CD163, and S100 and are negative for Langerhans cell markers CD1a and CD207.6

The etiology of RDD remains poorly understood. Classic RDD has been associated with both sporadic and familial forms, with somatic mutations identified in the mitogen-activated protein kinase/KRAS pathway in up to one-third of cases, and less frequently in the BRAF gene.14,15 Germline mutations in familial cases of RDD have been identified in the SLC29A3 gene; mutations in this gene are associated with a spectrum of syndromes with histiocytosis and lymphadenopathy.14,15 In contrast, molecular drivers have yet to be identified in cutaneous RDD lesions, and the current predominant hypothesis is that cutaneous RDD has a reactive or immunologic pathophysiology. Autoimmune diseases, infections, and lymphomas have been reported to co-occur with both classic and cutaneous RDD.15 While subclinical viral infections such as Epstein-Barr virus and human herpesvirus 6 have been identified in RDD cases, studies have failed to prove their role as pathogenic drivers of the disease.14,16,17 Commonly reported comorbidities include systemic lupus erythematous, diabetes, hemolytic anemia, acute/chronic uveitis (though it is controversial whether these cases represent orbital involvement in systemic RDD), and Crohn disease.7,8,18,19 Immunohistochemical findings have supported that cells within RDD are activated monocytes responding to T-cell cytokine signaling following an infectious or immunologic insult.20,21

Consensus guidelines on treatment for cutaneous RDD recommend either observation for asymptomatic disease or surgical excision for unifocal lesions with consideration of systemic therapy for refractory cutaneous disease.22,23 Most patients with cutaneous RDD have self-limited disease, but long-term follow-up is recommended following surgical excision to monitor for recurrence, especially if there is a residual positive margin.24 Radiation therapy also may have to be utilized for residual or recurrent disease that becomes symptomatic; however, further studies are needed to determine its efficacy in limiting recurrence.4,12,25 Systemic treatment options include immunosuppressive or immunomodulatory agents such as corticosteroids, methotrexate, and rituximab.5 There currently are no guidelines on length of follow-up, but surveillance is recommended initially at 4 months, followed by 6- to 12-month intervals.22

THE DIAGNOSIS: Cutaneous Rosai-Dorfman Disease

The clinical differential diagnosis in our patient included a broad array of soft-tissue neoplasms ranging from benign entities to sarcomas. Histology was notable for a dense, dermal-based, lymphohistiocytic infiltrate with alternating hypocellular and hypercellular areas imparting a marbled appearance on low-power view (Figure, A). Further immunohistochemical staining revealed large, S100-positive histiocytes containing intact inflammatory cells (emperipolesis), which confirmed a diagnosis of cutaneous Rosai-Dorfman disease (RDD)(Figure, B). Our patient elected to undergo surgical removal of the mass, and he will be monitored for recurrence.

CT117004012_e-Fig_AB
FIGURE. A, A punch biopsy from the lesion in the right axilla demonstrated a dense, dermal inflammatory infiltrate with alternating hypocellular and hypercellular zones (H&E, original magnification ×200 and ×300. B, High-power view showed large pale histiocytes containing intact lymphocytes and plasma cells within the cytoplasm (H&E, original magnification ×400

Rosai-Dorfman disease is a non–Langerhans cell histiocytosis that most commonly affects the lymph nodes but can affect other organs including the skin. Rosai-Dorfman disease initially was documented in the medical literature in 1969 by Rosai and Dorfman1 as benign sinus histiocytosis with massive lymphadenopathy. Classic RDD usually manifests with painless cervical lymphadenopathy in children or young adults along with fever, leukocytosis, anemia, polyclonal hypergammaglobulinemia, and elevated inflammatory markers.2,3 Extranodal involvement has been reported in up to 43% of cases, with common sites including the skin, central nervous system, and gastrointestinal tract.3,4

Cutaneous RDD is a distinct, less common clinical entity that is limited to the skin and shows no nodal involvement or systemic symptoms such as fever, night sweats, or weight loss.5 Cutaneous RDD classically manifests with localized indurated papules and plaques, but it can manifest with tumorlike lesions in the subcutaneous tissues.6 Cutaneous RDD is very rare, with fewer than 200 known case reports in the literature as of 2014; in comparison to classic forms of RDD, cutaneous RDD has a female predominance.7,8 There are few reports of isolated cutaneous disease manifesting as soft-tissue masses, and our case represents a rare case of cutaneous RDD manifesting as a solitary soft-tissue mass in the axilla.9-11 Diagnosis of cutaneous RDD is challenging due to its variable clinical manifestations and nonspecific imaging findings, requiring clinicopathologic correlation.

Imaging of subcutaneous RDD lesions typically shows well-defined, irregularly shaped masses with homogenous enhancement on computed tomography/ magnetic resonance imaging. Additional imaging with positron emission tomography/computed tomography is recommended to examine for organ involvement, as RDD lesions have avid uptake.12,13 Imaging may help differentiate RDD lesions from malignant neoplasms prior to biopsy. Additional workup includes baseline laboratory testing with inflammatory markers and a complete blood count for evaluation of laboratory abnormalities seen in classic RDD, including leukocytosis, anemia, or systemic inflammation.12 Following imaging and laboratory testing, definitive diagnosis of RDD necessitates histopathologic examination.

Although cutaneous RDD is clinically distinct from its classic RDD counterpart, the conditions share the same characteristic histologic features.5 Histology is notable for a dense mixed inflammatory infiltrate comprised of large pale histiocytes exhibiting emperipolesis, lymphocytes, plasma cells, and occasional eosinophils and neutrophils. Histiocytes stain positive for CD68, CD163, and S100 and are negative for Langerhans cell markers CD1a and CD207.6

The etiology of RDD remains poorly understood. Classic RDD has been associated with both sporadic and familial forms, with somatic mutations identified in the mitogen-activated protein kinase/KRAS pathway in up to one-third of cases, and less frequently in the BRAF gene.14,15 Germline mutations in familial cases of RDD have been identified in the SLC29A3 gene; mutations in this gene are associated with a spectrum of syndromes with histiocytosis and lymphadenopathy.14,15 In contrast, molecular drivers have yet to be identified in cutaneous RDD lesions, and the current predominant hypothesis is that cutaneous RDD has a reactive or immunologic pathophysiology. Autoimmune diseases, infections, and lymphomas have been reported to co-occur with both classic and cutaneous RDD.15 While subclinical viral infections such as Epstein-Barr virus and human herpesvirus 6 have been identified in RDD cases, studies have failed to prove their role as pathogenic drivers of the disease.14,16,17 Commonly reported comorbidities include systemic lupus erythematous, diabetes, hemolytic anemia, acute/chronic uveitis (though it is controversial whether these cases represent orbital involvement in systemic RDD), and Crohn disease.7,8,18,19 Immunohistochemical findings have supported that cells within RDD are activated monocytes responding to T-cell cytokine signaling following an infectious or immunologic insult.20,21

Consensus guidelines on treatment for cutaneous RDD recommend either observation for asymptomatic disease or surgical excision for unifocal lesions with consideration of systemic therapy for refractory cutaneous disease.22,23 Most patients with cutaneous RDD have self-limited disease, but long-term follow-up is recommended following surgical excision to monitor for recurrence, especially if there is a residual positive margin.24 Radiation therapy also may have to be utilized for residual or recurrent disease that becomes symptomatic; however, further studies are needed to determine its efficacy in limiting recurrence.4,12,25 Systemic treatment options include immunosuppressive or immunomodulatory agents such as corticosteroids, methotrexate, and rituximab.5 There currently are no guidelines on length of follow-up, but surveillance is recommended initially at 4 months, followed by 6- to 12-month intervals.22

References
  1. Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. a newly recognized benign clinicopathological entity. Arch Pathol. 1969;87:63-70.
  2. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. 1990;7:19-73.
  3. Stefanato CM, Ellerin PS, Bhawan J. Cutaneous sinus histiocytosis (Rosai-Dorfman disease) presenting clinically as vasculitis. J Am Acad Dermatol. 2002;46:775-778.
  4. Dalia S, Sagatys E, Sokol L, et al. Rosai-Dorfman Disease: tumor biology, clinical features, pathology, and treatment. Cancer Control. 2014;21:322-327.
  5. Bruce-Brand C, Schneider JW, Schubert P. Rosai-Dorfman disease: an overview. J Clin Pathol. 2020;73:697.
  6. Bolognia J, Jorizzo J, Schaffer J. Dermatology. 3rd ed. ed. Elsevier Saunders 2012.
  7. Salva KA, Stenstrom M, Breadon JY, et al. Possible association of cutaneous rosai-dorfman disease and chronic crohn disease: a case series report. JAMA Dermatol. 2014;150:177-181.
  8. Brenn T, Calonje E, Granter SR, et al. Cutaneous Rosai-Dorfman disease is a distinct clinical entity. Am J Dermatopathol. 2002; 24:385-391.
  9. Betini N, Munger AM, Rottmann D, et al. Rare presentation of Rosai- Dorfman disease in soft tissue: diagnostic findings and surgical treatment. Case Rep Surg. 2022;2022:8440836.
  10. Cravero JC, Ibrahim S. Recurrent soft tissue rosai dorfman disease of right medial thigh lipoma with lymph node involvement. Fed Pract. 2024;41(suppl 2):S20-S23
  11. Tenny SO, McGinness M, Zhang D, et al. Rosai-Dorfman disease presenting as a breast mass and enlarged axillary lymph node mimicking malignancy: a case report and review of the literature. Breast J. 2011;17:516-520.
  12. Goyal G, Ravindran A, Young JR, et al. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica. 2020;105:348-357.
  13. Li H, Li D, Xia J, et al. Radiological features of Rosai-Dorfman disease: case series and review of the literature. Clin Radiol. 2022;77:E799-E805.
  14. Elbaz Younes I, Sokol L, Zhang L. Rosai-Dorfman disease between proliferation and neoplasia. Cancers. 2022;14:5271.
  15. Ravindran A, Rech KL. How I diagnose Rosai-Dorfman disease. Am J Clin Pathol. 2023;160:1-10.
  16. Kutlubay Z, Bairamov O, Sevim A, et al. Rosai-Dorfman disease: a case report with nodal and cutaneous involvement and review of the literature. Am J Dermatopathol. 2014;36:353-357.
  17. Luppi M, Barozzi P, Garber R, et al. Expression of human herpesvirus 6 antigens in benign and malignant lymphoproliferative diseases. Am J Pathol. 1998;153:815-823.
  18. Wang KH, Chen WY, Liu HN, et al. Cutaneous Rosai-Dorfman disease: clinicopathological profiles, spectrum and evolution of 21 lesions in six patients. Br J Dermatol. 2006;154:277-286.
  19. Vaiselbuh SR, Bryceson YT, Allen CE, et al. Updates on histiocytic disorders. Pediatr Blood Cancer. 2014;61:1329-1335.
  20. Ravindran A, Goyal G, Go RS, et al. Rosai-Dorfman disease displays a unique monocyte-macrophage phenotype characterized by expression of OCT2. Am J Surg Pathol. 2021;45:35-44.
  21. Hoogewerf CJ, van Baar ME, Middelkoop E, et al. Impact of facial burns: relationship between depressive symptoms, self-esteem and scar severity. Gen Hosp Psychiatry. 2014;36:271-276.
  22. Abla O, Jacobsen E, Picarsic J, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018;131:2877-2890.
  23. Al-Khateeb THH. Cutaneous Rosai-Dorfman disease of the face: a comprehensive literature review and case report. J Oral Maxillofacial Surg. 2016;74:528-540.
  24. Cheng SP, Jeng KS, Liu CL. Subcutaneous Rosai–Dorfman disease: is surgical excision justified? J Eur Acad Dermatol Venereol. 2005; 19:747-750.
  25. Garcia RA, DiCarlo EF. Rosai-Dorfman disease of bone and soft tissue. Arch Pathol Lab Med. 2021;146:40-46.
References
  1. Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. a newly recognized benign clinicopathological entity. Arch Pathol. 1969;87:63-70.
  2. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease): review of the entity. Semin Diagn Pathol. 1990;7:19-73.
  3. Stefanato CM, Ellerin PS, Bhawan J. Cutaneous sinus histiocytosis (Rosai-Dorfman disease) presenting clinically as vasculitis. J Am Acad Dermatol. 2002;46:775-778.
  4. Dalia S, Sagatys E, Sokol L, et al. Rosai-Dorfman Disease: tumor biology, clinical features, pathology, and treatment. Cancer Control. 2014;21:322-327.
  5. Bruce-Brand C, Schneider JW, Schubert P. Rosai-Dorfman disease: an overview. J Clin Pathol. 2020;73:697.
  6. Bolognia J, Jorizzo J, Schaffer J. Dermatology. 3rd ed. ed. Elsevier Saunders 2012.
  7. Salva KA, Stenstrom M, Breadon JY, et al. Possible association of cutaneous rosai-dorfman disease and chronic crohn disease: a case series report. JAMA Dermatol. 2014;150:177-181.
  8. Brenn T, Calonje E, Granter SR, et al. Cutaneous Rosai-Dorfman disease is a distinct clinical entity. Am J Dermatopathol. 2002; 24:385-391.
  9. Betini N, Munger AM, Rottmann D, et al. Rare presentation of Rosai- Dorfman disease in soft tissue: diagnostic findings and surgical treatment. Case Rep Surg. 2022;2022:8440836.
  10. Cravero JC, Ibrahim S. Recurrent soft tissue rosai dorfman disease of right medial thigh lipoma with lymph node involvement. Fed Pract. 2024;41(suppl 2):S20-S23
  11. Tenny SO, McGinness M, Zhang D, et al. Rosai-Dorfman disease presenting as a breast mass and enlarged axillary lymph node mimicking malignancy: a case report and review of the literature. Breast J. 2011;17:516-520.
  12. Goyal G, Ravindran A, Young JR, et al. Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease. Haematologica. 2020;105:348-357.
  13. Li H, Li D, Xia J, et al. Radiological features of Rosai-Dorfman disease: case series and review of the literature. Clin Radiol. 2022;77:E799-E805.
  14. Elbaz Younes I, Sokol L, Zhang L. Rosai-Dorfman disease between proliferation and neoplasia. Cancers. 2022;14:5271.
  15. Ravindran A, Rech KL. How I diagnose Rosai-Dorfman disease. Am J Clin Pathol. 2023;160:1-10.
  16. Kutlubay Z, Bairamov O, Sevim A, et al. Rosai-Dorfman disease: a case report with nodal and cutaneous involvement and review of the literature. Am J Dermatopathol. 2014;36:353-357.
  17. Luppi M, Barozzi P, Garber R, et al. Expression of human herpesvirus 6 antigens in benign and malignant lymphoproliferative diseases. Am J Pathol. 1998;153:815-823.
  18. Wang KH, Chen WY, Liu HN, et al. Cutaneous Rosai-Dorfman disease: clinicopathological profiles, spectrum and evolution of 21 lesions in six patients. Br J Dermatol. 2006;154:277-286.
  19. Vaiselbuh SR, Bryceson YT, Allen CE, et al. Updates on histiocytic disorders. Pediatr Blood Cancer. 2014;61:1329-1335.
  20. Ravindran A, Goyal G, Go RS, et al. Rosai-Dorfman disease displays a unique monocyte-macrophage phenotype characterized by expression of OCT2. Am J Surg Pathol. 2021;45:35-44.
  21. Hoogewerf CJ, van Baar ME, Middelkoop E, et al. Impact of facial burns: relationship between depressive symptoms, self-esteem and scar severity. Gen Hosp Psychiatry. 2014;36:271-276.
  22. Abla O, Jacobsen E, Picarsic J, et al. Consensus recommendations for the diagnosis and clinical management of Rosai-Dorfman-Destombes disease. Blood. 2018;131:2877-2890.
  23. Al-Khateeb THH. Cutaneous Rosai-Dorfman disease of the face: a comprehensive literature review and case report. J Oral Maxillofacial Surg. 2016;74:528-540.
  24. Cheng SP, Jeng KS, Liu CL. Subcutaneous Rosai–Dorfman disease: is surgical excision justified? J Eur Acad Dermatol Venereol. 2005; 19:747-750.
  25. Garcia RA, DiCarlo EF. Rosai-Dorfman disease of bone and soft tissue. Arch Pathol Lab Med. 2021;146:40-46.
Issue
Cutis - 117(4)
Issue
Cutis - 117(4)
Page Number
E12-E14
Page Number
E12-E14
Publications
Publications
Topics
Article Type
Display Headline

A Solitary Axillary Subcutaneous Mass

Display Headline

A Solitary Axillary Subcutaneous Mass

Sections
Questionnaire Body

A 34-year-old man presented to our dermatology clinic for evaluation of a lesion in the right axilla of 1 year’s duration that had recently increased in size. The lesion was nontender and intermittently pruritic and was associated with focal hypohidrosis. The patient denied any fevers, chills, or recent weight change. His medical history was otherwise unremarkable. His only medications were daily ashwagandha and vitamin B and C supplements. On physical examination, a firm, 6-cm, subcutaneous nodule was noted in the right axilla with central alopecia and without a clear punctum. He had no palpable cervical, postauricular, or inguinal lymphadenopathy. The left axilla was clear, and there were no other relevant skin findings. Laboratory testing including a complete blood count, comprehensive metabolic panel, and sexually transmitted infections panel was unremarkable. Ultrasonography and subsequent magnetic resonance imaging of the right axilla showed a 4.9-cm nodule located in the subcutaneous fat with minimal deep infiltration and relatively smooth margins. An incisional biopsy of the lesion was performed.

Williams-PC-0326-Quiz
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date

Xylazine-Induced Skin Necrosis

Article Type
Changed
Display Headline

Xylazine-Induced Skin Necrosis

To the Editor:

Xylazine, commonly referred to by its street name tranq, is a veterinary tranquilizer that has recently gained attention due to its increasing misuse in human populations. It often is combined with recreational drugs like fentanyl to extend the duration of drug effects. As a partial α2 receptor agonist, xylazine acts by reducing dopamine and norepinephrine release, resulting in sedative effects. This case report highlights xylazine skin necrosis manifesting as wrist drop and chronic wounds in a patient with a history of intravenous (IV) drug use.

A 35-year-old man with a history of IV drug use presented to the emergency department with a nonprogressive right wrist drop that had persisted for 2 weeks, along with new-onset left wrist drop of 1 day’s duration. The patient did not report any sensory symptoms or pain. Physical examination revealed an ulcerated necrotic plaque with hemorrhagic crust and focal areas of scarring on the right posterior forearm (Figure 1). The left hand exhibited a well-healed pink scar symmetric to the ulcer on the right forearm. The patient reported a history of a similar ulcer on the left hand that had resolved after discontinuation of IV drug use in that arm. He denied any history of trauma to the area.

Fenstermacher-1
FIGURE 1. Ulcerated necrotic plaque with hemorrhagic crust and focal areas of scarring on the right posterior forearm.

The patient’s laboratory results demonstrated elevated inflammatory markers, including an erythrocyte sedimentation rate of 105 mm/h (reference range, <15 mm/h in men younger than 50 years) and a C-reactive protein level of 7.7 mg/dL (reference range, <0.9 mg/dL). Additionally, antinuclear antibody and antineutrophil cytoplasmic antibody tests were positive. A urine drug screen returned positive results for various substances, including cocaine, cocaine metabolites, fentanyl, norfentanyl, β-hydroxyfentanyl or fentanyl metabolite, caffeine, caffeine metabolite or theophylline, nicotine metabolite, and xylazine. Magnetic resonance imaging of the right upper extremity excluded osteomyelitis but revealed multiple subepidermal abscesses.

A punch biopsy from the right forearm demonstrated an ulcer with a mixed infiltrate, dermal necrosis, and clusters of Gram-positive cocci, indicating a bacterial infection. There was no evidence of leukocytoclastic vasculitis (Figures 2 and 3). Electromyography confirmed mononeuritis multiplex as the cause of the right wrist drop. The patient was found to have cytoplasmic antineutrophil cytoplasmic antibody–positive vasculitis in the setting of levamisole-adulterated cocaine use. Since no vasculitis was identified on histopathology of the ulcer and xylazine was detected on drug screening, a diagnosis of xylazine-induced skin necrosis was made. In our case, the patient did not show evidence of active osteomyelitis or sepsis and left the hospital against medical advice without adequate wound debridement.

Fenstermacher-2
FIGURE 2. Punch biopsy from the ulcer on the right forearm demonstrated a mixed infiltrate, dermal necrosis, and clusters of Gram-positive cocci (H&E, original magnification ×4).
Fenstermacher-3
FIGURE 3. Gram-stained punch biopsy from the right forearm demonstrated Gram-positive cocci consistent with a secondary bacterial infection (original magnification ×40).

Our case highlights xylazine-induced skin necrosis that can occur in individuals who use IV drugs. The combination of xylazine with other recreational drugs such as fentanyl poses unique challenges for clinicians. Xylazine has been increasingly found in cases of overdose-related mortality1 and recently has been reported to induce skin ulcers.2 Xylazine intoxication, though uncommon, can result in distinct clinical presentations, including recalcitrant skin ulcers and deep necrotizing wounds.

The precise mechanism behind these wounds remains unclear. Xylazine is a partial α2 receptor agonist, and it is postulated that the necrotic wounds develop secondary to local vasoconstriction, leading to decreased skin perfusion.3 A recent study found that xylazine used in combination with cocaine or an active metabolite in heroin can cause cytotoxicity to vascular endothelial cells, which can lead to dysregulation of vascular tone.4 Decreased perfusion and impaired wound healing put patients at risk for secondary infections, infected ulcers, osteomyelitis, and sepsis.

In patients with known fentanyl use in conjunction with skin necrosis, a high degree of suspicion for xylazine intoxication should be employed. Ruling out vasculitis (via serologic markers and skin biopsy) as well as atypical skin infections is important in these patients to identify potential cases of xylazine-induced skin necrosis. Other IV drugs such as krokodil (desomorphine) can cause severe skin necrosis and therefore should be considered in these patients. Early detection of these skin ulcers is imperative, as delayed diagnosis increases the risk for osteomyelitis and/or the need for amputation.

This case emphasizes the importance of health care providers remaining vigilant about emerging trends in drug misuse. Early recognition of xylazine intoxication and its potential complications is crucial for timely intervention and appropriate management, which may include wound debridement and antibiotic therapy. In addition, proper counseling regarding discontinuation of drug use is important in wound healing, though this poses a challenging conversation with the patient. Increased awareness among health care professionals and continued research in illicit drug–induced skin necrosis will aid in better understanding and addressing the growing issue of xylazine misuse.

References
  1. Friedman J, Montero F, Bourgois P, et al. Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022;233:109380. doi:10.1016/j.drugalcdep.2022.109380
  2. Malayala SV, Papudesi BN, Bobb R, et al. Xylazine-induced skin ulcers in a person who injects drugs in Philadelphia, Pennsylvania, USA. Cureus. 2022;14:E28160. doi:10.7759/cureus.28160
  3. McNinch J, Maguire M, Wallace L, et al. A case of skin necrosis caused by intravenous xylazine abuse. Abstract presented at: SHM Converge; May 3-7, 2021.
  4. Silva-Torres LA, Vélez C, Lyvia Alvarez J, et al. Toxic effects of xylazine on endothelial cells in combination with cocaine and 6-monoacetylmorphine. Toxicol In Vitro. 2014;28:1312-1319. doi:10.1016/j.tiv.2014.06.013
Article PDF
Author and Disclosure Information

From the Department of Dermatology, University of Pittsburgh, Pennsylvania.

The authors have no conflicts of interest to disclose.

Correspondence: Joseph C. English III, MD, Professor of Dermatology, University of Pittsburgh, Department of Dermatology, UPMC North Hills Dermatology, 9000 Brooktree Rd, Ste 200, Wexford, PA 15090 (engljc@UPMC.EDU).

Cutis. 2026 April;117(4):E10-E11. doi:10.12788/cutis.1382

Issue
Cutis - 117(4)
Publications
Topics
Page Number
E10-E11
Sections
Author and Disclosure Information

From the Department of Dermatology, University of Pittsburgh, Pennsylvania.

The authors have no conflicts of interest to disclose.

Correspondence: Joseph C. English III, MD, Professor of Dermatology, University of Pittsburgh, Department of Dermatology, UPMC North Hills Dermatology, 9000 Brooktree Rd, Ste 200, Wexford, PA 15090 (engljc@UPMC.EDU).

Cutis. 2026 April;117(4):E10-E11. doi:10.12788/cutis.1382

Author and Disclosure Information

From the Department of Dermatology, University of Pittsburgh, Pennsylvania.

The authors have no conflicts of interest to disclose.

Correspondence: Joseph C. English III, MD, Professor of Dermatology, University of Pittsburgh, Department of Dermatology, UPMC North Hills Dermatology, 9000 Brooktree Rd, Ste 200, Wexford, PA 15090 (engljc@UPMC.EDU).

Cutis. 2026 April;117(4):E10-E11. doi:10.12788/cutis.1382

Article PDF
Article PDF

To the Editor:

Xylazine, commonly referred to by its street name tranq, is a veterinary tranquilizer that has recently gained attention due to its increasing misuse in human populations. It often is combined with recreational drugs like fentanyl to extend the duration of drug effects. As a partial α2 receptor agonist, xylazine acts by reducing dopamine and norepinephrine release, resulting in sedative effects. This case report highlights xylazine skin necrosis manifesting as wrist drop and chronic wounds in a patient with a history of intravenous (IV) drug use.

A 35-year-old man with a history of IV drug use presented to the emergency department with a nonprogressive right wrist drop that had persisted for 2 weeks, along with new-onset left wrist drop of 1 day’s duration. The patient did not report any sensory symptoms or pain. Physical examination revealed an ulcerated necrotic plaque with hemorrhagic crust and focal areas of scarring on the right posterior forearm (Figure 1). The left hand exhibited a well-healed pink scar symmetric to the ulcer on the right forearm. The patient reported a history of a similar ulcer on the left hand that had resolved after discontinuation of IV drug use in that arm. He denied any history of trauma to the area.

Fenstermacher-1
FIGURE 1. Ulcerated necrotic plaque with hemorrhagic crust and focal areas of scarring on the right posterior forearm.

The patient’s laboratory results demonstrated elevated inflammatory markers, including an erythrocyte sedimentation rate of 105 mm/h (reference range, <15 mm/h in men younger than 50 years) and a C-reactive protein level of 7.7 mg/dL (reference range, <0.9 mg/dL). Additionally, antinuclear antibody and antineutrophil cytoplasmic antibody tests were positive. A urine drug screen returned positive results for various substances, including cocaine, cocaine metabolites, fentanyl, norfentanyl, β-hydroxyfentanyl or fentanyl metabolite, caffeine, caffeine metabolite or theophylline, nicotine metabolite, and xylazine. Magnetic resonance imaging of the right upper extremity excluded osteomyelitis but revealed multiple subepidermal abscesses.

A punch biopsy from the right forearm demonstrated an ulcer with a mixed infiltrate, dermal necrosis, and clusters of Gram-positive cocci, indicating a bacterial infection. There was no evidence of leukocytoclastic vasculitis (Figures 2 and 3). Electromyography confirmed mononeuritis multiplex as the cause of the right wrist drop. The patient was found to have cytoplasmic antineutrophil cytoplasmic antibody–positive vasculitis in the setting of levamisole-adulterated cocaine use. Since no vasculitis was identified on histopathology of the ulcer and xylazine was detected on drug screening, a diagnosis of xylazine-induced skin necrosis was made. In our case, the patient did not show evidence of active osteomyelitis or sepsis and left the hospital against medical advice without adequate wound debridement.

Fenstermacher-2
FIGURE 2. Punch biopsy from the ulcer on the right forearm demonstrated a mixed infiltrate, dermal necrosis, and clusters of Gram-positive cocci (H&E, original magnification ×4).
Fenstermacher-3
FIGURE 3. Gram-stained punch biopsy from the right forearm demonstrated Gram-positive cocci consistent with a secondary bacterial infection (original magnification ×40).

Our case highlights xylazine-induced skin necrosis that can occur in individuals who use IV drugs. The combination of xylazine with other recreational drugs such as fentanyl poses unique challenges for clinicians. Xylazine has been increasingly found in cases of overdose-related mortality1 and recently has been reported to induce skin ulcers.2 Xylazine intoxication, though uncommon, can result in distinct clinical presentations, including recalcitrant skin ulcers and deep necrotizing wounds.

The precise mechanism behind these wounds remains unclear. Xylazine is a partial α2 receptor agonist, and it is postulated that the necrotic wounds develop secondary to local vasoconstriction, leading to decreased skin perfusion.3 A recent study found that xylazine used in combination with cocaine or an active metabolite in heroin can cause cytotoxicity to vascular endothelial cells, which can lead to dysregulation of vascular tone.4 Decreased perfusion and impaired wound healing put patients at risk for secondary infections, infected ulcers, osteomyelitis, and sepsis.

In patients with known fentanyl use in conjunction with skin necrosis, a high degree of suspicion for xylazine intoxication should be employed. Ruling out vasculitis (via serologic markers and skin biopsy) as well as atypical skin infections is important in these patients to identify potential cases of xylazine-induced skin necrosis. Other IV drugs such as krokodil (desomorphine) can cause severe skin necrosis and therefore should be considered in these patients. Early detection of these skin ulcers is imperative, as delayed diagnosis increases the risk for osteomyelitis and/or the need for amputation.

This case emphasizes the importance of health care providers remaining vigilant about emerging trends in drug misuse. Early recognition of xylazine intoxication and its potential complications is crucial for timely intervention and appropriate management, which may include wound debridement and antibiotic therapy. In addition, proper counseling regarding discontinuation of drug use is important in wound healing, though this poses a challenging conversation with the patient. Increased awareness among health care professionals and continued research in illicit drug–induced skin necrosis will aid in better understanding and addressing the growing issue of xylazine misuse.

To the Editor:

Xylazine, commonly referred to by its street name tranq, is a veterinary tranquilizer that has recently gained attention due to its increasing misuse in human populations. It often is combined with recreational drugs like fentanyl to extend the duration of drug effects. As a partial α2 receptor agonist, xylazine acts by reducing dopamine and norepinephrine release, resulting in sedative effects. This case report highlights xylazine skin necrosis manifesting as wrist drop and chronic wounds in a patient with a history of intravenous (IV) drug use.

A 35-year-old man with a history of IV drug use presented to the emergency department with a nonprogressive right wrist drop that had persisted for 2 weeks, along with new-onset left wrist drop of 1 day’s duration. The patient did not report any sensory symptoms or pain. Physical examination revealed an ulcerated necrotic plaque with hemorrhagic crust and focal areas of scarring on the right posterior forearm (Figure 1). The left hand exhibited a well-healed pink scar symmetric to the ulcer on the right forearm. The patient reported a history of a similar ulcer on the left hand that had resolved after discontinuation of IV drug use in that arm. He denied any history of trauma to the area.

Fenstermacher-1
FIGURE 1. Ulcerated necrotic plaque with hemorrhagic crust and focal areas of scarring on the right posterior forearm.

The patient’s laboratory results demonstrated elevated inflammatory markers, including an erythrocyte sedimentation rate of 105 mm/h (reference range, <15 mm/h in men younger than 50 years) and a C-reactive protein level of 7.7 mg/dL (reference range, <0.9 mg/dL). Additionally, antinuclear antibody and antineutrophil cytoplasmic antibody tests were positive. A urine drug screen returned positive results for various substances, including cocaine, cocaine metabolites, fentanyl, norfentanyl, β-hydroxyfentanyl or fentanyl metabolite, caffeine, caffeine metabolite or theophylline, nicotine metabolite, and xylazine. Magnetic resonance imaging of the right upper extremity excluded osteomyelitis but revealed multiple subepidermal abscesses.

A punch biopsy from the right forearm demonstrated an ulcer with a mixed infiltrate, dermal necrosis, and clusters of Gram-positive cocci, indicating a bacterial infection. There was no evidence of leukocytoclastic vasculitis (Figures 2 and 3). Electromyography confirmed mononeuritis multiplex as the cause of the right wrist drop. The patient was found to have cytoplasmic antineutrophil cytoplasmic antibody–positive vasculitis in the setting of levamisole-adulterated cocaine use. Since no vasculitis was identified on histopathology of the ulcer and xylazine was detected on drug screening, a diagnosis of xylazine-induced skin necrosis was made. In our case, the patient did not show evidence of active osteomyelitis or sepsis and left the hospital against medical advice without adequate wound debridement.

Fenstermacher-2
FIGURE 2. Punch biopsy from the ulcer on the right forearm demonstrated a mixed infiltrate, dermal necrosis, and clusters of Gram-positive cocci (H&E, original magnification ×4).
Fenstermacher-3
FIGURE 3. Gram-stained punch biopsy from the right forearm demonstrated Gram-positive cocci consistent with a secondary bacterial infection (original magnification ×40).

Our case highlights xylazine-induced skin necrosis that can occur in individuals who use IV drugs. The combination of xylazine with other recreational drugs such as fentanyl poses unique challenges for clinicians. Xylazine has been increasingly found in cases of overdose-related mortality1 and recently has been reported to induce skin ulcers.2 Xylazine intoxication, though uncommon, can result in distinct clinical presentations, including recalcitrant skin ulcers and deep necrotizing wounds.

The precise mechanism behind these wounds remains unclear. Xylazine is a partial α2 receptor agonist, and it is postulated that the necrotic wounds develop secondary to local vasoconstriction, leading to decreased skin perfusion.3 A recent study found that xylazine used in combination with cocaine or an active metabolite in heroin can cause cytotoxicity to vascular endothelial cells, which can lead to dysregulation of vascular tone.4 Decreased perfusion and impaired wound healing put patients at risk for secondary infections, infected ulcers, osteomyelitis, and sepsis.

In patients with known fentanyl use in conjunction with skin necrosis, a high degree of suspicion for xylazine intoxication should be employed. Ruling out vasculitis (via serologic markers and skin biopsy) as well as atypical skin infections is important in these patients to identify potential cases of xylazine-induced skin necrosis. Other IV drugs such as krokodil (desomorphine) can cause severe skin necrosis and therefore should be considered in these patients. Early detection of these skin ulcers is imperative, as delayed diagnosis increases the risk for osteomyelitis and/or the need for amputation.

This case emphasizes the importance of health care providers remaining vigilant about emerging trends in drug misuse. Early recognition of xylazine intoxication and its potential complications is crucial for timely intervention and appropriate management, which may include wound debridement and antibiotic therapy. In addition, proper counseling regarding discontinuation of drug use is important in wound healing, though this poses a challenging conversation with the patient. Increased awareness among health care professionals and continued research in illicit drug–induced skin necrosis will aid in better understanding and addressing the growing issue of xylazine misuse.

References
  1. Friedman J, Montero F, Bourgois P, et al. Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022;233:109380. doi:10.1016/j.drugalcdep.2022.109380
  2. Malayala SV, Papudesi BN, Bobb R, et al. Xylazine-induced skin ulcers in a person who injects drugs in Philadelphia, Pennsylvania, USA. Cureus. 2022;14:E28160. doi:10.7759/cureus.28160
  3. McNinch J, Maguire M, Wallace L, et al. A case of skin necrosis caused by intravenous xylazine abuse. Abstract presented at: SHM Converge; May 3-7, 2021.
  4. Silva-Torres LA, Vélez C, Lyvia Alvarez J, et al. Toxic effects of xylazine on endothelial cells in combination with cocaine and 6-monoacetylmorphine. Toxicol In Vitro. 2014;28:1312-1319. doi:10.1016/j.tiv.2014.06.013
References
  1. Friedman J, Montero F, Bourgois P, et al. Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis. Drug Alcohol Depend. 2022;233:109380. doi:10.1016/j.drugalcdep.2022.109380
  2. Malayala SV, Papudesi BN, Bobb R, et al. Xylazine-induced skin ulcers in a person who injects drugs in Philadelphia, Pennsylvania, USA. Cureus. 2022;14:E28160. doi:10.7759/cureus.28160
  3. McNinch J, Maguire M, Wallace L, et al. A case of skin necrosis caused by intravenous xylazine abuse. Abstract presented at: SHM Converge; May 3-7, 2021.
  4. Silva-Torres LA, Vélez C, Lyvia Alvarez J, et al. Toxic effects of xylazine on endothelial cells in combination with cocaine and 6-monoacetylmorphine. Toxicol In Vitro. 2014;28:1312-1319. doi:10.1016/j.tiv.2014.06.013
Issue
Cutis - 117(4)
Issue
Cutis - 117(4)
Page Number
E10-E11
Page Number
E10-E11
Publications
Publications
Topics
Article Type
Display Headline

Xylazine-Induced Skin Necrosis

Display Headline

Xylazine-Induced Skin Necrosis

Sections
Inside the Article

Practice Points

  • Dermatologists should be aware of the potential for xylazine to cause ulcers in patients with a history of intravenous drug use.
  • Early recognition of xylazine skin ulcers is imperative, as delayed diagnosis increases morbidity such as soft-tissue and bone infection, sepsis, and death.
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Gate On Date
Un-Gate On Date
Use ProPublica
CFC Schedule Remove Status
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article
survey writer start date